

NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE

Annual Report

2002



AND FIVE-YEAR REVIEW OF ACTIVITIES



PUBLISHED BY:

NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE

UNSW Sydney NSW 2052

22-32 King Street,

Randwick, New South Wales

Telephone (02) 9385 0333 Fax (02) 9385 0222

<http://med.unsw.edu.au/ndarc>

Design & layout by Superkern Design P/L SK1827

Foreword

I have much pleasure in commending this report to the reader. The Centre has much to be proud of in its achievements. Success brings, however, new challenges. We are keen to take up these challenges and are presently addressing them through our strategic planning process.

I would like to take this opportunity to thank all who have contributed to the work of the Centre, especially over the last three years, the Board, the staff led by Professors Wayne Hall and Richard Mattick, our conjoint appointments, Collaborating Centres, government departments and our wider network of stakeholders. It has been a wonderful team effort.

Kevin Rozzoli
Chairman



Board of Management



The Hon K Rozzoli, Dip Law, MP (Chair)
Member for Hawkesbury

Prof S B Dowton, MB, BS, MD, FRCMG, FRACP
Dean, Faculty of Medicine, University of New South Wales

Mr K R Evans, BA, SRN, RMN, ANZIM
Director, Alcohol Tobacco & Other Drugs, Queensland Health

Dr J Gray, BA(Hons), PhD
Director, NSW Drug Programs Bureau, NSW Department of Health

Ms S Kerr, BCom
Assistant Secretary, Drug Strategy and Population Health Social Marketing Branch,
Commonwealth Department of Health and Aged Care

A/Prof A Mant, MBBS, MD, MA, FRACG
Area Health Advisor, Quality Use of Medicine, South East Health

Prof R Milbourne, BCom, MCom(Hons), PhD, FASSA
Pro Vice-Chancellor, Research Office, University of New South Wales

Dr N Swan, MBChB, MRCP, DCH(RCP & Eng)
Australian Broadcasting Corporation (ABC)

Prof W Hall, BSc, PhD, AM
Executive Director, National Drug and Alcohol Research Centre

A/Prof R P Mattick, BSc, PhD
Research Director, National Drug and Alcohol Research Centre

Contents

Director's Report	vi
1 CURRENT STRATEGIC PLANNING PROCESSES, GOALS AND PRIORITIES2
1.1 Planning and development of personnel and procedures2
1.2 Operational Workplans3
1.3 Project management principles4
1.4 Collaboration of development of plans between Research Centres4
2 THE RELATIONSHIP OF ACTIVITIES TO NDARC AND NDS GOALS AND PRIORITIES5
2.1 Relevance of NDARC Workplan projects to objectives in Strategic Plan.5
2.2 Evidence that research has led to policy formulation and the development of programs to achieve the identified goals and priorities.5
3 DO NDARC GOALS AND ACTIVITIES REFLECT THE NEEDS OF KEY STAKEHOLDERS?7
3.1 Regular liaison with stakeholders7
3.2 Evidence that stakeholder needs are considered in determining activities.9
3.3 Evidence of projects commissioned by stakeholders9
3.4 Impact at community level9
4 QUALITY OF RESEARCH AND PRODUCTS PRODUCED9
4.1 Excellence and leadership in research, nationally and internationally9
4.2 Research appearing in prestigious journals and other publications9
4.3 Citations of Centre staff in Social Sciences Citation Index10
4.4 Appearances of personnel as key speakers at conferences, seminars and workshops both nationally and internationally10
4.5 Evidence that research has led to policy formulation10
4.6 Research funds from prestigious sources (e.g., competitive research funds).10
4.7 Uptake of other products developed by NDARC.11
5 BUILDING CAPACITY TO UNDERTAKE RESEARCH AND DISSEMINATE KNOWLEDGE11
5.1 Number of new researchers per year working on Centre projects11
5.2 Number of postgraduate students under Centre supervision12
5.3 Centre staff editorial responsibilities for international peer-reviewed journals13
6 MECHANISMS FOR DISSEMINATING RESEARCH AND INFORMING POLICY DEVELOPMENT13
6.1 Seminars on research findings and policy analysis.13

6.2	Literature reviews with implications for policy development	14
6.3	Regular briefings and submissions to government and parliamentary inquiries	14
6.4	Membership of state and national policy committees	14
6.5	Provision of information on drug-related harms and intervention strategies	15
6.6	Evidence from stakeholders of receipt of information in a timely fashion.	16
7	NDARC RELATIONSHIPS/COLLABORATIVE ARRANGEMENTS WITH KEY ORGANISATIONS	17
7.1	Confirmation from various groups that they feel part of a collaboration	17
7.2	Evidence of collaborative projects with other research groups.	18
8	EFFECTIVENESS OF NDARC'S ORGANISATION AND MANAGEMENT STRUCTURES	18
8.1	Providing information such as workplans and annual reports and other performance and research updates	18
8.2	Regular liaison, informal/formal	18
9	'CORE FUNDING ARRANGEMENTS' AND ALTERNATIVE FUNDING ARRANGEMENTS	19
9.1	Information provided by the Centre concerning their funding	19
9.2	Success in obtaining external funding to conduct additional projects.	19
10	FUTURE OPERATION UNDER POTENTIAL POLICY CHANGES	19
10.1	Capacity for innovation and foresight in addressing drug and alcohol use	19

APPENDICES

APPENDIX 1	21
APPENDIX 2	24
APPENDIX 3	49
APPENDIX 4	65
APPENDIX 5	71
APPENDIX 6	74
APPENDIX 7	77
APPENDIX 8	86

Director's Report

The attached report is derived from the submission to the Fifth Review of the National Drug and Alcohol Research Centre at the University of New South Wales, as part of the 2002 Evaluation of the National Research Centres funded under the Australian Government Department of Health and Ageing.

The last review was a Triennial Review and was reported on in October 1997. It covered the period from 1994 to June 1997 inclusive. This review covered the period from July 1997 to June 2002, a period of five years. Several sections from the original review document have been expanded to ensure that this report captures all of the relevant information for 2002. These sections include publications, presentations, staffing and grants from external sources.

We have decided to use the submission in this way as the information comes in a timely fashion to represent the achievements of this Centre, not just in the current year, but for the five or so years preceding that time. It is a useful summary of the work conducted by the Centre in one document providing a good overview of the achievements of the Centre and of the Centre staff.

We are extremely proud of the work which has been carried out over the past five years. This document stands as a benchmark of our achievements in the past and hopefully is an indication of the work we will continue to do into the future.

Of course, NDARC relies on the assistance of many other important individuals and research centres both nationally and internationally to achieve our goals. We hope to continue working with our current collaborators, and to develop new ties and relationships, to ensure that we may continue to assist in increasing the effectiveness of the Australian treatment response to drug problems.



Richard Mattick

The National Drug and Alcohol Research Centre (NDARC) was established at the University of New South Wales in May 1986 with funds provided by the Government of the Commonwealth of Australia to undertake research into the methods of intervention to improve the health of persons affected by drug and alcohol use. NDARC is a multidisciplinary research centre. It collaborates with staff of the schools of medicine, social sciences and other schools of the University of New South Wales, and with other institutions and individuals in Australia and overseas. Facilities at the Centre include a local area computer network accessing a wide-area campus network, a Document Archive with an extensive bibliographic database, and seminar and conference facilities.

In addition to research projects currently being carried out within the Centre, NDARC engages in collaborative projects with other researchers throughout Australia to provide a national focus for research in this field. NDARC also has links with researchers overseas.

Other activities include an Annual Symposium, special conferences, workshops and monthly research seminars, which are open to workers in the field. As well as contributing to scientific journals and other publications, NDARC produces its own Research Monographs and Technical Report Series. In conjunction with the National Drug Research Institute in Perth, it also produces a free quarterly newsletter, CentreLines, to increase communication between the national research centres, other researchers and workers in the drug and alcohol field in Australia.

Mission Statement.

The overall mission of NDARC is:

“by research and related activities to contribute to the minimisation of the harmful consequences of alcohol and other drug use in Australia by increasing the effectiveness of the Australian treatment response to drug-related problems”.

In order to increase the effectiveness of the Australian treatment response to drug problems, four goals need to be achieved:

The key goals of NDARC are to:

- Improve our understanding of the nature and extent of drug-related harms to which treatment should be directed;
- Increase the range of treatment and intervention methods that are effective in reducing identified forms of drug related harm;
- Increase knowledge among treatment providers about which treatment programs are effective and which patients are most suited to them; and
- Increase the community's knowledge of appropriate and effective treatment programs for drug and alcohol problems.

The **terms of reference** and the **performance indicators** for the 1997–2002 Review of NDARC are set out overleaf and are addressed in turn.

1. Current strategic planning processes, goals and priorities

The first term of reference addresses four performance indicators, specifically current strategic planning processes for staff and workplace procedures, workplans to achieve the Centre's goals and priorities, methods for project management, and collaboration in the planning process with the other two Centres.

1.1 Planning and development of personnel and procedures

1.1.1 Planning of the personnel complement of the Centre.

The National Drug and Alcohol Research Centre takes a planned approach to development and the maintenance of a suitably skilled and competent workforce.

The Centre currently has the aim of maintaining at least ten senior post-doctoral research staff within the Centre's staff complement (usually in academic positions, but also in senior general staff positions) to meet the demands for quality research activities in the drug and alcohol area. These ten post-doctoral positions are separate from our conjoint academic staff and from the honorary research fellow positions.

NDARC also aims to have a substantial number of research officers at different levels able to meet the needs of research projects, and to allow for appropriate succession of staff through the research officer levels. Some of these research staff will progress to become the new leaders of NDARC research efforts, a succession that is encouraged and supported.

The administrative staff of the Centre are very important as a resource for the effective functioning of NDARC, and NDARC's plan to review the duties of these staff in order to maintain a suitably qualified administrative staff has been a recent focus of work. Succession plans are to be developed in the near future.

Currently, there are nine academic positions, two further academic positions in the form of NH&MRC clinical research fellowships, and two post-doctoral researchers employed in the Centre. In terms of research staff, there are approximately thirty research officers employed at various levels. There are six administrative staff members.

Additionally, NDARC has four Conjoint Academic Appointments at Senior Lecturer and Associate Professor level, and a further eight Research Fellows who contribute significantly to the work of the Centre.

1.1.2 Development of personnel.

NDARC's intellectual capital is its prime resource for the

production of relevant research in a timely and reliable manner. Maintenance of a secure and happy workplace, where an emphasis is placed on staff development and occupational health and safety, is paramount in maintaining this intellectual capital. In recognition that NDARC's most valuable asset is its staff, the National Drug and Alcohol Research Centre adheres to the guidelines of the University of New South Wales (UNSW) for staff development, and the Centre takes advantage of the range of courses offered by the University to develop the skill-base of these staff. These approaches are detailed below.

■ **Support for formal studies:** Staff are strongly encouraged and supported in the pursuit of relevant postgraduate tertiary qualifications (e.g., Master of Public Health, Master of Psychology, doctoral degrees, etc.). Staff are provided with study time and examination leave under the UNSW policy which provides assistance to staff who are undertaking studies which the Centre considers appropriate to their current positions and to develop their potential to meet future need within the Centre. NDARC has been successful in obtaining ongoing government support for three specific PhD scholarships to fully support full-time doctoral scholars.

This process of routine encouragement and support of postgraduate study has been successful in providing NDARC with a source of suitably skilled staff. Evidence for this claim of success comes from the number of current academic staff (Dr Jan Copeland, Dr Louisa Degenhardt, Dr Kate Dolan, Dr Jo Ross, Dr Catherine Spooner, Dr Wendy Swift) and senior research staff (Dr Libby Topp), all of whom have undertaken their doctoral degrees while working as research staff at the Centre.

■ **UNSW Career Development Scheme:** As a further way of ensuring NDARC has an effective workforce, all Centre staff now participate in the formal UNSW *Career Development Scheme* (developed from the earlier Staff Appraisal Scheme), which is designed to provide all staff with the opportunity to plan and implement career development opportunities to enhance their skills at NDARC and to enhance career opportunities within the Centre.

■ **Staff training courses:** The Centre strongly encourages all staff to enrol in staff training courses offered by the UNSW (either the Faculty of Medicine or the UNSW more generally) and elsewhere. To achieve participation in staff training courses, a senior staff member (Dr Libby Topp) has the role of gathering and collating information about training courses, and then informing and organising staff participation. This training is usually provided free to the Centre either in-house or through external training courses.

Included over the recent past are courses in areas such as:

- intermediate and advanced word-processing;
- database and spreadsheet software (Access, Excel, etc.);
- statistics packages (e.g., SPSS, SAS, geographical software, etc.);
- literature search software;
- conference and seminar presentation skills and use of MS PowerPoint;
- UNSW accounting procedures;
- UNSW Staff Orientation;
- staff management skills;
- grievance resolution procedures (separately for general staff and for management);
- superannuation/financial planning and salary sacrificing; and
- more generic workplace skills and competencies (e.g., first aid and first-attack fire-fighting training).

■ **UNSW Special Studies Program (SSP):** NDARC academic staff are able to take advantage of the UNSW Special Studies Program, which is available to productive researchers and used solely for the furtherance of their research. Currently, Dr Teesson is on internal release as a part of a special program.

■ **Staff progression:** NDARC participates in the normal UNSW *staff progression* processes which provide staff with incremental progression within each level based on satisfactory performance of duties. General staff in research officer roles are able to realise career progression within the Centre, by taking on increasingly more independent research duties and changing employment level to higher positions on new projects as the opportunity arises. Academic staff may apply for progression between levels in recognition of excellent research performance (e.g., from Lecturer to Senior Lecturer, etc.).

1.1.3 Planning and development of procedures.

The use of the policies and procedures of the UNSW is augmented by local initiatives at NDARC.

■ **Regular Board of Management meetings** are held four times per year to advise the Board of progress in work and to seek assistance or advice in dealing with any issues that arise for the management of the Centre.

■ **Regular staff and research meetings** are held, with monthly staff meetings for the exchange of information on NDARC activities and monthly meetings of the Research Committee. The Research Committee is comprised of all senior research staff and includes general staff and doctoral student representatives.

■ **An NDARC Orientation Manual** provides an overview of the Centre's operation, the relevant policies and procedures including authorship of research documents, in-house staff training and development, grievance procedures, and explanation of work role responsibilities.

■ **A manual on Interviewer Safety In The Drug And Alcohol Field: A Safety Protocol And Training Manual For Staff of the National Drug And Alcohol Research Centre**, endorsed by the Research Committee, addresses staff safety and incorporates an incident reporting procedure and register. This manual is an innovation of NDARC and has been taken up by similar research organisations. All staff will be introduced to the manual at induction.

1.2 Operational Workplans

1.2.1 Strategic Plan 1997-2002.

The Centre's operations are guided by the NDARC *Mission Statement and Key Goals*, as currently presented in the *National Drug and Alcohol Research Centre Strategic Plan 1997-2002*. This Strategic Planning document is revised in timing with the NDARC Review Process. A new NDARC *Strategic Plan 2003-2007* will be developed as a consequence of the current Review process, to take account of NDARC's achievements to date, the NDS research priorities and relevant recommendations from the Review.

1.2.2 Key Goals.

As noted earlier, the key goals of NDARC involve improving the understanding of the nature and extent of drug-related harms; increasing the range of treatment and intervention methods that are effective in reducing harm; increasing knowledge among treatment providers about which treatment programs are effective and which patients are most suited to them; and increasing the community's knowledge of appropriate and effective treatment programs for drug and alcohol problems.

1.2.3 Annual Workplan.

The mechanisms to achieve the goals outlined in the *NDARC Strategic Plan 1997-2002* are specified each year using the complementary Annual Workplan. The Annual Workplan content is determined by a process of discussion and exchange of ideas between staff within the Centre and our conjoint appointments, research fellows, and Collaborating Centres. These ideas are then, in turn, discussed with the members of the NDARC Board of Management and the senior staff of the Branch of the Department of Health and Ageing. Areas of common inter-

est and relevance to the NDS are thereby identified and research methods to address the issues raised are subsequently developed. Areas that are not funded by the Commonwealth Department of Health and Ageing are then developed to be submitted to other funding bodies.

1.3 Project management principles

1.3.1

The Centre academic staff ensure that projects conform to a number of procedural guidelines for research.

- The project management approaches used adhere to the *Joint NH&MRC/AVCC Statement and Guidelines on Research Practice* addressing issues of project selection, initiation and organisation, forecasting, planning and scheduling, budgeting, risk-management, communication and monitoring, management and evaluation, reporting, auditing, and project termination.
- The UNSW Ethics Committee and other institutional ethics committees have strict requirements for the management and reporting of research projects, which are adhered to by NDARC staff as required.
- Other research principles such as those embodied in the Therapeutic Goods Administration *Guidelines to Clinical Research Practice* are utilised as needed.
- These guidelines are complemented by additional documents such as the *Interviewer Safety In The Drug And Alcohol Field: A Safety Protocol And Training Manual For Staff of The National Drug And Alcohol Research Centre*.

1.3.2

NDARC holds monthly Research Committee meetings, and twice monthly in-house seminar series to monitor the progress of projects.

- The Research Committee is the main administrative body of the Centre comprised of the Director, the Executive Director, Deputy Director, the academic staff, a PhD student representative, the Media Officer and the Professional Officer. The Research Committee process of review allows for regular checks on the progress of projects, and a regular review of the progress of PhD candidates and the assessment of the Centre's success in enacting its Strategic Plan.
- In-house seminars provide staff at NDARC with information about the projects being conducted and the results of those studies as they come to hand. In-house seminars also provide a useful forum by which to seek collegial input – this can cover all types of issues from research design to analyses and interpretation.

1.3.3

The Centre has a formal internal process of initiating and monitoring the development of NH&MRC grants, including external peer review prior to submission. This activity is augmented by having a staff member take on the role of informing research staff of the range of additional potential funding bodies and the relevant guidelines.

Additionally, in 2001, NDARC put in place a strategic process for generating research grant ideas and funding, in addition to the annual workplan projects agreed with the Commonwealth. The major impetus for establishing this process was agreement that NDARC could apply for competitive research funding from NH&MRC, provided there was no overlap between projects funded by the Commonwealth Department of Health and Ageing and projects for which NH&MRC funding is being sought. This agreement was formalised in a letter from Professor McLachlan on behalf of the NH&MRC Centre for Research Management, dated 24 November 1999 (ref: 98/26418), to the Executive Director of NDARC. Given that NDARC had been previously blocked from applying for NH&MRC funding by the NH&MRC Access Committee, an internal process was required for developing expertise within the centre in successfully applying for competitive research funding from a number of funding bodies, including NH&MRC. This process provides all NDARC staff with the opportunity to contribute innovative research ideas, within the strategic framework for research approved by NDARC's Research Committee, essentially comprising senior academics and staff.

1.4 Collaboration of development of plans between Research Centres

The three centres (NCETA, NDRI and NDARC) have distinct but at times overlapping roles and expertise. In order to minimise duplication and foster collaboration, a number of steps are taken by NDARC staff.

- The Centres exchange workplans as they are developed and finalised. Upon invitation, NDARC staff provide advice on the development of other Centres' workplans.
- The Centres conduct collaborative research (NDRI is a collaborating Centre of NDARC), or collaborate in the development of relevant products and materials where such opportunities are identified.
- The three Centre Directors have regular teleconferences to identify and progress collaborative research activities, and this process further informs the staff of the Centres of common research interests and opportunities.

- The Centres cooperate in the publication of a newsletter with national and international distribution, *CentreLines*.
- The Centres exchange annual reports of their research activities and achievements.
- Centre staff have the opportunity to interact in ad-hoc ways when they meet at the national APSAD conference and at international conferences.

2. The relationship of activities to NDARC and NDS goals and priorities

The second term of reference addresses two performance indicators, specifically the relationship of current and projected activities to the stated goals and priorities of the Centres and the extent to which they reflect, and can inform, current and emerging priorities under the National Drug Strategy.

2.1 Relevance of NDARC Workplan projects to objectives in Strategic Plan

NDARC Workplans are set out to address the objectives in the Strategic Plan.

- The Workplan (For Workplan see Appendix One) relies on the NDARC Strategic Plan Mission Statement, the Key Goals and related Activities, and the research priorities to define new work directions.
- Inspection of the Workplan shows that there are no projects conducted by the Centre staff that do not fall within the Strategic Plan Key Goals and Activities, or are not consistent with the Research Objectives.

2.2 Evidence that research has led to policy formulation and the development of programs to achieve the identified goals and priorities

NDARC staff have had a close relationship with policy makers at the government and service provision levels. A large number of initiatives over the past five years have had a direct impact on policy formulation, and some indicative examples of these activities and the application of NDARC research are presented below.

- **Dance party resources.** In 1997, the Commonwealth Department of Health and Family Services funded NDARC to conduct the National Ecstasy/Dance Party Project. This study aimed to determine current levels of MDMA-related harms and the need for interventions in three states across Australia. As a direct result of this research a series of resources were developed under the banner - 'Project E'. These included a venue information guide and an information resource for potential ecstasy

users. These federally funded resources were the first of their type anywhere in the world and were disseminated nationally.

- **Opioid pharmacotherapies including methadone.** NDARC staff have been at the forefront of the collection of original research and the synthesis of research information relevant to the use of methadone in Australia (and internationally for the past ten years).
 - **Reviews of methadone treatment.** The early substantial and highly successful monograph entitled *Key issues in methadone maintenance treatment* (Ward, Mattick and Hall, 1992) was an important resource for state/territory and national policy development in this controversial area, and it was updated in the review period and republished as an international monograph entitled *Methadone maintenance treatment and other opioid replacement therapies* (Ward, Mattick and Hall, 1998).
 - **NEPOD.** The findings from the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) resulted in a number of recommendations to the IGCD and Ministerial Council on Drug Strategy with respect to the provision of pharmacotherapies for heroin dependence. This multi-trial, multi-site study facilitated by NDARC provided a number of clear recommendations that detoxification therapies must be linked to continuing treatment and that, of all the pharmacotherapies for detoxification, buprenorphine was the most cost effective as well as flexible to post detoxification treatment linkage. Other recommendations that have direct policy implications include ensuring there is a role for general practitioners in a shared care model, and that methadone should be continued to be used as a key method of maintenance therapy given that it was the most cost effective option of those available. Key among the recommendations was that a number of treatment options should be available.
 - **Harms of methadone.** The published work of NDARC on the prevalence and harms of the injection of methadone syrup in NSW was a major factor in the decision of the NSW Health Department to withdraw 10 and 20ml syringes from distribution in NSW needle and syringe programs in 1998, in order to reduce the prevalence of this harmful practice.
 - **Registration and PBS listing of buprenorphine.** The investigation of buprenorphine as a pharmacotherapy for the management of opioid dependence was a significant activity for NDARC in

the period that is the focus of the current review. NDARC staff conducted the largest randomised controlled trial of buprenorphine against methadone. This trial has had a major role in the registration of the medication in Australia; NDARC staff wrote the Expert Report for the registration of the medication via the Therapeutic Goods Administration. Additionally, Professor Mattick provided expert advice to the Pharmaceutical Benefits Advisory Committee on the role of medication for the management of opioid dependence. The medication was registered for the treatment of opioid dependence and subsequently listed on the Pharmaceutical Benefits Scheme.

- **Opioid pharmacotherapies resources.** NDARC (Ms Susannah O'Brien, with Professor Mattick and Mr Paul Dillon) has been commissioned by the Commonwealth Government to disseminate the findings of the NEPOD project. The aim of the dissemination strategy is to ensure that balanced, accurate information regarding opioid dependence and intervention strategies is made available to health care providers, senior administrators, drug and alcohol workers, clinicians, opioid users, the media and the general community. Four resources are to be produced: two booklets (one targeting users and one targeting their families and significant others), an on-line resource targeting frontline workers, and a CD-ROM/overhead presentation package, containing an overview of NEPOD findings and clinical implications, to be used as a key resource in the delivery of information and training to clinicians and other health service staff.
- **National Minimum Dataset for Clients of Alcohol and Other Drug Treatment Agencies (NMDS-AODTS).** NDARC staff developed the methodology, conducted the feasibility study and lobbied the Commonwealth Department of Health and Ageing to fund the development and pilot testing of the specialist alcohol and other drug items for the National Health Data Dictionary. This national collection is now in its third year. This has been followed by the development of the Brief Treatment Outcome Measure for Alcohol and Other Drug Treatment Services (BTOM). The preliminary work for this project led to two Technical Reports, one with an international collaborator. The routine collection of the BTOM is now mandatory in publicly funded opioid maintenance pharmacotherapy clinics in New South Wales and the measure is being refined for use in detoxification, counselling and rehabilitation services across the range of drug types.
- **Adolescent cannabis users experiences and expectations of school drug education** The NSW Department of Education and Training commissioned research to identify the adolescent cannabis users' experiences and expectations of school drug education. This work was published as a departmental monograph and was used to inform the development of the Department's cannabis drug education strategy.
- **The National Comorbidity Project** reflects the high levels of comorbidity between drug and alcohol use disorders and mental disorders and was undertaken as a joint initiative of the Commonwealth and NDARC with the purpose of informing policy. It is a unique initiative, bringing together policy-makers in both mental health and the drug and alcohol fields to develop an evidence-based response.
- **Heroin overdose.** NDARC has led the research in Australia and internationally into the patterns, correlates and causes of opioid overdose deaths. The extensive work of the Centre on the causes and circumstances of heroin overdose resulted directly in the first specific intervention to reduce the morbidity and mortality associated with heroin overdose, the "Don't Slow it Alone" campaign. This campaign, conducted conjointly by the South Australian Drug and Alcohol Services Council and NDARC, was the first specific intervention on overdose in the world. A major component of this campaign was a change in police protocols for attendance at overdoses in South Australia, and subsequently in NSW. The materials have subsequently been distributed in all Australian jurisdictions, and in the United Kingdom. Specific state-based overdose campaigns have also arisen out of the NDARC work in this field.
- **The Illicit Drug Statistics Conjoint Appointment.** The appointment of an academic to a specific illicit drug statistics position has had direct policy relevance in providing information on the number of heroin users in Australia and heroin-related harms.
- **Benzodiazepines.** NDARC has published extensively on the prevalence and harms of the injection of benzodiazepine tablets by injecting drug users.

 - A recent result of this research has been the introduction in 2002 of a requirement of an Authority to Prescribe for temazepam 10mg capsules, in order to reduce the harm associated with the injection of these capsules.
 - NDARC is further assisting within the policy development area by assessing the impact of this Authority

to Prescribe for temazepam on prescribing and injecting practices.

- **The Illicit Drug Reporting System.** Since 1996, NDARC has coordinated the Illicit Drug Reporting System (IDRS), Australia's strategic early warning system designed to detect emergent trends in illicit drug markets. On an annual basis and across every state /territory, data from a number of sources relating to illicit drug use and associated harms are triangulated to provide comparable 'snapshots' of illicit drug markets.
 - Since its inception, the IDRS has successfully broadened the knowledge base from which evidence-based policy decisions and drug control strategies can be developed. For example, the IDRS has provided detailed information on recent patterns and trends in drug use at the jurisdictional level, for which there is demand from policymakers in the health and law enforcement sectors.
 - Prior to the implementation of the IDRS in Tasmania, policy decisions in that jurisdiction were usually based on data collected from other, larger jurisdictions that had the funding and dedicated bodies to conduct specialist research. The IDRS clearly demonstrated that smaller jurisdictions such as Tasmania and the NT have patterns of illicit drug use that are substantially different from those of the larger jurisdictions. Thus, by providing locally relevant information, the IDRS significantly improved the information base for drug policy in Tasmania.
 - For numerous other examples in which IDRS data have constituted an appropriate evidence base from which to develop policy, please see: Topp, L. & McKetin, R. (in press) *Supporting evidence-based policy-making: A case study of the Illicit Drug Reporting System. Bulletin on Narcotics.*
- **Diversion.** A range of projects relating to the diversion of drug offenders have been commissioned relevant to policy development:
 - Production of a strategic review of drug diversion programs for NSW Police;
 - Involvement in the evaluation of the COAG Illicit Drug Initiatives (diversion) for the Commonwealth Dept of Finance and Administration (with Health Outcomes International);
 - Review of diversion and treatment options for Aboriginal and Torres Strait Island youth arrested for alcohol-and-other-drug-related crimes in each jurisdiction of Australia for the ANCD (with Siggins Miller Consultants); and
 - Involvement in jurisdictional diversion programs: DAAP in SA (with Siggins Miller Consultants) and MERIT in NSW.
- Psychostimulants. In response to an increase in cocaine use in Sydney, a needs assessment was conducted (survey of users, survey of services and literature review) and a response initiated. The policy response by NSW Department of Health included: identification and development of resources (information and protocols) for health, welfare and law enforcement agencies; a forum was conducted to increase service capacity to respond to cocaine problems; and development and trial of a brief intervention for cocaine users.
- Police role in NDS. In response to concern about the police role in the harm reduction (HR) and demand reduction (DR) aspects of harm minimisation, NDLERF commissioned a research project to: investigate what police are doing in relation to illicit drug HR/DR (identified via national consultations with police, health and users) and what research suggests should be done (identified by literature review); and produce documents and resources to assist frontline police and policy-makers to improve the police role in this area.

3. Do NDARC goals and activities reflect the needs of key stakeholders?

3.1 Regular liaison with stakeholders

NDARC staff liaise regularly with stakeholders in a number of ways, and through our extensive collaborations (details of collaborations are set out later in this document). Examples of our regular liaison are provided below.

- NDARC staff attend and present on a regular basis to the Intergovernmental Committee on Drugs (IGCD), the NEACID, NEACA, and other Expert Advisory Groups as invited.
- Key stakeholders have been represented on the NDARC Board of Management, including:
 - the Assistant Secretary of the Branch of the Department of Health and Ageing which funds the Centre (Ms Sue Kerr);
 - the Chair of the Intergovernmental Committee on Drugs and Queensland Department of Health Representative (Mr Keith Evans);
 - the Director of the NSW Department of Health Drugs Program Bureau (Dr Jennifer Gray);
 - the Dean of the UNSW Faculty of Medicine; (Professor Bruce Downton) and

- the UNSW Deputy Vice-Chancellor, Research and International, (Professor Elspeth McLachlan).
- NDARC has extensive relations with treatment providers, members of staff in health departments, and to a lesser extent with users groups. However, regular contact with drug users is achieved through the very large number of users interviewed for research projects, and community members through the frequent talks/seminars given to community groups. Health professionals, illicit drug users, family members, and community members are often involved in focus testing of resources.
- Projects which are funded through competitive mechanisms (e.g., NH&MRC, NDLERF, etc.) have a separate formal reporting mechanism, but are usually developed in a process that has input from stakeholders.
- Where possible, regular telephone or face-to-face conferences on project progress are held. For example, using just a sample of some current and recent past indicative projects the extent of liaison can be gauged as quite substantial:
 - In the three-year National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) project, there were quarterly teleconferences with all of the jurisdictional representatives over the three-year life of the project. There was separate liaison with the funding body on a regular frequent basis to discuss progress and to identify impediments. Obviously there was extensive liaison with the investigators.
 - In the current National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) dissemination project there are regular teleconferences with the funding body, and other key stakeholders (treatment professionals, families of users and users groups and users) are included in the development of the products from the project.
 - There are bimonthly teleconferences on progress over the current *Management of Alcohol Dependence (MAD)* project to update staff of the Department of Health and Ageing on the progress of the project. A national expert panel was formed who receive material regularly to review.
 - The staff on the trial of *Two brief interventions for cannabis problems among young offenders in NSW*, meet face-to-face quarterly with the funding body and investigators. A written quarterly report is provided to the State and Commonwealth Attorney-Generals and an annual report to the NSW Department of Juvenile Justice. The project was presented twice last year to the Department of Juvenile Justice Collaboration Research Unit.
- Staff on the *Implications for health and law enforcement of increased availability of potent forms of methamphetamines* project liaise weekly via email and telephone to the CHDA, IGCD, Australian Customs Service, NSW Police Service and the funding body NDLERF. Six-monthly progress reports are provided.
- The staff on the *Illicit Drug Reporting System (IDRS)* project liaise as required and provide a six-monthly provisional progress report to the funding body NDLERF. Six-monthly Steering Committees and an Annual Conference are held with the State and National Health Departments. Annual reports and brief quarterly bulletins are provided nationally and to each jurisdiction. Via telephone, the IDRS liaises with approximately 60 NSW key informants who work directly with clients, and these are important key stakeholders.
- The *Brief Treatment Outcome Measures (BTOM)* project staff have monthly face-to-face meetings with the NSW Department of Health and are involved in the *Monitoring and Outcomes Project (MOP)* which meet monthly face-to-face. A report is provided to the NSW Department of Health quarterly.
- The *Randomised trial of naltrexone, methadone and counselling in NSW prisons* study staff meet every two months with stakeholders from the Department of Health, NSW Corrections Health/Corrective Services staff and prison representatives.
- The *Follow-up study of subjects in a randomised controlled trial of methadone treatment in prisons* project staff meet face-to-face six-monthly with the stakeholders, NSW Department of Health, NSW Corrections Health and Department of Corrective Services. A six-monthly report is provided to the funding body (NH&MRC).
- The staff on *Global Indicators Project* liaise via email, telephone and meet as required with the NSW Cabinet Office, Office of Drug Policy.

3.2 Evidence that stakeholder needs are considered in determining activities

The needs of stakeholders are considered in NDARC activities.

- The Branch of the Department of Health and Ageing which funds the Centre has direct input to the major initiatives in the NDARC Workplan on an annual basis and frequently initiates new projects outside this cycle.
- Stakeholders from federal/state/territory governments often determine our activity by virtue of their funding initiatives or requests for research assistance. To the extent that their initiatives reflect the broader stakeholders, so do those of NDARC.

3.3 Evidence of projects commissioned by stakeholders

NDARC has been highly successful in securing funding for projects commissioned by stakeholders. The details of NDARC projects for 2002 including the funding source and the amount of funding is presented in Appendix 1.

3.4 Impact at community level

NDARC research has been instrumental in the alteration of drug policy and intervention procedures and has raised and informed the discussion of drug problems at the community level. In fact, in an area where the policy is frequently polarized, NDARC research is frequently able to provide balance to the debate. NDARC's focus on evidence has impacted on the information available at the community level. Examples of this form of impact are found in the following:

- NDARC's high media profile has raised the level of debate and information provided through mass media.
- The extent of heroin overdose deaths is much better understood at the community level through the extensive coverage of the subject through mass media driven substantially by NDARC research findings.
- Community action teams initiatives at the community level are informed by NDARC research such as the IDRS and allow a better basis for approaches to adopt and drug problems to target.
- The IDRS has had a major impact on awareness of drug trends at the community level.
- NDARC has distributed hundreds of thousands of brochures to the community over the past six years informing the community of the nature of, and ways to assist with, numerous licit and illicit drug problems.
- The *Quitting Cannabis Strategy* has been broadly disseminated by staff of the Centre to primary health care workers.

- The availability of buprenorphine in Australia is largely reliant on NDARC research involvement. NEPOD has had a significant impact on the quality of the debate on pharmacotherapies for opioid dependence.
- The debate on the medical uses of cannabis has been directly influenced by NDARC work.

4. Quality of research and products produced

4.1 Excellence and leadership in research, nationally and internationally

The fact that the work conducted by Centre staff is highly valued is evidenced by the fact that it is widely cited by both national researchers and international groups (see Section 4.3 below).

NDARC has led the field in studying areas of drug overdose patterns/correlates and causes, effectiveness of opioid pharmacotherapies, illicit drug use trends, prison drug research, mental health/comorbidity and substance use, health effects of cannabis and intervention for cannabis use, health economics and treatment effectiveness, as well as the value of injecting centres, and other new initiatives.

4.2 Research appearing in prestigious journals and other publications

The Centre staff publish NDARC work in a range of quality international and national peer-review scientific journals. These journals include:

- *Addiction* (formerly *British Journal of Addiction*);
- *Drug and Alcohol Dependence*;
- *British Journal of Psychiatry*;
- *The Lancet*;
- *AIDS*;
- *Journal of Personality Disorders*;
- *Drug and Alcohol Review*;
- *Medical Journal of Australia*;
- *Australian and New Zealand Journal of Public Health*; and
- *Australian and New Zealand Journal of Psychiatry*.

NDARC authors publish regularly in *Drug and Alcohol Dependence* and *Addiction*, two of the most prestigious and most cited international journals in the drug and alcohol field.

Since its inception, NDARC has published its work extensively in a number of formats. To date there have been:

- 600 scientific articles in peer-review journals;
- 276 books/book chapters/government reports/conference proceedings;
- 142 technical reports; and
- 49 monographs.

Figures for the period 1997–2002 are as follows:

- 307 scientific articles;
- 136 books/book chapters/government reports/conference proceedings;
- 103 technical reports; and
- 20 monographs.

The scientific articles, books/book chapters/government reports/conference proceedings, technical reports, and monographs are presented at Appendices 2–5.

For further information on NDARC peer-reviewed articles, please see the following:

<http://notes.med.unsw.edu.au/ndarc.nsf/website/Publications.articles>

For further information on NDARC books, book chapters and government reports, please see the following:

<http://notes.med.unsw.edu.au/ndarc.nsf/website/Publications.books>

For further information on NDARC Technical Reports, please see the following:

<http://notes.med.unsw.edu.au/ndarc.nsf/website/Publications.reports>

For further information on NDARC Monographs, please see the following:

<http://notes.med.unsw.edu.au/ndarc.nsf/website/Publications.monographs>

4.3 Citations of Centre staff in Social Sciences Citation Index

The works of the Centre are extensively cited in the scientific and clinical literature.

- The published works of the Centre were cited 4,620 times by authors of scientific publications over the period 1997–2002. This rate represents an average of 924 citations per year, or 77 citations per month in the scientific literature.
- The impact of the Centre’s work on the drug and alcohol field is illustrated by the fact that the works that Professor Wayne Hall (Director 1994–2001) produced whilst at the Centre have placed him among the top 0.5% of cited authors in the scientific literature.

4.4 Appearances of personnel as key speakers at conferences, seminars and workshops both nationally and internationally

Many NDARC staff members have been invited to present their research at conferences, both here and overseas. Some of the international conferences include:

- Annual Scientific Meeting of the U.S. College on Problems of Drug Dependence (CPDD);

- International Conference on the Reduction of Drug-Related Harm;
- International Conference on Nightlife, Substance Use and Related Health Issues;
- Australian National Methadone Conference;
- APSAD Conference; and
- Australian Health Economist Conference.

Full details of all conference and other presentations since 2000 can be found in Appendices 7 and 8, and the details for presentations prior to that time are presented in NDARC Annual Reports.

4.5 Evidence that research has led to policy formulation

This performance indicator was addressed at 2.2.

4.6 Research funds from prestigious sources (e.g., competitive research funds)

NDARC staff have been blocked from applying as first investigators to the NH&MRC until the recent past (see earlier). However, in the period of the review, NDARC staff were successful in securing research funds from a number of peer-review and prestigious competitive grant schemes.

-
- The Drug Abuse Research and Evaluation Advisory Committee: \$210,317
 - The Research into Drug Abuse Program: . . \$882,696
 - The National Drug Law Enforcement Research Fund: \$877,116
 - NH&MRC: \$2,768,297
-

Allocation for base-line core funding from the Commonwealth Department of Health and Aged Care for the financial year 2001/02 was \$1,243,728. This was expended as follows:

	2000–1 \$	2001–02 \$
Salaries	933,965	933,739
Operational	262,798	278,400
Equipment and Furniture	23,892	31,589
Total	1,220,655	1,243,728

Expenditure during 2002 of funds from external grants awarded to NDARC was \$3,198,450. Details of these grants may be found in Appendix 2.

4.7 Uptake of other products developed by NDARC

4.7.1

Resources/pamphlets: A series of resources has been developed by NDARC that continue to be extremely popular with workers in the field and drug users. These resources or pamphlets, which are based on the results of projects conducted at the Centre, are as follows:

- *Steroid Facts*
- *An Injecting Drug User's Guide to Benzos*
- *A Users Guide to Speed*
- *Ecstasy: Facts and Fiction*
- *Heroin*
- *What you need to know about methadone and other treatment options*
- *What's the deal on grass? Cannabis facts for young people*
- *What's the deal on grass? Cannabis facts for parents*
- *What's the deal on grass? Talking to a young person about cannabis*
- *What's the deal on quitting? A do it yourself guide*
- *Club Drugs*
- *Cocaine: Cutting it fine*
- *Drugs: Just the Facts*

Another resource, written for the Commonwealth Government, *Quitting Cannabis*, comprised a Client booklet and a Clinician guideline, and is distributed through NDARC.

The volume of sales in the four months from January to April 2002, was such that over 22,000 copies of NDARC resources were sold to a variety of agencies across Australia and New Zealand, including government and non-government agencies, schools, doctors' surgeries and private businesses. The Community Drug Information and Public Libraries Project, a joint initiative between the State Library of NSW, Health Information Service and the NSW Premier's Department, recently chose a selection of our resources to be part of a package to go to over 500 libraries across NSW.

4.7.2

Exhibitions: In 2003 an exhibition on 'Drugs' will be presented by the Historic Houses Trust of NSW in association with NDARC. Mr Paul Dillon is a consultant to the exhibition and it is proposed that it will provide a broad overview of the historical, social, legal and medical perspectives of drug use in Australian society. There is every likelihood that this exhibition will be displayed nationally, thus providing a valuable opportunity to disseminate some of NDARC's research findings to the general public.

5. Building capacity to undertake research and disseminate knowledge

This term of reference addresses the need to make progress in the building of the national capacity and expertise required to undertake research and the development of projects in the area of prevention, treatment and workforce development regarding harmful drug use and dissemination of knowledge and information.

5.1 Number of new researchers per year working on Centre projects

The numbers of staff per year working on projects in the Centre for the financial years of the Review (1998 = 31, 1999 = 29, 2000 = 42, and for 2001 = 49) are presented in Appendix 6. The current year staffing of 53 positions is presented below.

Staff List 2002

Richard P. Mattick	Director and Professor
<vacant>	Deputy Director and A/Professor
Shane Darke	Associate Professor
Jan Copeland	Senior Lecturer
Kate Dolan	Senior Lecturer
Maree Teesson	Senior Lecturer
Louisa Degenhardt	Lecturer
Erol Digiusto	Lecturer
Wendy Swift	Lecturer
Joanne Ross	Lecturer
Anthony Shakeshaft	NH&MRC Clinical Research Fellow
Nick Lintzeris	NH&MRC Clinical Research Fellow (currently based at the National Addiction Centre, London)
Paul Adamson	IT Officer
Eva Congreve	Archivist
Paul Dillon	Media Liaison Officer/Information Manager
Chris Doran	Health Economist
Marian Shanahan	Health Economist
Peter Lawrinson	Senior Research Officer
Greg Martin	Senior Research Officer
Susannah O'Brien	Senior Research Officer
Fiona Shand	Senior Research Officer
Libby Topp	Senior Research Officer
Anne Maree Weatherall	Senior Research Officer
Linette Collins	Senior Research Officer
Heli Wolk	Professional Officer
Lucy Burns	Doctoral Student
Carolyn Day	Doctoral Student
Amanda Reid	Doctoral Student

Claire Thetford	Doctoral Student
Emma Black	Research Officer
Courtney Breen	Research Officer
Elizabeth Conroy	Research Officer
Sandra Fairbairn	Research Officer
Julia Fawcett	Research Officer
Saul Gerber	Research Officer
Jenny Gates	Research Officer
Nicky Henderson	Research Officer
Kate Hetherington	Research Officer
Sharlene Kaye	Research Officer
Erin Kelly	Research Officer
Jo Kimber	Research Officer
Etty Matalon	Research Psychologist
Katherine Mills	Research Officer
Heather Niven	Research Officer
Kate Pryce	Research Officer
Heather Proudfoot	Research Officer
Amanda Roxburgh	Research Officer
James Shearer	Research Officer
Evelyn Wilhelm	Research Officer
Anna Williamson	Research Officer
Bethany White	Research Officer
Julie Hodge	Centre Receptionist
Josephina Kim	Personal Assistant to the Director

Conjoint Appointment

Andrea Mant	Associate Professor
Alex Wodak	Senior Lecturer
James Bell	Senior Lecturer
Catherine Spooner	Senior Lecturer

Visiting Fellows

Robert Ali	Visiting Fellow
Ross Coomber	Visiting Fellow
Linda Gowing	Visiting Fellow
Wayne Hall	Visiting Professor
John Howard	Visiting Fellow
Nadia Solowij	Visiting Fellow
Ingrid Van Beek	Visiting Fellow
Deborah Zador	Visiting Fellow

5.2 Number of postgraduate students under Centre supervision

As noted earlier, an important part of NDARC's activity is to supervise students undertaking postgraduate degrees. There have been 28 PhD candidates graduated or in progress. There are 10 masters/honours students.

- Specifically, seventeen PhD candidates have completed studies since NDARC began operation, with eight of these completing their research and graduating in the

past five years. Two masters students and three honours students also successfully completed work toward their degrees in this review period. These students are listed below, along with their research thesis title.

- Currently, sixteen postgraduates, 11 enrolled in a PhD candidature, and five enrolled in Masters degrees, are currently being supervised by the academic staff at NDARC. These students are listed below, along with their research thesis title.

Past PhD Candidates

Kate Dolan: HIV in Australian prisons: Transmission, risk behaviours and prevention (1997).

Margaret Cooke: Barriers to the systematic provision of smoking cessation education during pregnancy (1998).

Rebecca McKetin: Cognitive functioning and psychological morbidity among illicit amphetamine users (1998).

Jo Ross: Benzodiazepine use among heroin users in Sydney, Australia (1998).

Catherine Spooner: Nature and treatment of psychoactive substance use disorders among adolescents (1999).

Wendy Swift: Patterns and correlates of cannabis dependence (1999).

Libby Topp: Nature of the amphetamine dependence syndrome (1999).

Louisa Degenhardt: Co-morbidity between substance use and mental health in Australia: Relationship of alcohol, tobacco and cannabis use with other substance use and mental disorders (2001).

Past Masters Students:

Jenny Gates: Risk factors for hepatitis C among NSW prison inmates (2002).

Linette Collins: Police activity at heroin overdoses (2002).

Past Honours Students:

Kerry Taylor: Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls (1998).

John Marsh: Attention and memory in cannabis users: Comparison with non-drug-using controls (1999).

Neil Simon: Effects of "ecstasy" use on memory function (2000).

Current PhD candidates:

Lucy Burns: Relationship between alcohol use disorders, anxiety and depression.

Carolyn Day: Blood borne viruses and injecting drug use.

Neil Donnelly: Applied statistical methods in pharmaco-epidemiology in primary care.

Sharlene Kaye: Patterns and harms of injecting and non-injecting cocaine use.



Jo Kimber: Health services evaluation.

Peter Lawrinson: Development of a brief treatment outcome measure for alcohol and other drug treatment services.

Greg Martin: Brief motivational interventions for adolescent cannabis users.

Heather Proudfoot: Treatment seeking for alcohol use disorders.

Amanda Reid: Adolescent cannabis risk-perception.

Clare Thetford: Childbearing decision-making among hepatitis C positive women.

Jan Bashford: Development of cannabis screening questionnaire.

Current Masters students: Degree

Louisa Degenhardt: Master of Clinical Psychology

Fiona Shand: Master of Clinical Psychology

Susannah O'Brien: Master of Clinical Psychology

Courtney Breen: Master of Public Health

Bethany White: Master of Public Health

5.3 Centre staff editorial responsibilities for international peer-reviewed journals

There is extensive involvement in peer-reviewed journals.

NDARC houses the Editorial Office of the international peer-reviewed journal, the *Drug and Alcohol Review* and Australasian Editorial Office of the international peer-reviewed journal, *Addiction*.

NDARC staff have taken on a substantial role nationally and internationally in the area of the management of international peer-reviewed paper and electronic journals. They fulfil the following editorial roles on journals, separate from the significant contributions which they make as referees to these and other journals.

Addiction

Professor Wayne Hall, Australasian Regional Editor

Professor Richard P Mattick, Assistant Editor

Associate Professor Shane Darke, Assistant Editor

Dr Jan Copeland, Assistant Editor

Dr Michael Lynskey, Assistant Editor

Dr Alex Wodak, Assistant Editor

Addiction Abstracts

Professor Wayne Hall, Member of the Editorial Board

Dr Alex Wodak, Member of International Advisory Board

Applied Health Economics and Health Policy Journal

Ms Marian Shanahan, Member of Editorial Board

Current Therapeutics

Dr Alex Wodak, Member of Editorial Board

Drug and Alcohol Dependence

Associate Professor Shane Darke, Assistant Editor

Drug and Alcohol Review

Professor Richard P Mattick, Deputy Editor 1995-2000, Executive Editor 2000 - current, Member of Editorial Board

Dr Alex Wodak, Member of Editorial Board

Heroin Addiction and Related Clinical Problems

Dr James Bell, Member Editorial Board

International Journal of Drug Policy

Dr Kate Dolan, Assistant Editor

Dr Alex Wodak, Member of Editorial Board

Journal of Drug Education and Awareness

Mr Paul Dillon, Associate Editor

Journal of Substance Abuse Treatment

Dr Jan Copeland, Assistant Editor

Modern Medicine

Dr Alex Wodak, Member of Editorial Board

Patient Management

Dr Alex Wodak, Member of Editorial Board

Cochrane Review Group for Drugs and Alcohol, Rome

Professor Richard P Mattick, Editor (1998 - current)

6. Mechanisms for disseminating research and informing policy development

6.1 Seminars on research findings and policy analysis

A key activity of NDARC is the dissemination of the research findings. Seminars, external lectures, workshops and presentations are an effective way of accessing a range of groups in the community. Full details of staff presentations since 2000 can be found in Appendix 7 and 8.

NDARC staff continue to be asked to speak at a variety of forums. Presentations have been commissioned by such diverse groups as a number of NSW Area Health Services, the Australian Medical Association, the NSW Police Service, the Commonwealth Department of Health and Ageing, as well as a range of government and non-government agencies, schools and peak bodies.

The NSW Drug Summit and the development of the Community Drug Action Teams (CDATs) have led many community groups to attempt to provide good quality drug information to audiences including business leaders, parents and young people. Mr Paul Dillon, and other members of NDARC staff have given presentations to schools, community groups and other interested parties on a variety of drug issues. Youth drug use, cannabis use, and current drug trends have proved the three most popular topics with these audiences.



The NDARC Annual Symposium has proved extremely popular with workers from within the alcohol and other drug field. With a focus on current research conducted by NDARC staff, including PhD students, the last Annual Symposium was entitled 'New Research: An Update of Current Projects' and attracted an audience of almost 200 registrants.

The NDARC Seminar Series continues to include open seminars on a monthly basis alternating with in-house seminars. These open seminars are an effective way of disseminating the results of current projects conducted by both NDARC staff and other organizations. The in-house seminars are intended as informal presentations of ongoing research projects with a view to obtaining feedback on progress and also as a means of facilitating discussion and teamwork among staff.

6.2 Literature reviews with implications for policy development

NDARC staff have been successful in producing influential and timely literature reviews from the early days of the Centre's operations. The list of publications should be consulted, and some indicative reviews are specified below.

- Systematic literature reviews of methadone, naltrexone, buprenorphine, LAAM and other pharmacotherapies have been produced in a substantial book published internationally (Ward et al., 1998), and these reviews have been directly relevant to policy development at a departmental and service provider level;
- Extensive work on the health effects of cannabis and on cannabis and psychosis have been published in book form and in journals (Hall and colleagues), with significant impact on the national and international understanding of these important issues;
- A review of the evidence on the neurotoxic effects of MDMA has been published in a prestigious international journal;
- Timely national review of the effectiveness of naltrexone and rapid opioid detoxification was produced to meet government need for balanced advice (Mattick and colleagues);
- Two Cochrane Collaboration reviews were recently submitted and accepted by the Rome Cochrane Review Group on Alcohol and Drugs (Mattick et al., 2002);
- Reviews of management of alcohol abuse and dependence form an important part of the current workplan (Shand, Gates, Fawcett, in preparation).

6.3 Regular briefings and submissions to government and parliamentary inquiries

See 6.4.

6.4 Membership of state and national policy committees

NDARC staff have a substantial involvement in numerous state/territory and national committees. Details are listed below.

Congreve, Eva

- Member, Expert Reference Group for the New South Wales Community Drug Information and Public Libraries Project, 2002 – current.

Copeland, Jan

- New South Wales Department of Health Cannabis Strategy Steering Committee, 2000;
- New South Wales Drug and Alcohol Training Providers Forum to identify current workforce development and training initiatives, 2002;
- New South Wales Department of School Education's Advisory Committee on the cannabis education strategy;
- Queensland Health Department's Women's Services Strategic Planning Group, 2001;
- Intergovernmental Committee on Drugs Working Party on national minimum datasets, 1998 – current; and
- Member, Steering Committee of the Collaborative Research Unit, NSW Department of Juvenile Justice, 1999.

Degenhardt, Louisa

- Member of NSW Health's Expert Advisory Committee on Heroin Overdose, 2001 – current;
- Member of the Alcohol and other Drugs Council of Australia Research Reference Group, 2001 – current.

Dillon, Paul

- Member, National Project Reference Group for the "Candidly Cannabis" Education Kit, 2001 – current;
- Member, National Expert Working Group for the School Drug Education Information (SDEI) Project, 2001 – current;
- Member, National Working Group on Performance and Image Enhancing Drugs, 2000.

Dolan, Kate

- Member, Advisory Group to oversee the implementation of the NSW Heroin Overdose Prevention and Management Strategy, NSW Department of Health, 2001;
- Member, NSW Ministerial Advisory Committee on Hepatitis C infection, 2001;



- Member, ANCAHRD CTARC Working Group on Best Practice Guidelines for Prevention of HIV/AIDS, Hepatitis C and Related Diseases in Correctional Institutions, 2000;
- Member, Diversion Programs Evaluation Advisory Committee (Cannabis Cautioning Scheme) with the Drug Programs Coordination Unit of the NSW Police Service, as part of the Drug Summit Action Plan, 2000;
- Advisor, Victorian Department of Justice with respect to their prison methadone program, 2000; and
- Member, Melbourne's Drug Forum examining new approaches to drug problems.

Hall, Wayne

- Member, Australian National Council on Drugs, March 1998 to March 2001;
- Member, NSW Premier's Expert Advisory Group on Drugs, December 1999 to August 2001;
- Chair, NSW Premier's Working Group on the Medicinal Uses of Cannabis. December 1999 to August 2000;
- Member, National Expert Advisory Committee on Illicit Drugs, 1998-2002;
- Member, Drug Utilization Subcommittee, Pharmaceutical Benefits Advisory Committee, Commonwealth Department of Health and Ageing, 2001 – current.

Mattick, Richard P.

- Scientific adviser, Western Australian Community Drug Summit, Perth, Australia, 12-17 August, 2001;
- Member, New South Wales Premier's Expert Advisory Committee on Drugs, 2001 – current;
- Chair, Evaluation Committee for the Evaluation of the New South Wales Medically Supervised Injecting Centre, 2001 – current;
- Member, Northern Territory Ministerial Task Force on Illicit Drugs, 2001 – 2002; and
- Member, New South Wales Drug and Alcohol Clinical Advisory Group, 2002 – current.

Shakeshaft, Anthony

- Delegate to the Intergovernmental Committee on Drugs' National Alcohol Strategy priority setting programme.

Teesson, Maree

- Member of the Data Analysis and Outputs Committee for the Commonwealth Department of Human Services and Health National Survey of Mental Health and Wellbeing;
- External Evaluator for the Commonwealth Department of Human Services and Health Youth Suicide Prevention Projects, 1997 – 1999;

- Member of the Expert Working Group on National Standards for Mental Health Services, Commonwealth Department of Human Services and Health;
- Member of the Research Reference Group for the Alcohol and Other Drugs Council of Australia, 1998 – 2002;
- Member of the Commonwealth Advisory Committee on Homelessness, Commonwealth Department of Family and Community Services, 1998 – 2000;
- Advisor to the Federal Minister for Family and Community Services, 1998 – 2000;
- Member of the Expert Working Group on Dual Diagnosis, New South Wales Department of Health, Mental Health Branch, 1998 – 2000;
- Member of the Expert Working Group on Early Intervention for Psychosis, New South Wales Department of Health, Mental Health Branch, 1998 – 2000;
- Member of the Expert Working Group on Treatment Planning for Drug and Alcohol Services in NSW, New South Wales Department of Health, Drug Strategy Branch, 1999 – 2001.

Topp, Libby

- Member of NSW Department of Health Psychostimulant Strategy Steering Committee, 2001 – current;
- Member of Advisory Committee for QLD Crime and Misconduct Commission/QLD Health collaborative project Amphetamine Use in QLD, 2002 – current;
- Member of National Steering Committee for Update of NDS Monograph on Models of Treatment and Care for Psychostimulant Users, 2001 – current;
- Member of National Steering Committee for joint venture between NSW Police and NSW Department of Education to update school crime prevention education programs, 2002 – current;
- Member of National Steering Committee for AIVL Psychostimulant Project, 2002 – current; and
- Member of Advisory Committee for Turning Point Education and Training development of a manual on management of amphetamines for Drug and Alcohol Workers 2002 – current.

6.5 Provision of information on drug-related harms and intervention strategies

NDARC's Information/Media Liaison Manager, Mr Paul Dillon, has continued to develop positive relationships with journalists representing a variety of media. He, along with many other members of staff, has conducted many inter-



views responding to media interest in news stories of the day.

Mr Paul Dillon continues to host a regular spot on the ABC Youth Network, Triple J, where he discusses a range of drug issues. This program has now been running for almost seven years and has become so popular that an internet forum called 'Doing Drugs with Paul Dillon' has been constructed on the ABC webpage where people can post questions and comments around drug issues. This has also proven to be a great success and is a novel and effective way of providing accurate and up-to-date information to young people. Mr Dillon also continues to write regularly for a number of street newspapers and internet sites.

Apart from general media dissemination it remains vital that research findings are able to be accessed by drug and alcohol workers and policy makers. *CentreLines* has continued to expand its readership across Australia and internationally and is currently being received by over 1200 subscribers. *CentreLines* is a joint newsletter from NDARC and the Perth Centre, NDRI, published bi-monthly, alternating between each centre. NDARC issues primarily have a treatment focus, while NDRI issues take a closer look at prevention, reflecting the research direction of each centre.

NDARC is continuing to maintain a webpage on the Medical Faculty server of the University of New South Wales. The webpage lists as main entry points NDARC's mission statement; members of staff with their e-mail address and short curriculum vitae; current research projects and a number of completed projects; monograph and technical reports with abstracts or prefaces where they are available; as well as a news section featuring coming events such as seminars and symposia. Press releases are also included here. Our webpage is constantly evolving and is becoming increasingly popular among alcohol and other drug workers, policy makers and member of the general public alike. One of the new pages on our site deals with drug information. In response to requests we have developed Fact Sheets on a number of different topic areas which can be easily downloaded. Some of these include: amphetamines; ecstasy; the medical use of cannabis; drug use amongst secondary students; and nitrous oxide. NDARC's web page is located at <http://ndarc.med.unsw.edu.au>

6.6 Evidence from stakeholders of receipt of information in a timely fashion

The performance indicator can be addressed directly with stakeholders.

7. NDARC relationships / collaborative arrangements with key organisations

7.1 Confirmation from various groups that they feel part of a collaboration

NDARC has developed and fostered collaborative links with numerous scientists from a range of government and non-government organisations both nationally and internationally.

7.1.1

Formal collaborative research arrangements.

NDARC has formal collaborative arrangements with four other research centres one associated teaching hospital, and with one international organisation:

- Drug and Alcohol Services Council (DASC), SA Department of Human Services;
- National Drug Research Institute (NDRI), Curtin University;
- Queensland Alcohol and Drug Research and Education Centre (QADREC), University of Queensland;
- Turning Point Alcohol and Drug Centre, Inc, Victoria;
- The Langton Centre of the Prince of Wales Hospital group is a dedicated associated teaching hospital of the UNSW with specific relationship with NDARC; and
- NDARC is a World Health Organization Collaborating Centre.

NDARC is currently negotiating to develop formal collaborative arrangements with two other important research centres.

7.1.2

Other collaborative research arrangements. NDARC has had collaborative arrangements with a number of national groups, including:

- **Medical organisations:** Australian Medical Association; Academic Unit of General Practice, Calvary Hospital;
- **Councils/Foundations/Associations:** ANCD; AIDS Council of NSW; Alcohol and Other Drugs Council of Australia; Alcohol and Drug Foundation of Australia; Damian Trimmingham Foundation Family Drug Support; NSW Users and AIDS Association;
- **Criminal justice groups:** Australian Bureau of Criminal Intelligence; Australian Institute of Criminology;
- **Research organisations:** National Centre for Epidemiology and Population Health, ANU; National

Centre in HIV Epidemiology and Clinical Research, UNSW; National Centre in HIV Social Research, UNSW; National Drug Research Institute, Curtin University; Australian Institute of Health & Welfare; Centre for Adolescent Health, University of Melbourne; MacFarlane Burnet Centre for Medical Research, Centre for Harm Reduction; Centre for Behavioural Research in Cancer, Anti-Cancer Council of Victoria; Department of Social and Preventive Medicine, University of Queensland, North Queensland Clinical School, Cairns; Queensland Alcohol & Drug Research & Education Centre; Queensland Centre for Schizophrenia Research; Queensland Institute of Medical Research;

- **Health services:** Warinilla Clinic, Adelaide, South Australia; Next Step, Perth; South Eastern Sydney Area Health Service, NSW; South Western Sydney Area Health Service, NSW; Central Sydney Area Health Service, NSW; Drug & Alcohol Department, Royal Prince Alfred Hospital; Greater Murray Area Health Service, NSW; Jacaranda Clinic, Liverpool, NSW; Kirketon Road Centre; Ryde Drug and Alcohol Service; St Vincent's Hospital; South East Sydney Area Health Service; Ted Noffs Foundation; We Help Ourselves, Sydney; Odyssey House;
- **Health economics research groups:** Centre for Health Economics Research & Evaluation, University of Technology, Sydney; Centre for Health Program Evaluation, Monash University;
- **Government departments:** Commonwealth Department of Health & Ageing, Drug Strategy and Public Health Social Marketing Branch, Pharmaceutical Benefits Branch, HIC; Commonwealth Attorney General's Department; NSW Attorney General's Department Crime Prevention Division; NSW Bureau of Crime Statistics and Research, NSW Attorney General's Department; NSW Health Department; NSW Ambulance Service; NSW Department of Corrective Services; NSW Department of Juvenile Justice; NSW Department of School Education; NSW Department of School Education and Training; Australian Customs Service; Australian Federal Police Service; NSW Police Service; Northern Territory Department of Health and Community Services; Queensland Health Department – Alcohol, Tobacco & Other Drug Services.

The international collaborative links are:

- Department of Epidemiology & Social Medicine, Montefiores Medical Centre, NY; Department of Psychology, University of Rhode Island; Institute of Psychiatry, London; Missouri Alcohol Research Centre;

National Addiction Centre in London; Programme on Substance Abuse, World Health Organisation, Geneva (WHO); UNDCP; University of Washington in Seattle; Virginia Polytechnic Institute and State University; Washington University, St Louis; and the World Bank.

During the period of review, NDARC staff were involved in a number of research projects that involved collaborating with researchers at the above centres/organisations. By way of example, an incomplete list of indicative projects has included:

- 1) The three-year *National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)* project with Dr Ali from the Drug and Alcohol Services Council (DASC) in Adelaide, Drs Ritter and Lintzeris from Turning Point in Melbourne, Dr Bell from the Langton Centre in Sydney, Dr Quigley from Next Step in Perth, A/Prof Glasgow and Dr Bammer from Australian National University in Canberra, Dr Hawken from Gold Coast District Health, Prof Saunders from the University of Queensland, and Prof White from University of Adelaide. Consultants to this project also included: Mr Phil Marshall (Panacea Research & Evaluation), Ms Marian Shanahan (Centre for Health Economics Research & Evaluation, University of Sydney), Mr Anthony Harris & Ms Elena Gospodarevskaya (Centre for Health Program Evaluation, Monash University), and Mr Alan Shiell (Department of Public Health & Community Medicine, University of Sydney). There was a large NDARC team involved and the staff had to liaise effectively with the investigators and the research staff in 15 trials in these states/territory.
- 2) *A magnetic resonance imaging study of brain structure and function in long term cannabis users* with Prof Hall from the Centre for Health Economics Research and Evaluation, University of Technology in Sydney; Dr P Ward from the School of Psychiatry, UNSW; Dr B Grenyer from University of Wollongong, and Mr R Peters from Macquarie University.
- 3) *The implications for health and law enforcement of the increased availability and use of potent forms of methamphetamine* with Mr Robert Rushby from Australian Customs Service, and Constable Jo Kenworthy from the NSW Police Service Crime Agencies.
- 4) *The evaluation of the Medically-Supervised Injecting Centre (MSIC)* with Prof John Kaldor and Ms Margaret MacDonald from NCHECR at the UNSW, Dr Don Weatherburn from BOSCAR, NSW Attorney General's, and Ms Helen Lapsley of the School of Community Medicine at the UNSW.

- 5) *A survey of alcohol and other drug use amongst NSW juvenile justice detainees* with Dr John Howard from Macquarie University, Mr T Keogh and Ms K Seidler from the Department of Juvenile Justice.
- 6) *A randomised controlled trial examining computer delivered brief intervention for alcohol problems in general practice* with Prof Mark Harris from Community Medicine at UNSW, Dr Alex Wodak from St Vincents Drug and Alcohol Services, A/Prof Robyn Richmond from Community Medicine at UNSW, and Prof Enrico Coiera from Centre for Health Informatics at UNSW.
- 7) *The causes, effects and implications of the heroin shortage in the ACT, NSW and Victoria* with Paul Deitze and Craig Fry from Turning Point in Melbourne, and Paul Williams and Maria Borzycki from the Australian Institute of Criminology).
- 8) *The development of a brief multi-dimensional instrument designed to measure outcomes for clients receiving alcohol and other drug treatment: The Brief Treatment Outcome Measure (BTOM)* with Dr Jennifer Gray, Dr Tony Gill, Devon Indig, and Antoinette Aloï from the NSW Health Drug Program Bureau.
- 9) *Risks for Hepatitis C transmission: transition and initiation to injecting drug use among youth in a range of injecting drug user networks* with Prof Sue Kippax from the National Centre for HIV Social Research, Ms Annie Madden from IV League, and Dr John Howard from the Ted Noffs Foundation.
- 10) *A pilot study looking at the effectiveness of bupropion for tobacco smoking cessation among offenders* with Drs Alex Wodak and Kate Wilhelm from St Vincents Drug and Alcohol Services, A/Prof Robyn Richmond from Community Medicine at UNSW, and Tony Butler from Corrective Health Services.
- 11) *Longitudinal study examining the effect of cannabis use among persons with psychosis* with Prof Chris Tennant and Dr Louise Nash from the Royal North Shore Hospital.
- 12) *A series of collaborative research efforts examining drug use and co-morbidity among a cohort of adolescents in Victoria* with Prof George Patton and Ms Carolyn Coffey from the Centre for Adolescent Health, University of Melbourne.
- 13) *The Illicit Drug Reporting System* reporting trends in illicit drug use has required extensive collaboration with research groups and government departments in each Australian jurisdiction since its inception, and is a model project of the successful and productive collaborations in which NDARC can engage.

7.2 Evidence of collaborative projects with other research groups.

During the same period there have been a number of projects with scientists from international centres/organisations. These included:

- collaboration with Dr Michael Lynskey from the University of Washington on the Australian Treatment Outcome Study (ATOS) and a project titled *Substance use, dependence and treatment seeking in the United States and Australia: A cross-national comparison*;
- collaboration between Jan Copeland, Prof Roger Roffman from the University of Washington, and A/Prof Robert Stephens from Virginia Polytechnic & State University, comparing two brief interventions for cannabis problems among young offenders in NSW;
- collaboration between Prof Mattick and Prof Nick Heather from the University of Newcastle, UK investigating the efficacy of moderation-oriented cue exposure for problem drinkers using a randomised controlled trial;
- collaboration between Dr Louisa Degenhardt, Prof Richard P. Mattick, Mr Peter Lawrinson, Ms Heather Niven from NDARC and Dr Elliot Nelson from the University of Washington and Dr Michael Lynskey from the University of Washington examining the association between childhood trauma and opioid dependence with collection and analysis of genetic information to assess possible genetic mediation.

8. Effectiveness of NDARC's organisation and management structures

8.1 Providing information such as workplans and annual reports and other performance and research updates

See earlier.

8.2 Regular liaison, informal/formal

See earlier.



9. 'Core funding arrangements' and alternative funding arrangements

This term of reference addresses the efficiency and cost-effectiveness of the existing 'core funding arrangements' under the program and proven ability to generate alternative funding arrangements to enhance current Commonwealth core funding.


9.1 Information provided by the Centre concerning its funding

NDARC provides quarterly reports to the Board of Management, and the University sends formal reports of expenditure against budget allocations on a regular basis as specified in the contracts formed with the UNSW.

Annual reports set out all funding sources, project titles, amounts secured and expended for all NDARC projects.

9.2 Success in obtaining external funding to conduct additional projects

NDARC has been successful in obtaining external funding to conduct additional projects to add value to the Commonwealth investment through baseline core funding. The size of the Centre allows it to be responsive to requests in a timely fashion and to have the expertise to deliver products of quality. The investment from the Commonwealth has paid dividends to the Department of Health and Ageing.



10. Future operation under potential policy changes

This term of reference addresses the future operation of NDARC in the context of potential policy changes affecting the National Drug Strategic Framework.

10.1 Capacity for innovation and foresight in addressing drug and alcohol use

NDARC has, as noted elsewhere, led the field in Australia in terms of research, and delivering information for the use of policy makers and politicians. NDARC has a flexible staffing with broad ability and expertise and an interest in changing and reforming the directions and the activities of the Centre to meet new challenges.



Appendices

-
1. Externally funded NDARC research projects 2002
 2. Research appearing in prestigious journals and other publications
 3. Books/book chapters/government reports/conference proceedings
 4. Technical Reports
 5. Monographs
 6. Staff Lists 1998 – 2001
 7. Appearances of personnel at conferences both nationally and internationally
 8. Appearances of personnel at seminars and workshops both nationally and internationally
-

Externally funded NDARC research projects 2002

PROJECT TITLE	FUNDING SOURCE	TOTAL AWARD (\$)	EXPENDITURE 2001	EXPENDITURE 2002
Illicit Drug Reporting System	CDHAC	1,333,354 (5 years)	291,268	290,380
Illicit drug statistical analysis	CDHAC	755,600 (5 years)	139,198	206,034
Research support	DETYA	419,880 (2 years)	215,000	204,880
Estimating the demand for new pharmacotherapies within the heroin dependent population in Australia	CDHAC	39,561	28,459	7,437
Follow-up study of subjects in a randomized controlled trial of methadone treatment in prison	NHMRC	121,246 (3 years)	32,260	60,027
A cost-effectiveness analysis of prison methadone programs in Australia	NHMRC	61,157	0	38,171
Extension of Addiction Treatment Outcome Study (ATOS)	CDHAC	615,587 (3 years)	204,278	156,425
Addiction Treatment Outcome Study (ATOS)	NHMRC	430,264 (3 years)	161,250	161,206
Adolescents' attitudes and beliefs about cannabis and school drug education	NSW DEAT	27,437	12,539	7,969
Adolescent cannabis check up and intervention trial	CDHAC	330,257 (3 years)	131,815	83,494
Brief cannabis intervention for primary health care providers	CDHAC	169,206	42,804	32,896
Feasibility of long-term follow-up of NEPOD cohort	NHMRC	60,000	10,188	49,812
Expansion of the Illicit Drug Reporting System	NDLERF	235,630 (2 years)	117,130	60,609
Designer drugs component of the Illicit Drug Reporting System	NDLERF	85,886 (2 years)	35,493	31,894
The development of a comorbidity monograph	CDHAC	99,849	48,339	32,646
A trial of two brief interventions for cannabis problems among young offenders in NSW	NSW AGD	313,207 (3 years)	50,677	97,140
Randomized controlled trial of naltrexone, methadone, alcohol and other drug treatment programs in NSW prisons	NSW CHS	259,176 (3 years)	33,471	75,803
Evaluation of the Medically Supervised Injecting Centre	DH	270,497 (2 years)	70,138	116,925
Cost analysis of methadone maintenance treatment and cytokine expression in cerebral arteriovenous malformations	DH	100,000 (2 years)	76,715	23,285
Risks of injecting: infectious disease	ANCD	84,473	21,441	46,770

PROJECT TITLE	FUNDING SOURCE	TOTAL AWARD (\$)	EXPENDITURE 2001	EXPENDITURE 2002
Development of a brief multi-dimensional instrument to measure outcomes of alcohol and other drug treatments	DH	343,700	64,358	135,045
Development of appropriate interventions for amphetamine users	CDHAC	148,107 (1.5 years)	0	94,554
Quality assurance in the treatment of alcohol dependence	CDHAC	160,604 (1.5 years)	0	94,210
Cost analysis of pharmacotherapies for nicotine and alcohol dependence	CDHAC	260,121 (1.5 years)	0	151,920
Drug use and HIV HCV prevalence among rural injecting drug users	CDHAC	20,000 (1.5 years)	0	14,776
Physical and psychological health of cocaine users	CDHAC	58,909 (1.5 years)	0	36,828
Web-based intervention: review of the evidence	CDHAC	13,655	0	13,655
Monitoring of global drug indicators for NSW	NSW CO	34,216	0	27,656
Review of correctional services responses to reduce the initiation level and impact of drug use within Australian prisons	ANCD	40,000	0	13,127
Extension of IDU survey of the Illicit Drug Reporting System	NDLERF	161,275	0	36,108
The causes, effects and implications of the heroin drought in ACT, NSW and Vic	NDLERF	367,585	0	106,532
Illicit drug use and driving among injecting drug users	NDLERF	75,553	0	47,530
Psychosocial interventions for methadone/buprenorphine project	TP	6,318	0	6,318
The emergence of potent forms of methamphetamine in Sydney	NDLERF	245,781	0	0
NEPOD dissemination strategy	CDHAC	99,752 (1.5 years)	0	60,095
Study of temazepam injecting in Australia	CDHAC	55,497 (1.5 years)	0	30,305
Program of International Research and Training (PIRT)	CDHAC	60,000	0	0
Validity and reliability of a cannabis questionnaire	CDHAC	20,000	0	0
Recreational pharmaceutical drug use amongst party drug users	CDHAC	49,956	0	6,891
Information about party drugs	CDHAC	49,956	0	6,781
An examination of the feasibility of conducting Australian trials of therapeutic cocaine vaccines	CDHAC	20,000	0	6,855
Patterns of injecting drug use, risk behaviours and blood-borne viral incidence following changes in the drug market	DH	49,843	0	0
Adolescents' beliefs about psychostimulants and psychostimulant drug education	NSW DEAT	34,598	0	0

PROJECT TITLE	FUNDING SOURCE	TOTAL AWARD (\$)	EXPENDITURE 2001	EXPENDITURE 2002
Effectiveness of HIV prevention and care interventions for young and new injecting drug users	WHO	6,580	0	0
Identifying strategies to achieve behaviour change among providers of health care services	NHMRC	12,500	0	0
SUB TOTALS FOR PROJECTS (OVER 1 TO 5 YEARS)		8,206,593	1,786,821	2,672,989
INFORMATION DISSEMINATION	FUNDING SOURCE	TOTAL AWARD (\$)	EXPENDITURE 2001	EXPENDITURE 2002
The health and psychological consequences of cannabis use (update)	CDHAC	47,942	31,325	16,617
INFRASTRUCTURE	FUNDING SOURCE	TOTAL AWARD (\$)	EXPENDITURE 2001	EXPENDITURE 2002
Support for research infrastructure	DETYA	478,990 (2 years)	219,103	259,887
SCHOLARSHIPS	FUNDING SOURCE	TOTAL AWARD (\$)	EXPENDITURE 2001	EXPENDITURE 2002
Postgraduate scholarship	DH	131,700 (3 years)	30,213	28,846
Postgraduate scholarships (2)	CDHAC	215,697 (5 years)	36,584	35,630
Post Doctoral Research Scholarship: Computer delivered brief intervention for alcohol abuse	NHMRC	221,516 (4 years)	23,372	59,880
Neil Hamilton Fairley Fellowship: Examining pharmacotherapy treatment systems for heroin dependence	NHMRC	361,590 (4 years)	0	124,601
SUB-TOTALS FOR SCHOLARSHIPS (OVER 3 TO 5 YEARS)		930,503	90,169	248,957
GRAND TOTALS OF AWARDS TO NDARC (OVER 1 TO 5 YEARS)		9,664,028	2,127,418	3,198,450

Glossary

ANCD	Australian National Council on Drugs	NHMRC	National Health and Medical Research Council
CDHAC	Commonwealth Department of Health and Aged Care	NSW AGD	NSW Attorney General's Department
DETYA	Department of Education, Training and Youth Affairs	NSW CO	NSW Cabinet Office
DH	Department of Health, NSW	NSW CHS	NSW Corrections Health Service
NDLERF	National Drug Law Enforcement Research Fund	NSW DEAT	NSW Department of Education and Training
		TP	Turning Point Alcohol and Drug Centre
		WHO	World Health Organisation

Research appearing in prestigious journals and other publications

1987

1. **Crawford, J. & Heather, N.** (1987). Public attitudes to the disease concept of alcoholism. *International Journal of the Addictions* 22, 1129-1138.
2. **Prescott, J. & Saunders, J.** (eds) (1987). Proceedings of the Conference on Early Detection and Intervention for Persons with Harmful Alcohol and Drug Use, University of Sydney, December, 1985. *Australian Drug and Alcohol Review* 6, 283-358.
11. **Heather, N.** (1989). Disulfiram treatment for alcoholism: Deserves re-examination. *British Medical Journal* 299, 471-472.
12. **Heather, N.** (1989). Problem drinking as a form of learned behaviour. A reply to Gorman. *British Journal of Addiction* 84, 847-848.
13. **Heather, N.** (1989). Problem drinking as a form of learned behaviour: A final rejoinder to Gorman and Edwards. *British Journal of Addiction* 85, 617-620.

1988

3. **Dzialdowski, A., Heather, N., & Crawford, J.** (1988). Perceptions of drinkers and abstainers in a sample of Scottish adults. *Alcohol and Alcoholism* 23, 7-16.
4. **Greeley, J., Le A.D., Poulos, C.X., & Cappell, H.** (1988). Paradoxical analgesia induced by naloxone and naltrexone. *Psychopharmacology*, 96, 36-39.
5. **Heather, N.** (1988). Lessons from a controlled evaluation of a general practice minimal intervention for problem drinking. *Australian Drug and Alcohol Review* 7, 317-328.
6. **Mattick, R.P. & Peters, L.** (1988). Treatment of severe social phobia: Effects of guided exposure with and without cognitive restructuring. *Journal of Consulting and Clinical Psychology* 56, 251-260.
7. **Prescott, J.** (1988). Random breath testing in NSW and its implications for drug driving legislation. *Australian Drug and Alcohol Review* 7, 243-250.
8. **Prescott, J.** (1988). Research issues and priorities in methadone maintenance. *Australian Drug and Alcohol Review*, 7, 375-381.
14. **Heather, N. & Tebbutt, J.** (1989). Definitions of non-abstinent and abstinent categories in alcoholism treatment outcome classifications. *Drug and Alcohol Dependence* 24, 83-93.
15. **Mattick, R.P., Peters, L., & Clarke, J. C.** (1989). Exposure and cognitive restructuring for social phobia: A controlled study. *Behavior Therapy* 20, 3-23.
16. **Miller, W.R.** (1989). Raiding the lost ark: Do we need new models to study behaviour change in spiritual contexts? *Spiritual and Religious Issues in Behaviour Change* 4, 6-15.
17. **Webster, I.W. & Richmond, R.L.** (1989). Utilisation of 'Smokescreen' smoking-cessation programme (letter to the editor). *Medical Journal of Australia* 151, 487-488.

1990

18. **Chesher, G., & Wodak, A.** (1990). Evolving a new policy for illicit drugs. *Journal of Drugs Issues* 20, 555-561.
19. **Darke, S. & Hall, W.** (1990). The injecting and sexual behaviour of intravenous drug users (Letter to the editor). *Medical Journal of Australia* 153, 43.
20. **Darke, S., Hall, W., & Carless, J.** (1990). Drug use, injecting practices, and sexual behaviour of opioid users in Sydney, Australia. *British Journal of Addiction* 85, 1603-1609.
21. **Darke, S., Hall, W., & Carless, J.** (1990). The injecting and sexual behaviour of intravenous drug users in Sydney (Letter to the Editor) *Medical Journal of Australia* 152, 488.

1989

9. **Greeley, J.** (1989). Pavlovian conditioning and pain regulation: Insights from pharmacological conditioning with morphine and naloxone. *Biological Psychology* 28, 41-65.
10. **Heather, N.** (1989). Psychology and brief interventions. *British Journal of Addiction* 84, 357-370.

22. **Edwards, P., Wodak, A., Cooper, D.A., Thompson, I.L., & Penny, R.** (1990). The gastroenterological manifestation of AIDS. *Australian and New Zealand Journal of Medicine* 20(2), 141-148.
23. **Elkins, L. & Richmond, R.** (1990). Control can go up in smoke. *Diabetes Conquest, Spring*, 6-9.
24. **Greeley, J. & Westbrook, R.F.** (1990). Some effects of exposure to a heat stressor upon the rat's subsequent reactions to that stressor. *Quarterly Journal of Experimental Psychology*, 42B, 241-265.
25. **Guinan, J.J., Darke, S., & Gold, J.** (1990). The epidemiology of HIV infection and risk behaviour of intravenous drug users: A reply to Donovan et al. (Letter to the editor). *Medical Journal of Australia* 152, 499.
26. **Heather, N.** (1990). DRAMS A reply from Nick Heather. *Drug and Alcohol Review* 9, 290.
27. **Heather, N. & Bradley, B.P.** (1990). Cue exposure as a practical treatment for addictive disorders: Why are we waiting? *Addictive Behaviours* 15, 335-337.
28. **Heather, N. & Greeley, J.** (1990). Cue exposure in the treatment of drug dependence: The potential of a new method for preventing relapse. *Drug and Alcohol Review* 9, 155-168.
29. **Heather, N., Kisson-Singh, J., & Fenton, G.W.** (1990). Assisted natural recovery from alcohol problems: Effects of a self-help manual with and without supplementary telephone contact. *British Journal of Addiction* 85, 1177-1185.
30. **Homel, P., Flaherty, B., Reilly, C., Hall, W., & Carless, J.** (1990). The market position of cocaine among young Australian adults. *British Journal of Addiction* 85, 891-897.
31. **Mant, A., Kehoe, L., Eyland, E.A., Purcell, C., Pond, C.D., Hewitt, H., & Saunders, N.A.** (1990). Use of medications by the elderly. *Australian Family Physician* 9, 511.
32. **Mant, A. & Saunders, N.A.** (1990). Polypharmacy in the elderly (letter to the editor). *Medical Journal of Australia* 152, 612.
33. **Mattick, R.P., Andrews, G., Hadzi-Pavlovic, D., & Christensen, H.** (1990). Treatment of panic and agoraphobia: An integrative review. *Journal of Nervous and Mental Disease* 178, 567-576.
34. **Mattick, R.P. & Grenyer, B.F.** (1990). Quality assurance in drug and alcohol treatment: The development of standards for treatment content. *Drug and Alcohol Review* 9, 75-79.
35. **Miller, W.R.** (1990). Spiritually: The silent dimension in addictions research. *Drug and Alcohol Review* 9, 259-266.
36. **Morlet, A., Darke, S., Guinan, J.J., Wolk, J., & Gold, J.** (1990). Intravenous drug users who present to the Albion Street (AIDS) Centre for diagnosis and management of human immunodeficiency virus infection. *Medical Journal of Australia* 152, 78-80.
37. **Prescott, J.** (1990). Kava use in Australia. *Drug and Alcohol Review* 9, 325-331.
38. **Richmond, R.L. & Heather, N.** (1990). General practitioner interventions for smoking cessation: Past results and future prospects. *Behaviour Change* 7, 110-119.
39. **Richmond, R.L. & Webster, I.W.** (1990). Which anti-smoking programme? (letter to the editor). *Medical Journal of Australia* 154, 367.
40. **Richmond, R.L., Webster, I., & Heather, N.** (1990). *Drug Use Amongst Youth: Patterns, Psychological Factors and Prevention*. Document prepared for the Parliamentary Standing Committee on Social Issues.
41. **Swift, W., Williams, G., Neill, O., & Grenyer, B.** (1990). Prevalence of minor psychopathology in opioid users seeking treatment. *British Journal of Addiction* 85, 629-634.
42. **Westbrook, R.F. & Greeley, J.** (1990). Some effects of the opioid antagonist, naloxone, upon the rat's reactions to a heat stressor. *Quarterly Journal of Experimental Psychology* 42b, 1-40.
43. **Wodak, A.** (1990). Alcohol and women's health: Cause for concern? *Healthright* 9(3), 17-22.
44. **Wodak, A.** (1990). Heroin legalisation: Totem and taboo revisited. *Modern Medicine* 3(5), 76-95.
45. **Wodak, A.** (1990). Alcoholism – what can the GP do? *Modern Medicine* 33(7), 76-95.
46. **Wodak, A.** (1990). Put your question: How do I get through the denial used by alcoholics? *Patient Management* 19(10), 59.
47. **Wodak, A.** (1990). The connection between HIV infection in injecting drug users and drugs policy. *The International Journal on Drugs Policy* 1(16), 22-23.
48. **Wodak, A.** (1990). The never-ending story. *Drug and Alcohol Review* 9(4), 346-350.
49. **Wodak, A., McArthur, T., & Carroll, T.** (1990). Drug and AIDS education for Australian youth

the get real project. *Hygie International Journal of Health Education*, IX 8-10.

50. **Wodak, A. & Monheit, B.M.** (1990). Methadone. *Medical Journal of Australia* 153, 742.
 51. **Wodak, A. & Moss, A.** (1990). HIV infection and intravenous drug users: From epidemiology to public health. *AIDS* 4 (suppl 1), S105-S109.
 52. **Wodak, A., Richmond, R.L., & Wilson, A.** (1990). Thiamine in beer: Issues in fortification of alcoholic beverages. *Medical Journal of Australia* 152, 97-99.
 53. **Wolk, J., Wodak, A., Morlet, A., Guinan, J.J., & Gold, J.** (1990). HIV-related risk-taking behaviour, knowledge and serostatus of intravenous drug users in Sydney. *Medical Journal of Australia* 152, 453-458.
 54. **Wolk, J., Wodak, A., Guinan, J., Macaskill, P., & Simpson, J.M.** (1990). The effect of a needle and syringe exchange on a methadone maintenance unit. *British Journal of Addiction* 85, 1445-1450.
- 1991**
55. **Baldwin, S., Lawson, A., Mooney, J., Braggins, F., Carnegie, E., McLean, G., Robertson, I., & Heather, N.** (1991). Effectiveness of pre-release alcohol education courses for young offenders in a penal institution. *Behavioural Psychotherapy* 19, 321-331.
 56. **Baldwin, S., Lawson, A., Mooney, J., Braggins, F., Carnegie, E., McLean, G., Robertson, I., & Heather, N.** (1991). Comparison of effectiveness of behavioural and talk-based alcohol education courses. *Behavioural Psychotherapy* 19, 157-172.
 57. **Barber, J.G., Cooper, B.K., & Heather, N.** (1991). The Situational Confidence Questionnaire (heroin) *International Journal of Addictions* 26, 565-575.
 58. **Bell, J.** (1991). Pain and addiction. *Drug and Alcohol Review* 10, 247-252.
 59. **Darke, S., Hall, W., Heather, N., Ward, J., & Wodak, A.** (1991). The reliability and validity of a scale to measure HIV risk-taking among intravenous drug users. *AIDS* 5, 181-185.
 60. **Darke, S., Heather, N., Hall, W., Ward, J., & Wodak, A.** (1991). Estimating drug consumption in opioid users: Reliability and validity of a 'recent use episodes' method. *British Journal of Addiction* 86, 1311-1316.
 61. **Darke, S., Ward, J., Zador, D., & Swift, G.** (1991). A scale for measuring the health status of opiate users. *British Journal of Addiction* 86, 1317-1322.
 62. **Flaherty, B., Homel, P., & Hall, W.** (1991). Public attitudes towards alcohol control policies. *Australian Journal of Public Health* 15, 301-306.
 63. **Haber, P.S., Wilson, J.S., McGarity, B.M., Hall, W., Thomas, M.C., & Pirola, R.C.** (1991). Alpha-1-antitrypsin phenotypes and alcoholic pancreatitis. *Gut* 32, 945-948.
 64. **Hall, W., Carless, J., Homel, P., Flaherty, B., & Reilly, C.** (1991). The characteristics of cocaine users among young Sydney adults. *Medical Journal of Australia* 155(1), 11-13.
 65. **Hall, W. & Heather, N.** (1991). Issue of statistical power in comparative evaluations of minimal and intensive controlled drinking interventions. *Addictive Behaviours* 16, 83-87.
 66. **Heather, N. & Richmond, R.** (1991). Research into brief interventions for excessive drinkers and smokers. *Journal of Drug Issues* 22, 641-660.
 67. **Heather, N., Stallard, A., & Tebbutt, J.** (1991). Importance of substance cues in relapse among heroin users: Comparison of two methods of investigation *Addictive Behaviours* 16, 41-49.
 68. **Hunter, E.M.** (1991). The intercultural and socio-historical context of Aboriginal personal violence in remote Australia. *Australian Psychologist* 26(2), 89-98.
 69. **Hunter, E.M.** (1991). Out of sight, out of mind – 1. Emergent patterns of self-harm among Aborigines of remote Australia. *Social Science Medicine*, 33(6), 655-659.
 70. **Hunter, E.M.** (1991). Out of sight, out of mind – 2. Social and historical contexts of self-harm behaviour among Aborigines of remote Australia. *Social Science Medicine* 33(6), 661-671.
 71. **Kahn, M.W., Hunter, E., Heather, N., & Tebbutt, J.** (1991). Australian Aborigines and alcohol: A review *Drug and Alcohol Review* 10, 351-367.
 72. **Mant, A.** (1991). Are your patients over sedated? And if so, is it worth worrying about? *Patient Management* 16, 15-17.
 73. **Mattick, R.P. & Newman, C.** (1991). Social phobia and avoidant personality disorder. *International Review of Psychiatry* 3, 163-173.

74. **Miller, W.R., Heather, N., & Hall, W.** (1991). Calculating standard drink units: International comparisons. *British Journal of Addictions* 86, 43-47.
75. **Miller, W.R. & Page, A.C.** (1991) Warm turkey: Other routes to abstinence. *Journal on Substance Abuse Treatment*, 8, 227-232.
76. **Mitchell, P. & Mant, A.** (1991). Insomnia Update. *Medical Journal of Australia* 154, 193-194.
77. **Ross, M.W., Gold, J., Wodak, A.D., & Miller, M.E.** (1991). Sexually transmissible diseases in injecting drug users. *Genitourinary Medicine* 67, 32-36.
78. **Solowij, N., Michie, P.T., & Fox, A.M.** (1991). Effects of long term cannabis use on selective attention: An event-related potential study. *Pharmacology, Biochemistry and Behaviour* 40, 683-688.
79. **Swift, W.** (1991). Helping to prevent relapse: The role of 'cue exposure'. *Drugwise*, February.
80. **Ward, J., Mattick, R.P., & Hall, W.** (1991). The current role of methadone therapy for injecting drug users: An overview. *Venereology* 4(3), 109-111.
81. **Westbrook, R.F., Greeley, J.D., Nabke, C., Swinbourne, A., & Harvey, A.** (1991). Effects of morphine and naloxone on rats' reactions to a heat stressor. *Quarterly Journal of Experimental Psychology* 43B, 323-346.
82. **Westbrook, R.F., Greeley, J.D., Nabke, C., & Swinbourne, A.** (1991). Aversive conditioning and analgesia in the rat: Effects of intensity of nociceptive stimulation, extinction, midazolam, morphine and naloxone. *Journal of Experimental Psychology: Animal Behaviour Processes* 17(3), 219-230.
83. **Wodak, A.** (1991). Preventing HIV spread among injecting drug users. *The Lancet*, 336, 482.
84. **Wodak, A.** (1991). Recent advances in alcohol and drug research. *The Australian Journal of Psychopharmacology* 5, 17-19.
85. **Wodak, A.** (1991). A wider view of alcohol consumption in Australia. *Medical Journal of Australia* 154, 838-839.
86. **Wodak, A.** (1991). Why the war on drugs has failed. *Medical Journal of Australia* 155, 37-38.
87. **Wodak, A.** (1991). Helping a medical colleague with a drinking or drug problem. *Modern Medicine* 34, 22-23.
88. **Wodak, A.** (1991). I feel like an alcohol advertisement (Editorial). *Australian Journal of Public Health* 15(3), 170-171.
- 1992
89. **Bell, J.** (1992). Treatment dependence. Preliminary description of yet another syndrome. *British Journal of Addiction* 87, 1049-1054.
90. **Bell, J. & Batey, W.** (1992). Medicine and the addictions (Editorial). *Australian and New Zealand Journal of Medicine* 22, 202-203.
91. **Bell, J., Digiusto, E., & Byth, K.** (1992). Who should receive methadone maintenance? *British Journal of Addiction* 87, 527-532.
92. **Bell, J., Hall, W., & Byth, K.** (1992). Changes in criminal activity after entering methadone maintenance. *British Journal of Addiction* 87, 251-258.
93. **Carey, D.L., Day, R.O., Cairns, D.R., Pearce, G.A., Wodak, A.D., & Lauchlan, R.L.** (1992). An attempt to influence hypnotic and sedative drug usage. *Medical Journal of Australia* 156, 389-393.
94. **Chesher, G. & Greeley, J.** (1992). Tolerance to the effects of alcohol. *Alcohol, Drugs and Driving* 8, 93-106.
95. **Copeland, J.** (1992). "She who pays the piper calls the tune": a response (letter to the editor). *Drug and Alcohol Review* 11, 401-402.
96. **Copeland, J. & Hall, W.** (1992). A comparison of predictors of treatment drop-out of women seeking drug and alcohol treatment in a specialist women's and two traditional mixed-sex treatment services. *British Journal of Addiction* 87, 1293-1302.
97. **Copeland, J. & Hall, W.** (1992). A comparison of women seeking drug and alcohol treatment in a specialist women's & two traditional mixed-sex treatment services. *British Journal of Addiction* 87, 1293-1302.
98. **Darke, S.** (1992). Injecting drug users and Human Immunodeficiency Virus: What do we know? *Drug and Alcohol Review* 11, 153-161.
99. **Darke, S.** (1992). The measurement of outcome in opiate treatment evaluation studies. *Drug and Alcohol Review* 11, 169-175.
100. **Darke, S.** (1992). AIDS and Alcohol/Drug Abuse. Psychosocial Research (book review). *Drug and Alcohol Review* 11, 207.
101. **Darke, S.** (1992). Cocaine, AIDS, and Intravenous Drug Use (book review). *British Journal of Addiction* 87, 1604.

102. **Darke, S., Baker, A., Dixon, J., Wodak, A., & Heather, N.** (1992). Drug use and HIV risk-taking behaviour among clients in methadone maintenance treatment. *Drug and Alcohol Dependence* 29, 263-268.
103. **Darke, S., Hall, W., Heather, N., Wodak, A., & Ward, J.** (1992). Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opioid users: The Opiate Treatment Index. *British Journal of Addiction* 87, 593-602.
104. **Darke, S., Hall, W., & Ross, M.W.** (1992). Benzodiazepine prescribing and injecting drug users (letter to the editor). *Medical Journal of Australia* 157, 573-574.
105. **Darke, S., Hall, W., Ross, M.W., & Wodak, A.** (1992). Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. *Drug and Alcohol Dependence* 31, 31-36.
106. **Darke, S., Hall, W., Wodak, A., Heather, N., & Ward, J.** (1992). Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users. The Opiate Treatment Index. *British Journal of Addiction* 87, 733-742.
107. **Darke, S., Wodak, A., Hall, W., Heather, N., & Ward, J.** (1992). Prevalence and predictors of psychopathology among opioid users. *British Journal of Addiction*, 87, 771-776.
108. **Greeley, J.** (1992). The nature of opioid dependence [Editorial] *Australian Journal of Psychopharmacology* 6, 1.
109. **Greeley, J., Swift, W., & Heather, N.** (1992). Depressed affect as a predictor of increased desire for alcohol in current drinkers of alcohol. *British Journal of Addiction* 87, 1005-1012.
110. **Grenyer, B.F.S., Williams, G., Swift, W., & Neill, O.** (1992). The prevalence of social-evaluative anxiety in opioid users seeking treatment. *The International Journal of the Addictions* 27(6), 665-673.
111. **Guinan, J.J., Hall, W., Clarke, J.C., & Gold, J.** (1992). Alcohol and recreational drug use by HIV-seropositive homosexual men. *Drug and Alcohol Review* 11, 355-362.
112. **Hall, W.** (1992). The Australian debate about the legalisation of heroin and other illicit drugs. *Journal of Drug Issues* 22, 563-577.
113. **Hall, W., Flaherty, B., & Homel, P.** (1992). Public perceptions of the risks and benefits of alcohol use. *Australian Journal of Public Health* 16, 38-42.
114. **Hayward, L., Mant, A., Eyland, E.A., Hewitt, H., Pond, C.D., & Saunders, N.A.** (1992). Neuropsychological functioning and sleep patterns in the elderly. *Medical Journal of Australia* 157, 51-52.
115. **Heather, N.** (1992). Why alcoholism is not a disease. *Medical Journal of Australia* 156, 212-215.
116. **Heather, N.** (1992). Comments on S. Peele, 'Alcoholism, politics and bureaucracy: The consensus against controlled- drinking therapy in America'. *Addictive Behaviours* 17, 73-74.
117. **Heather, N.** (1992). Addictive disorders are essentially motivational problems Commentary on Davidson's 'Prochaska and DiClemente's model of change: A case study' *British Journal of Addiction* 87, 825-835.
118. **Hunter, E., Hall, W., & Spargo, R.** (1992). Patterns of alcohol consumption in the Kimberley Aboriginal population. *Medical Journal of Australia*, 156(1), 764-768.
119. **Jarvis, T.** (1992). Implications of gender for alcohol treatment research: A quantitative and qualitative review. *British Journal of Addiction* 87(9), 1249-1261.
120. **Kehoe, L., Hall, W., & Mant, A.** (1992). Estimating the number of dependent heroin users in the Eastern Area Health Service of Sydney. *Australian Journal of Public Health* 16, 232-237.
121. **Mant, A., Whicker, S.D., & Kwok, Y.S.** (1992). Over-the-counter self medication: The issues. *Drugs and Aging* 2, 257-261.
122. **Mattick, R.P. & Ward, J.** (1992). Drug and alcohol treatment research, policy and practice: An Australian perspective. *Journal of Drug Issues* 22, 625-640.
123. **Perdices, M., Dunbar, N., Grunseit, A., Hall, W., & Cooper, D.** (1992). Anxiety, depression and HIV related symptomatology across the spectrum of HIV disease. *Australian and New Zealand Journal of Psychiatry* 26, 560-566.
124. **Rollnick, S., Heather, N., & Bell, A.** (1992). Negotiating behaviour change in medical settings: The development of brief motivational interviewing. *Journal of Mental Health* 1, 25-37.

125. **Rollnick, S., Heather, N., Gold, R., & Hall, W.** (1992). Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. *British Journal of Addiction* 87, 743-754.
126. **Ross, M.W. & Darke, S.** (1992). Mad, bad and dangerous to know: Dimensions and measurement of attitudes toward injecting drug users. *Drug and Alcohol Dependence* 30, 71-74.
127. **Ross, M.W., Wodak, A.D., Gold, J., & Miller, M.E.** (1992). Differences across sexual orientation on HIV risk behaviours in injecting drug users. *AIDS Care* 156, 139-148.
128. **Saltman, D.C. & Mant, A.** (1992). General practitioner data bases in Australia. *Medical Journal of Australia* 156, 16-20.
129. **Solowij, N., Hall, W., & Lee, N.** (1992). Recreational MDMA use in Sydney: A profile of 'Ecstasy' users and their experiences with the drug. *British Journal of Addiction* 87, 1161-1172.
130. **Stowe, A., Wodak, A., & Ross, M.W.** (1992). Contact between injecting drug users and general practitioners and its implications for health education. *Journal of the Royal Society on Health* 112, 125-126.
131. **Velicer, W., Redding, C.A., Richmond, R., Greeley, J., & Swift, W.** (1992). A time series investigation of alternative measures of smoking habit strength. *Addictive Behaviours* 17, 325-345.
132. **Ward, J., Darke, S., Hall, W., & Mattick, R.P.** (1992). Methadone maintenance and the human immunodeficiency virus: Current issues in treatment and research. *British Journal of Addiction* 87, 447-453.
133. **Webster, P., Mattick, R.P., & Baillie, A.J.** (1992). Characteristics of clients receiving treatments in Australian drug and alcohol agencies: A national census. *Drug and Alcohol Review* 11, 111-119.
134. **Westbrook, R.F. & Greeley, J.D.** (1992). Conditioned tolerance to morphine: Compensatory hyperalgesia in the experimental group or conditioned hypoalgesia in the control group? *Quarterly Journal of Experimental Psychology*, 45B.
135. **Wodak, A.** (1992). Taming demons: The reduction of harm resulting from the use of illicit drugs. *Australian and New Zealand Journal of Medicine* 22, 204-208.
136. **Wodak, A.** (1992). The dismal science and our favourite drug. (Editorial). *Medical Journal of Australia* 156, 747-748.
137. **Wodak, A.** (1992). The epidemic that Australia does not have to have. *Today's Life Sciences* 4(6), 26-30.
138. **Wodak, A.** (1992) She who pays the piper calls the tune. (Editorial). *Drug and Alcohol Review* 11, 107-109.
139. **Wodak, A.** (1992). Controlling HIV infection behind bars: Questions, strategies and obstacles. *Current Issues in Criminal Justice*, 4(11), 28-36.
140. **Wodak, A.** (1992). HIV Infection and injecting drug use in Australia: Responding to a crisis. *Journal of Drug Issues* 22, 549-562.
- 1993**
141. **Baker, A., Heather, N., Wodak, A., Dixon, J., & Holt, P.** (1993). Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. *AIDS* 7, 247-256.
142. **Copeland, J.** (1993). Feminism and Addiction (book review). *Drug and Alcohol Review* 12(1), 117-118.
143. **Copeland, J., Hall, W., Didcott, P., & Biggs, V.** (1993). A comparison of a specialist women's alcohol and other drug treatment service with two traditional mixed-sex services: client characteristics and treatment outcome. *Drug and Alcohol Dependence* 32(1), 81-92.
144. **Crisp, B.R., Barber, J.G., Ross, M.W., Wodak, A., Gold, J., & Miller, M.E.** (1993). Injecting drug users and HIV/AIDS: risk behaviours and risk perception. *Drug and Alcohol Dependence* 33, 73-80.
145. **Dolan, K.A., Stimson, G.V., & Donoghoe, M.C.** (1993). Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. *Drug and Alcohol Review* 12, 133-42.
146. **Friedman, S.R., De Jong, W., & Wodak, A.** (1993). Community development as a response to HIV among drug injectors. *AIDS* 7(suppl 1) S263-S269.
147. **Gaughwin, M., Kliever, E., Ali, R., Faulkner, C., & Wodak, A.** (1993). The prescription of methadone for opiate dependence in Australia, 1985-1991. *Medical Journal of Australia*, 159, 107-108.

148. **Gomel, M., Oldenburg, B., Lemon, J., Owen, N., & Westbrook, F.** (1993). Pilot study of the effects of a workplace smoking ban on indices of smoking, cigarette craving, stress and other health behaviours. *Psychology and Health* 8, 223-229.
149. **Greeley, J., Swift, W., & Heather, N.** (1993). To drink or not to drink?: Assessing conflicting desires in dependent drinkers in treatment. *Drug and Alcohol Dependence* 32, 69-179.
150. **Greeley, J., Swift, W., Prescott, J., & Heather, N.** (1993). Reactivity to alcohol-related cues in heavy and light drinkers. *Journal of Studies on Alcohol* 54, 359-368.
151. **Hall, W.** (1993). Perfectionism in the therapeutic appraisal of methadone maintenance. *Addiction* 88, 1181-1182.
152. **Hall, W., Bell, J., & Carless, J.** (1993). Crime and drug use among applicants for methadone maintenance. *Drug and Alcohol Dependence* 31, 123-129.
153. **Hall, W., Darke, S., Ross, M., & Wodak, A.** (1993). Patterns of drug use and risk-taking among opioid and amphetamine injecting drug users in Sydney. *Addiction* 88, 509-516.
154. **Hall, W. & Hando, J.** (1993). Illicit amphetamine use as a public health problem in Australia. *Medical Journal of Australia* 159, 643-644.
155. **Hall, W., Hunter, E., & Spargo, R.** (1993). Alcohol-related problems among a population sample of Aboriginal drinkers in the Kimberley region of Western Australia. *Addiction* 88, 1091-1100.
156. **Hall, W., Saunders, J., Babor, T., Aasland, O.G., Amundsen, A., Hodgson, R., & Grant, M.** (1993). The structure and correlates of alcohol dependence: WHO Collaborative Project on Early Detection of Person with Harmful Alcohol Consumption - III. *Addiction* 88, 1627-1636.
157. **Hall, W., Ward, J., Mattick, R.P.** (1993). Methadone maintenance treatment in prisons: The New South Wales experience. *Drug and Alcohol Review* 12, 193-203. Also reprinted in *Psychiatry, Psychology & Law*, 1, 33-44 (1994).
158. **Heather, N., Tebbutt, J., Mattick, R.P., & Zamir, R.** (1993). Development of a scale for measuring impaired control over alcohol consumption. *Journal of Studies on Alcohol* 58, 700-709.
159. **Lemon, J., Chesher, G., Fox, A., Greeley, J., & Nabke, C.** (1993). Investigation of the "hangover" effects of an acute dose of alcohol on psychomotor performance. *Alcoholism: Clinical and Experimental Research*, 17(3), 665-668.
160. **McLachlan, C., Crofts, N., Wodak, A., & Crowe, S.** (1993). The effects of methadone on immune function in injecting drug users: a review. *Addiction* 88(2), 257-263.
161. **Mant, A.** (1993). Insomnia: Evaluate first before considering hypnotics. *Drug and Therapeutic Perspectives* 2, 7.
162. **Marley, J., & Mant, A.** (1993). Post marketing surveillance - traps for the unwary. *Australian Family Physician* 22(6), 1009-1013.
163. **Mattick, R.P., & Heather, N.** (1993). Developments in cognitive and behavioural approaches to substance misuse. *Current Opinion in Psychiatry* 6, 424-429.
164. **Prescott, J., Jamieson, D., Edmur, N., & Duffield, P.** (1993). Acute effects of kava on measures of cognitive performance, physiological function and mood. *Drug & Alcohol Review* 12, 49-58.
165. **Richmond, R.** (1993). Physicians can help patients to stop smoking. *Fellowship Affairs, newsletter of the Royal College of Physicians*.
166. **Richmond, R.** (1993). Increasing resource allocation into tobacco control activities: A comprehensive approach including primary prevention and treatment including brief intervention. *Drug and Alcohol Review* 12, 205-215.
167. **Richmond, R.L., Kehoe, L., & Webster, I.W.** (1993). Weight change after smoking cessation in general practice. *The Medical Journal of Australia* 158, 821-822.
168. **Richmond, R., Makinson, R., Kehoe, L., Giugni, A., & Webster, I.** (1993). A one year evaluation of three smoking cessation programmes administered by general practitioners. *Addictive Behaviours* 18(12) 187-199.
169. **Ross, M.W., Stowe, A., Wodak, A., Miller, M.E., & Gold, J.** (1993). A comparison of drug use and HIV infection risk behaviour between injecting drug users in treatment, previously-in-treatment and never in treatment. *Journal of Acquired Immunodeficiency Syndromes* 6, 518-528.

170. **Ross, M.W., Wodak, A., & Gold, J.** (1993). Accuracy of self-reporting of sexually transmissible disease in injecting drug users. *Journal of the European Academy of Dermatology and Venereology [letter]* 2, 147-148.
171. **Ross, M.W., Wodak, A., Miller, M.E., & Gold, J.** (1993). Sexual partner choice in injecting drug users from a "critical incident" measure: Its implications for assessing risk of HIV Spread. *Sexological Review* 1(1), 77-92.
172. **Solowij, N.** (1993). Ecstasy (3, 4 methylenedioxymethamphetamine). *Current Opinion in Psychiatry* 6(3), 411-415.
173. **Solowij, N., Michie, P.T., & Fox, A.M.** (1993). Frequency and duration of cannabis use differentially affect brain function in a selective attention task. *International Journal of Neuroscience* 71, 107-133.
174. **Turnbull, P.J., Dolan, K.A., & Stimson, G.V.** (1993). HIV testing and the care and treatment of HIV positive people in English prisons. *AIDS Care* 5(2), 199-206.
175. **Wodak, A.** (1993). HIV infection in drug and alcohol practice. *Medical Journal of Australia* 158, 266.
176. **Wodak, A., & Des Jarlais, D.C.** (1993). Strategies for the prevention of HIV infection among and from injecting drug users. *Bulletin on Narcotics* 45(1), 47-60.
177. **Wodak, A.** (1993). Here's to your Health? (Editorial). *Australian & New Zealand Journal of Medicine* 23, 242-243.
178. **Wodak, A., Fisher, R., & Crofts, N.** (1993). HIV infection among injecting drug users in Asia: An evolving public health crises. *AIDS Care* 5(3), 315-322.
179. **Wodak, A.** (1993). To takes up arms against a sea of drugs. *The Journal of Contemporary Health Law and Policy* 9, 323-335.
- 1994
180. **Baillie, A. J., Mattick, R.P., & Hall, W.** (1994). Self-quitting smoking: Estimation of an unaided abstinence rate by meta-analysis. *Australian Journal of Public Health* 19, 29-31.
181. **Baillie, A. J., Mattick, R.P., Hall, W., & Webster, P.** (1994). Meta-analytic review of smoking cessation interventions. *Drug and Alcohol Review* 13, 157-170.
182. **Darke, S.** (1994). The use of benzodiazepines among injecting drug users. *Drug and Alcohol Review* 13, 63-69.
183. **Darke, S.** (1994). Benzodiazepine use among injecting drug users: problems and implications (Editorial). *Addiction* 89, 379-382.
184. **Darke S.** (1994). The prescribing of benzodiazepines to injecting drug users. A reply to Dr Seivewright (Letter to the Editor). *Addiction* 89, 1703.
185. **Darke, S., Cohen, J., Ross, J., Hando, J., & Hall, W.** (1994). Transitions between routes of administration of regular amphetamine users. *Addiction* 89, 1077-1083.
186. **Darke, S., Hall, W., & Swift, W.** (1994). Prevalence, symptoms and correlates of anti-social personality disorder among methadone maintenance clients. *Drug and Alcohol Dependence* 34, 253-257.
187. **Darke, S., Hall, W., & Swift, W.** (1994). Geographical differences in risk-taking among Sydney methadone maintenance patients: A comparison of inner city and outer south western methadone maintenance patients. *Drug and Alcohol Review* 13, 301-305.
188. **Darke, S., Swift, W., & Hall, W.** (1994). Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. *Addiction* 89, 229-235.
189. **Darke, S., Swift, W., Hall, W., & Ross, M.** (1994). Predictors of injecting and injecting risk-taking behaviour among methadone maintenance clients. *Addiction* 89, 331-336.
190. **De Burgh, S., Mant, A., Mattick, R.P., Donnelly, N., Hall, W., & Bridges-Webb, C.** (1994). A controlled trial of educational visiting to improve benzodiazepine prescribing in general practice. *Australian Journal of Public Health* 19, 142-148.
191. **Dolan, K.** (1994). Sex in the Slammer. *National AIDS Bulletin* 8(6), 12-13.
192. **Dolan, K., Hall, W., Wodak, A., & Gaughwin, M.** (1994). Evidence of HIV transmission in an Australian prison (letter to the editor). *Medical Journal of Australia* 160, 734.
193. **Farrell, M., Ward, J., Mattick, R., Hall, W., Stimson, G., des Jarlais, D., Gossop, M., & Strang, J.** (1994). Methadone maintenance treatment in opiate dependence: A review. *British Medical Journal* 309, 997-1001.

194. Haber, P.S., Wilson, J.S., Apte, M.V., Hall, W., & Goumas, K. (1994). Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. *Gastroenterology* 106, 742-748.
195. Hall, W. (1994). Value for money in addiction services. *Addiction* 89, 919-923.
196. Hall, W. (1994). The health and psychological effects of cannabis use. *Current Issues in Criminal Justice*, 6, 208-220.
197. Hall, W. & Hando, J. (1994). Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. *Drug and Alcohol Review* 13, 277-284.
198. Hall, W., Hunter, E.M., & Spargo, R. (1994). Alcohol use and incarceration in a police lockup among Aboriginals in the Kimberley Region of Western Australia. *Australian and New Zealand Journal of Criminology* 27, 57-73.
199. Hando, J. & Hall, W. (1994). HIV risk-taking behaviour among amphetamine users in Sydney, Australia. *Addiction* 89, 79-85.
200. Heather, N., & Mattick, R.P. (1994). The development of guidelines for drug and alcohol dependence treatment: Affecting policy and practice. *Drug and Alcohol Review* 13, 119-126.
201. Mant, A., Mattick, R.P., DeBurgh, S., Donnelly, N., & Hall, W. (1994). Clinical and non-clinical determinants of benzodiazepine prescribing in general practice: Dispelling some myths. *Family Practice* 12, 37-43.
202. Mattick, R.P. (1994). Dual diagnosis: Evaluation, treatment, training, and program evaluation (book review). *Addiction* 90, 139-140.
203. Mattick, R.P. (1994). Dual diagnosis: Evaluation, treatment, training, and program evaluation (book review). *Drug and Alcohol Review* 13, 349-352.
204. Mattick, R.P., Baillie, A. J., Digiusto, E., Gourlay, S., Richmond, R., & Stanton, H. (1994). A summary of the recommendations for smoking cessation interventions: The quality assurance in the treatment of drug dependence project. *Drug and Alcohol Review* 13, 171-178.
205. Mattick, R.P. & Hall, W. (1994). A summary of the recommendations for the management of opioid problems: The quality assurance in the treatment of drug dependence project. *Drug and Alcohol Review* 13, 319-326.
206. Mattick, R.P. & Jarvis, T. J. (1994). Inpatient setting and long duration for the treatment of alcohol dependence? Outpatient care is as good. *Drug and Alcohol Review* 13, 127-136.
207. Mattick, R.P. & Jarvis, T. J. (1994). Brief or minimal intervention for 'alcoholics': The evidence suggests otherwise. *Drug and Alcohol Review* 13, 137-144.
208. Mattick, R.P. & Jarvis, T. J. (1994). A summary of the recommendations for the management of alcohol problems: The quality assurance in the treatment of drug dependence project. *Drug and Alcohol Review* 13, 145-156.
209. Ward, J., Mattick, R.P., & Hall, W. (1994). A review of the literature on the use of methadone maintenance treatment for opioid dependence. *Drug and Alcohol Review* 13, 327-336.
210. Wodak, A. & Dolan, K. (1994). A tale of three viruses. *Today's Life Science* 6(7), 60-64.
211. Wodak, A. & Dolan, K. (1994). Evidence of HIV transmission in an Australian Prison (letter to the editor - reply). *Medical Journal of Australia* 161, 509.
- 1995
212. Conigrave, K., Hall, W. & Saunders, J. B. (1995). The AUDIT questionnaire: choosing a cut-off score. *Addiction* 90, 1349-1356.
213. Copeland, J. (1995). Alcohol, Gender and Culture (book review). *Addiction* 90(3), 444-445.
214. Copeland, J. (1995). Women and Substance Use (book review). *Drug and Alcohol Review* 14(2), 245.
215. Copeland, J. (1995). Addictive Behaviors in Women (book review). *Drug and Alcohol Review* 14(3), 338.
216. Copeland, J. (1995). Maturing Out: An Empirical Study of Personal Histories and Processes in Hard-drug Addiction (book review). *Drug and Alcohol Review* 14(3), 340-341.
217. Darke, S. (1995) Ne'er the twain. Comments on Dr McKeganey's Editorial (Invited commentary) *Addiction* 90, 761-762.
218. Darke, S. (1995). Methodological Issues in AIDS Behavioural Research (book review). *Addiction* 90, 993-994.

219. **Darke, S. & Hall, W.** (1995). Levels and correlates of polydrug use among heroin users and regular amphetamine users. *Drug and Alcohol Dependence* 39, 231-235.
220. **Darke, S., Ross, J., Cohen, J., Hando, J., & Hall, W.** (1995). Injecting and sexual risk-taking behaviour among regular amphetamine users. *AIDS Care* 7, 17-24.
221. **Darke, S., Ross, J., & Hall, W.** (1995). Benzodiazepine use among injecting heroin users. *Medical Journal of Australia* 162, 645-647.
222. **Dolan, K., Wodak, A., & Penny, R.** (1995). AIDS behind bars: preventing HIV spread among incarcerated drug injectors. *AIDS* 9, 825-832.
223. **Donnelly, N., Hall, W., & Christie, P.** (1995). The effects of decriminalisation on cannabis use in South Australia 1985-1993. *Australian Journal of Public Health* 19, 281-287.
224. **Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J.** (1995). The Severity of Dependence Scale (SDS) in English and Australian samples of heroin, cocaine and amphetamine users. *Addiction* 90, 607-614.
225. **Hall, W.** (1995). The public health implications of cannabis use. *Australian Journal of Public Health* 19, 235-242.
226. **Hall, W.** (1995). What advice should family physicians give their patients about the health effects of cannabis? *Australian Family Physician* 24, 1237-1240.
227. **Hall, W.** (1995). Making research more relevant to practice. *Drug and Alcohol Review* 14, 149-150.
228. **Hall, W.** (1995). Variations in prohibition: Harm minimisation in Australia and Drug Wars in the USA. *Australian and New Zealand Journal of Criminology, Special Supplementary Issue*, 74-77.
229. **Hall, W., Chen, R., & Evans, B.** (1995). Characteristics of clients admitted to the Buttery, a therapeutic community, 1980-1992. *Drug and Alcohol Review* 14, 125-129.
230. **Loxley, W., Carruthers, S., Wodak, A., Crofts, N., Dolan, K., Gaughwin, M. & Kaldor, J.** (1995). Patterns of infection. *National AIDS Bulletin* 9(2), 26-27.
231. **Mant, A., De Burgh, S., Mattick, R.P., Donnelly, N., & Hall, W.** (1995). Insomnia in general practice: Results from the NSW general practice survey 1991-1992. *Australian Family Physician* 25, S15-S18.
232. **Mattick, R.P.** (1995). Residential treatment for alcohol dependent patients? (letter to the editor). *Drug and Alcohol Review* 14, 134-135.
233. **Mattick, R.P.** (1995). Addiction: From biology to drug policy. (book review). *Behaviour Change*.
234. **Mattick, R.P. & Darke, S.** (1995). Drug replacement treatments: Is amphetamine substitution a horse of a different colour? *Drug and Alcohol Review* 14, 389-394.
235. **Mattick, R.P., Farrell, M., Hall, W., Ward, J., Gossop, M., & Strang, J.** (1995). Methadone maintenance treatment: A reply. *British Medical Journal* 310, 1408.
236. **Roche, A., Saunders, J. Parle, M., Hall, W., & Stubbs, J.** (1995). Management and treatment efficacy of drug and alcohol problems: what do doctors believe? *Addiction* 90, 1357-1366.
237. **Spooner, C.** (1995). Adolescent Substance Abuse. A Comprehensive Guide to Theory and Practice (book review). *Drug and Alcohol Review* 14, 137-138.
238. **Spooner, C.** (1995). Preschoolers and Substance Abuse: Strategies for prevention and intervention. *Drug and Alcohol Review* 14, 417-418.
- 1996
239. **Baillie, A. J. & Mattick, R.P.** (1996). Benzodiazepine dependence questionnaire: Development, reliability and validity. *British Journal of Psychiatry* 169, 276-281.
240. **Cooke, M., Mattick, R.P., & Barclay, L.** (1996). Predictors of brief smoking intervention in a midwifery setting. *Addiction* 91, 1715-1725.
241. **Darke, S.** (1996). Psychotherapy, Psychological Treatments and the Addictions (book review). *British Medical Journal*, 312, 1309.
242. **Darke, S., Finlay-Jones, R., Kaye, S., & Blatt, T.** (1996). Anti-social personality disorder and response to methadone maintenance treatment. *Drug and Alcohol Review* 15, 271-276.
243. **Darke, S., Kelaher, M., Hall, W., & Flaherty, B.** (1996) Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-1992: I. Illicit drug problems. *Drug and Alcohol Review* 15, 127-132.
244. **Darke, S. & Mattick, R.P.** (1996). Commentary on Lintzeris *et al.* *Drug and Alcohol Review* 15, 197-198.

245. **Darke, S., Ross, J., & Hall, W.** (1996). Overdose among heroin users in Sydney, Australia I. Prevalence and correlates of non-fatal overdose. *Addiction* 91, 405-411.
246. **Darke, S., Ross, J., & Hall, W.** (1996). Overdose among heroin users in Sydney, Australia II. Responses to overdose. *Addiction* 91, 413-417.
247. **Darke, S., Ross, J., & Hall, W.** (1996). Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. *Drug and Alcohol Dependence* 43, 191-198.
248. **Darke, S. & Zador, D.** (1996). Fatal heroin overdose: A review. *Addiction* 91, 1765-1772.
249. **Dillon, P., Goldspink-Lord, L., & Parkhill, N.** (1996). Sex, drugs and just say no: A media perspective. *International Journal of Drug Policy* 7, 183-186.
250. **Dillon, P., & Singleton, M.** (1996). Anabolic Steroids. *Policing Issues and Practice Journal* 4 (4), 24-31.
251. **Dolan, K.A., Hall, W., & Wodak, A.** (1996). Methadone maintenance reduces injecting in prison. *British Medical Journal* 312, 1162.
252. **Dolan, K., Rutter, S., Wodak, A., Hall, W., Maher, L., & Dixon, D.** (1996). Is syringe exchange feasible in a prison setting? *Medical Journal of Australia* 164, 508.
253. **Dolan, K. & Wodak, A.** (1996). An international review of methadone provision in prisons. *Addictions Research* 4(1), 85-97.
254. **Dolan, K., Wodak, A., Hall, W., Gaughwin, M & Rae, F.** (1996). Risk behaviour of IDUs before, during and after imprisonment in NSW. *Addiction Research* 4(2), 151-60.
255. **Dolan, K., Wodak, A., Hall, W., Gaughwin, M & Rae, F.** (1996). La Trasmissione dell'infezione da HIV in Carcere. *Limitazione del Danno Suppl. ad ASPE* 8, 15-19.
256. **Dolan, K.A., Wodak, A.D., & Rutter, S.A.** (1996). Is syringe exchange feasible in a prison setting? [letter to the editor. (Reply)]. *Medical Journal of Australia* 165, 59.
257. **Hall, W.** (1996). How can we reduce the number of heroin "overdose" deaths? *Medical Journal of Australia* 164, 197-198.
258. **Hall, W.** (1996). Changes in the public perceptions of the health benefits of alcohol use, 1989 to 1994. *Australian Journal of Public Health* 20, 93-95.
259. **Hall, W.** (1996). Statistical questions. A commentary on Finney et al.'s "the effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects". *Addiction* 91, 1808.
260. **Hall, W.** (1996). What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders? *Drug and Alcohol Review* 15, 157-170.
261. **Hall, W.** (1996). Methadone maintenance treatment as a crime control measure. *Crime and Justice Bulletin Number* 29, June, 1-12.
262. **Hall, W. & Dolan, K.** (1996). Is there a role for contact tracing in preventing HIV transmission among drug users? Editorial. *Addiction* 91(7), 917-919.
263. **Hall, W., Hando, J., Darke, S., & Ross, J.** (1996). Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. *Addiction* 91, 81-87.
264. **Hall, W. & Mant, A.** (1996). Harm reduction as a focus for research. *Drug and Alcohol Review* 15, 5-6.
265. **Hall, W. & Nelson, J.** (1996). Correlates of the perceived health risks of marijuana among Australian adults. *Drug and Alcohol Review* 15, 137-144.
266. **Hall, W. & Sannibale, C.** (1996). Are there two types of alcoholism? *Lancet* 348, 1258.
267. **Hall, W., Solowij, N., & Lemon, J.** (1996). A Summary of "The Health and Psychological Effects of Cannabis". *Addiction* 91, 759-762.
268. **Kelaher, M., Darke, S., Hall, W., & Flaherty, B.** (1996). Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-1992: II. Alcohol problems. *Drug and Alcohol Review* 15, 133-136.
269. **McManus, P., Donnelly, N., Henry, D., Hall, W., Primrose, J., & Lindner, J.** (1996). Prescription drug utilization following patient co-payment changes in Australia. *Pharmacoepidemiology and Drug Safety* 5, 385 -392.
270. **Maher, L., & Daly, K.** (1996). Women in the street-level drug economy: continuity or change? *Criminology* 34 (4), 465-491.
271. **Mattick, R.P.** (1996). The stop smoking workbook: Your guide to healthy quitting (book review). *Addiction* 92, 223.

272. **Mattick, R.P.** (1996). How to have a high success rate in treatment: Commentary. *Addiction* 92(2), 484-485.
273. **Mattick, R.P. & Hall, W.** (1996). Are detoxification programmes effective? *Lancet* 347, 97-100.
274. **McManus, P., Donnelly, N., Henry, D., Hall, W., Primrose, J., & Lindner, J.** (1996). Prescription drug utilization following patient co-payment changes in Australia *Pharmacoepidemiology and Drug Safety* 5, 385 -392.
275. **Maher, L., & Daly, K.** (1996). Women in the street-level drug economy: continuity or change? *Criminology* 34 (4), 465-491.
276. **Mattick, R.P.** (1996). How to have a high success rate in treatment: Commentary. *Addiction* 92(2), 484-485.
277. **Richmond, R., Heather, N., & Holt, P.** (1996). Restrictions on tobacco and alcohol use in Australian work-places. *Drug and Alcohol Review* 15, 377-383.
278. **Richmond, R., Heather, N., & Holt, P.** (1996). Programmes for tobacco and alcohol users in Australian work-places. *Drug and Alcohol Review* 15, 385 -392.
279. **Ross, J., Darke, S., & Hall, W.** (1996). Benzodiazepine use among heroin users in Sydney: patterns of use, availability and procurement. *Drug and Alcohol Review* 15, 237-243.
280. **Shanley, C., Lodge, M., & Mattick, R.P.**(1996). The dissemination of research findings to alcohol and other drug practitioners. *Drug and Alcohol Review* 15, 89-94.
281. **Spooner, C., Bishop, J., & Parr, J.** (1996). Research methods for studying injecting drug users in a non-metropolitan setting. *Drug and Alcohol Review* 16, 349-355.
282. **Spooner, C., Bishop, J., & Parr, J.** (1996). Unsafe injecting practices and risk reduction in a non-metropolitan setting. *Health Promotion Journal of Australia* 6(3), 54-56.
283. **Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R.** (1996). Heroin overdose: Is there a case for take-home naloxone? (Editorial). *British Medical Journal* 312, 1435.
284. **Swift, W. & Copeland, J.** (1996). Treatment needs and experiences of Australian women with alcohol and other drug related problems. *Drug and Alcohol Dependence* 40(3), 211-219.
285. **Swift, W., Copeland, J., & Hall, W.** (1996). Characteristics of women with alcohol and other drug problems: findings of an Australian national survey. *Addiction* 91(8), 1141-1150.
286. **Swift, W., Hall, W., & Copeland, J.** (1996). Patterns and consequences of long term cannabis use. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 80-103.
287. **Topp, L.** (1996). Cue reactivity in amphetamine users. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 46-79.
288. **Ward, J., Bell, J., Mattick, R.P., & Hall, W.** (1996). Methadone maintenance therapy for opioid dependence: A guide to appropriate use. *CNS Drugs* 6, 440-449.
289. **Ward, J., Bell, J., Mattick, R.P., & Hall, W.** (1996). Methadone maintenance therapy: A guide to appropriate use. *New Ethicals: New Zealand Journal of Drugs and Therapy*, 63-68.
290. **Ward, J., Mattick, R., Darke, S., & Hall, W.** (1996). The effectiveness and safety of methadone maintenance (Letter). *Addiction* 91, 1727-1728.
291. **Ward, J., Mattick, R.P., Hall, W., & Darke, S.** (1996). The effectiveness and safety of methadone maintenance. *Addiction* 91, 1717-1718.
292. **Wodak, A. & Dolan, K.** (1996). HIV prevention in the community: injecting drug users. *Medical Journal of Australia* 165, 266-67.
293. **Zador, D. Sunjic, S., & Darke, S.** (1996). Heroin-related deaths in New South Wales, 1992: Toxicological findings and circumstances. *Medical Journal of Australia* 164, 204-207.
- 1997**
294. **Bell, J.** (1997). Australian trends in opioid prescribing for chronic, non-cancer pain, 1986-1996. *Medical Journal of Australia* 167, 26-29.
295. **Bell, J., Mattick, R., Chan, J., Hay, A., & Hall, W.** (1997). Methadone maintenance and drug-related crime. *Journal of Substance Abuse* 9, 15-25.
296. **Bell, J., Mattick, R., Hay, A., & Hall, W.** (1997). Methadone maintenance and drug-related crime. *Journal of Substance Abuse* 9, 15-25.
297. **Boot, B., Hall, W., & Andrews, G.** (1997). Disability, outcome and casemix in acute psychi-

- atric in-patient units. *British Journal of Psychiatry* 171, 242-246.
298. **Butler, T., Dolan, K., Ferson, M., McGuinness, L., Brown, P., & Robertson, P.** (1997). Hepatitis B and C in New South Wales prisons. Prevalence and risk factors. *Medical Journal of Australia* 166, 127-130.
 299. **Chan, J.S.K., Kuk, A.Y.C., & Bell, J.** (1997). A likelihood approach to analysing longitudinal bivariate binary data. *Biometrical Journal* 39(4), 409-421.
 300. **Copeland, J.** (1997). A qualitative study of the perceptions of treatment services and 12-step programs among women who self-managed change in addictive behaviours. *Journal of Substance Abuse Treatment* 13(5), 1-8.
 301. **Copeland, J. & Rankin, J.** (1997). Maximising the opportunity for a minimum data set. (Editorial). *Drug and Alcohol Review* 16(3), 205-206.
 302. **Crofts, N., Jolley, D., Kaldor, J., van Beek, I., & Wodak, A.** (1997). Epidemiology of hepatitis C virus infection among injecting drug users in Australia. *Journal of Epidemiology and Community Health* 51(6), 692-697.
 303. **Darke, S. & Hall, W.** (1997). The distribution of naloxone to heroin users. *Addiction* 92, 1195-1199.
 304. **Darke, S. & Ross, J.** (1997). Polydrug dependence and psychiatric comorbidity among heroin injectors. *Drug and Alcohol Dependence* 48, 135-141.
 305. **Darke, S. & Ross, J.** (1997). Overdose risk perceptions and behaviours among heroin users in Sydney, Australia. *European Addiction Research* 3, 87-92.
 306. **Darke, S., Sunjic, S., Zador, D., & Prolov, T.** (1997). A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. *Drug and Alcohol Dependence* 47, 45-53.
 307. **Darke, S., Zador, D., & Sunjic, S.** (1997). Heroin-related deaths in south-western Sydney (letter to the editor). *Medical Journal of Australia* 167 (2), 107.
 308. **Dolan, K.** (1997). AIDS, drugs and risk behaviour in prison: State of the art. *The International Journal of Drug Policy* 8(1), 5-17.
 309. **Dunlap, E., Johnson, B.D., Manwar, A., & Maher, L.** (1997). Female crack dealers in New York City: Who they are and what they do? *Women and Criminal Justice* 8(4), 25-55.
 310. **Hall, W.** (1997). Marijuana myths, marijuana fact (a book review). *Science* 278, 75.
 311. **Hall, W.** (1997). The recent Australian debate about the prohibition on cannabis use. *Addiction* 92, 1109-1115.
 312. **Hall, W.** (1997). Highs and lows. *Lancet* 350, (suppl. III): 1.
 313. **Hall, W.** (1997). Australia: la nuova sfida e l'overdose. *Aspe Disagio Pace Ambiente* 16, 6-7.
 314. **Hall, W.** (1997). The role of legal coercion in the treatment of offenders with alcohol and heroin problems. *Australian and New Zealand Journal of Criminology* 30, 103-120.
 315. **Hall, W.** (1997). Addiction: Highs and lows. *Review 1997*. Supplement to *Lancet* December, 20-27.
 316. **Hall, W.** (1997). An ongoing debate. *Science* 278, 75.
 317. **Hall, W. & Darke, S.** (1997). Prima i vecchi. *Aspe Disagio Pace Ambiente* 16, 8-10.
 318. **Hall, W. & Farrell, M.** (1997). Comorbidity of mental disorders with substance misuse. *British Journal of Psychiatry* 171, 4-5.
 319. **Hall, W. & Mattick, R.** (1997). Ultrarapid opiate detoxification. *Medical Journal of Australia* 176, 393-396.
 320. **Hall, W., Mattick, R., Saunders, J.B., & Wodak, A.** (1997). Rapid opiate detoxification treatment. (Editorial) *Drug and Alcohol Review*, 16, 325-328.
 321. **Hall, W. & Solowij, N.** (1997). Long-term cannabis use and mental health. An Editorial. *British Journal of Psychiatry* 171, 107-108.
 322. **Hall, W. & Zador, D.** (1997). The alcohol withdrawal syndrome. *Lancet* 349, 1897-1900.
 323. **Hando, J., Flaherty, B., & Rutter, S.** (1997). An Australian profile on the use of cocaine. *Addiction* 92(2), 173-182.
 324. **Hando, J., Howard, J., & Zibbert, E.** (1997). Risky drug practices and treatment needs of youth detained in New South Wales Juvenile Justice Centres. *Drug and Alcohol Review* 16, 137-145.
 325. **Hando, J., Topp, L., & Hall, W.** (1997). Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. *Drug and Alcohol Dependence* 46, 105-113.

326. **Jarvis, T.J. & Copeland, J.** (1997). Child sexual abuse as a predictor of psychiatric co-morbidity and its implications for drug and alcohol treatment. *Drug and Alcohol Dependence* 49, 61-70.
327. **MacDonald, M., Wodak, A., Ali, R., Crofts, N., Cunningham, P., Dolan, K., Kelaher, M., Loxley, W., van Beek, I., & Kaldor, J.** (1997). HIV prevalence and risk behaviour in needle exchange attenders - a national study. *Medical Journal of Australia* 166, 237 - 240.
328. **McKetin, R. & Mattick, R.** (1997). Attention and memory in illicit amphetamine users. *Drug and Alcohol Dependence* 48, 235-242.
329. **Martin, B.R. & Hall, W.** (1997/1998). The health effects of cannabis: key issues of policy relevance. *Bulletin on Narcotics* 49-50, 85-116.
330. **Mattick, R.P.** (1997). Single and Rohl on "Mapping the future". *Drug and Alcohol Review* 17, 5-8.
331. **Peters, R.** (1997). Muscle bound. *Australian Leisure Management*, 28-29.
332. **Quinn, D., Wodak, A., & Day, R.** (1997). Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. *Clinical Pharmacokinetics* 33(5), 344-400.
333. **Richmond, R. & Kehoe, L.** (1997). Smoking behaviour and attitudes among Australian medical students. *Medical Education* 31, 169-176.
334. **Richmond, R., Kehoe, L., & de Almedia Neto, A. C.** (1997). Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: one year outcome. *Addiction* 92, 27-31.
335. **Ross, J., Darke, S. & Hall, W.** (1997). Transitions between routes of benzodiazepine administration among heroin users in Sydney. *Addiction* 92(6), 697-705.
336. **Rutter, S., Dolan, K., & Wodak, A.** (1997). Rooms for rent: injecting and harm reduction in Sydney. (letter to the editor). *Australian and New Zealand Journal of Public Health* 21(1), 105.
337. **Topp, L. & Darke, S.** (1997). The applicability of the dependence syndrome to amphetamine. *Drug and Alcohol Dependence* 48, 113-118.
338. **Topp, L., & Mattick, R.P.** (1997). Validation of the amphetamine dependence syndrome and the SamDQ. *Addiction* 92(2), 151-162.
339. **Topp, L. & Mattick, R.P.** (1997). Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. *Addiction* 92 (7), 839-845.
340. **Wodak, A.** (1997). Hepatitis C: Waiting for the Grim Reaper. *Medical Journal of Australia* 166, 284-285.
341. **Wodak, A.** (1997). Needle exchange: Just do it! *AIDS Targetted Information* 11(5), R47-R49.
342. **Wodak, A.** (1997). Public health and politics - the demise of the ACT heroin trial (editorial). *Medical Journal of Australia* 167, 348-349.
343. **Wodak, A.** (1997). Injecting nation: Achieving control of hepatitis C in Australia. *Drug and Alcohol Review* 16, 275- 284.
344. **Wodak, A. & Lurie, P.** (1997). A tale of two countries: Attempts to control HIV among injecting drug users in Australia and the United States. *Journal of Drug Issues* 27(1), 117-134.
- 1998
345. **Bell, J.** (1998). Self report among injecting drug users. *Drug and Alcohol Dependence* 51, 267-268.
346. **Brady, M., Dawe, S., & Richmond, R.** (1998). Expanding knowledge among Aboriginal service providers on treatment options for excessive alcohol use. *Drug and Alcohol Review* 17, 69-76.
347. **Bramley-Moore, S.R., Wodak, A.D., Day, R.O., & Lachlan, R.L.** (1998). Patterns of analgesic prescribing patients with chronic non-malignant pain in NSW. *The Australian Journal of Hospital Pharmacy* 28(2), 83-88.
348. **Byrne, A. & Dolan, K.** (1998). Methadone treatment is widely accepted in prisons in New South Wales (letter to the editor). *British Medical Journal* 316, 1744.
349. **Cadman, M. & Bell, J.** (1998). Doctors detected self-administering opioids in New South Wales, 1985-1994: Characteristics and outcomes. *Medical Journal of Australia* 169, 419-421.
350. **Chan, J.S.K., Kuk, A.Y.C., Bell, J., & McGilchrist, C.** (1998). The analysis of methadone clinic data using marginal and conditional logistic models with mixture or random effects. *The Australian and New Zealand Journal of Statistics* 40(1), 1-10.
351. **Cooke, M., Mattick, R.P., & Campbell, E.** (1998). The influence of individual and organizational factors on the reported factors on the reported smoking intervention practices of staff in 20 ante-natal clinics. *Drug and Alcohol Review* 17, 175-185.

352. **Copeland, J.** (1998). Gender and Addictions: Men and Women in Treatment (book review). *Addiction* 93(10), 1599-1600.
353. **Copeland, J.** (1998). A qualitative study of self-managed change in substance dependence among women. *Contemporary Drug Problems* 25(2), 321-345.
354. **Copeland, J., Howard, J., & Fleischmann, S.** (1998). Gender, HIV knowledge and risk-taking behaviour among substance using adolescents in custody in New South Wales. *Journal of Substance Misuse* 3(4), 206-212.
355. **Copeland, J., Peters, R., & Dillon, P.** (1998). Anabolic-androgenic steroid dependence in a woman (Correspondence.) *Australian and New Zealand Journal of Psychiatry* 32(4), 589.
356. **Copeland, J., Peters, R., & Dillon, P.** (1998). A study of 100 anabolic-androgenic steroid users (letter to the editor). *Medical Journal of Australia* 168, 311.
357. **Darke, S.** (1998). Self-report among injecting drug users: a review. *Drug and Alcohol Dependence* 51, 253-263.
358. **Darke, S.** (1998). Antisocial personality disorder, psychopathy and injecting heroin use. *Drug and Alcohol Dependence* 52, 63-69.
359. **Darke, S., Kaye, S., & Finlay-Jones, R.** (1998). Drug use and injection risk-taking among prison methadone maintenance patients. *Addiction* 93(8), 1161-1167.
360. **Darke, S., Kaye, S., & Finlay-Jones, R.** (1998). Factor structure of psychopathy among methadone maintenance patients. *Journal of Personality Disorders*, 12(2), 162-171.
361. **Darke, S., Kaye, S., & Finlay-Jones, R.** (1998). Antisocial personality disorder, psychopathy and injecting heroin use. *Drug and Alcohol Dependence* 52, 63-69.
362. **Dillon, P.** (1998). Proactive or sensationalist? :The media and harm reduction. *International Journal of Drug Policy* 9(3), 175-179.
363. **Dolan, K., Wodak, A., & Hall, W.** (1998) Methadone maintenance treatment reduces heroin injection in New South Wales prisons. *Drug and Alcohol Review*, 17, 153-158.
364. **Dolan, K., Wodak, A. & Hall, W.** (1998). A bleach program for inmates in NSW: An HIV prevention strategy. *Australian and New Zealand Journal of Public Health*, 22(7), 838-840.
365. **Dolan, K., Wodak, A., Hall, W., & Kaplan, E.** (1998). A mathematical model of HIV transmission in NSW prisons. *Drug and Alcohol Dependence* 50, 197-202.
366. **Farrell, M. & Hall, W.** (1998). The Swiss Heroin Trials: testing alternative approaches. *British Medical Journal* 316, 639.
367. **Hall, W.** (1998). Creating space for a more reasoned debate about drug policy. *Policy Options* 19(8), 18-21.
368. **Hall, W.** (1998). Cannabis and psychosis. *Drug and Alcohol Review*, 17, 433-444.
369. **Hall, W.** (1998). The respiratory risks of cannabis smoking. *Addiction* 93(10), 1461-1463.
370. **Hall, W.** (1998). The search for an elixir of abstinence. *Australian Family Physician* 27, S1-S2.
371. **Hall, W. & Darke, S.** (1998). Trends in opiate overdose deaths in Australia 1979-1995. *Drug and Alcohol Dependence* 52, 71-77.
372. **Hall, W. & Degenhardt, L.** (1998). The decline in alcohol disorders with age: causes and implications. *Australasian Journal of Ageing* 17, 158-159.
373. **Hall, W. & Solowij, N.** (1998). Adverse effects of cannabis. *Lancet* 352, 1611-1616.
374. **Hando, J., Darke, S., O'Brien, S., Maher, L., & Hall, W.** (1998). The development of an early warning system to detect trends in illicit drug use in Australia: The Illicit Drug Reporting System. *Addiction Research*, 6(2), 97-113.
375. **Jarvis, T.J., Copeland, J., & Walton, L.** (1998). Exploring the nature of the relationship between child sexual abuse and substance use among women. *Addiction* 93(6), 865-875.
376. **Johnson, B.D., Dunlap, E., & Maher, L.** (1998). Nurturing for careers in drug abuse and crime: Conduct norms for children and youth in crack-abusing households. *Substance Use and Misuse* 33(7), 1515-1550.
377. **Johnston, S., Salkeld, G., Sanderson, K., Issakidis, C., Teesson, M., & Buhrich, N.** (1998). Intensive case management: a cost-effective analysis. *Australian and New Zealand Journal of Psychiatry* 32(4), 551-559.
378. **Kaye, S., Darke, S., & Finlay-Jones** (1998). The onset of heroin use and criminal behaviour: does order make a difference? *Drug and Alcohol Dependence* 53, 79-86.

379. **Lynskey, M.** (1998). The comorbidity of alcohol dependence and affective disorders: treatment implications. *Drug and Alcohol Dependence* 52, 201-209.
380. **Lynskey, M. & Hall, W.** (1998). Jurisdictional trends in opioid overdose deaths, 1988-96. *Australian and New Zealand Journal of Public Health*, 22(7), 802-807.
381. **Lynskey, M. & Hall, W.** (1998). Cohort trends in age of initiation to heroin use. *Drug and Alcohol Review* 17, 289-298.
382. **McGregor, C., Darke, S., Christie, P., & Ali, R.** (1998). Experience of non-fatal overdose among heroin users in Adelaide: circumstances and risk perception. *Addiction* 93, 701-711.
383. **Mattick, R.P. & Clarke, J.C.** (1998). Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behaviour Research and Therapy* 36, 455-470.
384. **Reilly, D., Didcott, P., Swift, W., & Hall, W. R.** (1998). Long-term cannabis use: Characteristics of users in an Australian rural area. *Addiction* 93(6), 837-846.
385. **Richmond, R.L., Gnovak, K., Kehoe, L., Calfas, G., Mendelsohn, C.P., & Wodak, A.** (1998). Effect of training on general practitioners' use of a brief intervention for excessive drinkers. *Australian and New Zealand Journal of Public Health* 22, 206-209.
386. **Richmond, R.L. & Wodak, A.** (1998). Where should alcohol and tobacco interventions be provided? *Australian and New Zealand Journal of Public Health* 22(7), 745-746.
387. **Richmond, R.L., Wodak, A., Bourne, S., & Heather, N.** (1998). Screening for unhealthy lifestyle factors in the workplace. *Australian and New Zealand Journal of Public Health* 22, 324-331.
388. **Richmond, R.L., Wodak, A., Kehoe, L., & Heather, N.** (1998). How healthy are the police? A survey of lifestyle factors. *Addiction* 93(11), 1729-1737.
389. **Sannibale, C. & Hall, W.** (1998). An evaluation of Cloninger's typology of alcohol abuse. *Addiction* 93(8), 1242-1250.
390. **Spooner, C.** (1998). The etiology and prevention of drug abuse among minority youth. *Drug and Alcohol Review* 17, 333-334.
391. **Swift, W. & Copeland, J.** (1998). Treatment needs of women with alcohol and other drug problems: experiences and views of Australian treatment personnel. *Drug and Alcohol Review* 17, 59-67.
392. **Swift, W., Copeland, J., & Hall, W.** (1998). Choosing a diagnostic cut-off for cannabis dependence. *Addiction* 93(11), 1681-1692.
393. **Swift, W., Hall, W. & Copeland, J.** (1998). Characteristics of long-term cannabis users in Sydney, Australia. *European Addiction Research* 4, 190-197.
394. **Swift, W., Hall, W., & Didcott, P.** (1998). Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. *Addiction* 93(8), 1149-1160.
395. **Swift, W., Hall, W., Didcott, P. & Reilly, D.** (1998). Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. *Addiction* 93, 1149-1160.
396. **Swift, W., Maher, L. & Sunjic, S.** (1998) Transitions between routes of heroin administration: A study of Caucasian and Indochinese heroin users in south-western Sydney, Australia. *Addiction* 94(1), 71-82.
397. **Teesson, M. & Gallagher, J.** (1998) Evaluation of a treatment programme for serious mental illness and substance use in an inner city area. *Journal of Mental Health* 8(1), 19-28.
398. **Topp, L., Lovibond, P.F., & Mattick, R.P.** (1998) Cue reactivity in dependent amphetamine users: Can monistic conditioning theories improve our understanding of reactivity? *Drug and Alcohol Review* 17, 277-288.
399. **Ward, J., W., Hall, W. & Mattick, R.P.** (1998). Role of maintenance treatment in opioid dependence. *Lancet* 353, 221-226.
400. **Wodak, A.** (1998). Health, HIV, infection, human rights and injecting drug use. *Health and Human Rights* 2(4), 24-41.
401. **Wodak, A.** (1998). Heroin prescribing: Nothing to fear but fear itself? (Editorial). *Medical Journal of Australia* 168, 590-591.
402. **Wodak, A.** (1998). Aspects of care for the hepatitis C positive patient. *Australian Family Physician* 27(9), 787-790.
403. **Wodak, A., Strathdee, S., Friedman, S.R., & Byrne, J.** (1998). The global response to the threat of HIV infection among and from drug users. *AIDS Targetted Information* 12(6), R41-R44.

1999

- 404. Bell, J., Young, M.R., Masterman, S., Morris, A., Mattick, R.P., & Bammer, G.** (1999). A pilot study of naltrexone-accelerated detoxification in opioid dependence. *Medical Journal of Australia* 171(1), 26-30.
- 405. Cooke, M., Mattick, R.P., & Campbell, E.** (1999). The dissemination of a smoking cessation program to 23 antenatal clinics: The predictors of program adoption by managers. *Australian & New Zealand Journal of Public Health* 23, 99-103.
- 406. Copeland, J.** (1999). Women and drink driving (letter to the editor). *Drug and Alcohol Review* 18, 113.
- 407. Copeland, J., Rees, V. & Swift, W.** (1999). Health concerns and help-seeking among a sample entering treatment for cannabis dependence (Correspondence.) *Australian Family Physician* 28, 540-541.
- 408. Darke, S.** (1999). Heroin in the Age of Crack Cocaine (book review). *Contemporary Psychology* 44, 95-97.
- 409. Darke, S.** (1999). Attacking overdose on the home front. Comments on Strang et al "Preventing opiate overdose fatalities with take-home naloxone: prelaunch study of possible impact and acceptability". *Addiction* 94, 205.
- 410. Darke, S., Hall, W., Weatherburn, D. & Lind, B.** (1999). Fluctuations in heroin purity and the incidence of fatal heroin overdose. *Drug and Alcohol Dependence* 54(2), 155-162.
- 411. Darke, S., Kaye, S. & Ross, J.** (1999). Transitions between the injection of heroin and amphetamines. *Addiction* 94(12), 1795-1803.
- 412. Darke, S. & Ross, J.** (1999). Heroin-related deaths in South Western Sydney, Australia, 1992-96. *Drug and Alcohol Review* 18, 39-46.
- 413. Dillon, P., Copeland, J. & Peters, R.** (1999). Exploring the relationship between male homo/bisexuality, body image and steroid use. *Culture, Health and Sexuality* 1(4), 317-327.
- 414. Dillon, P. & Singleton, M.** (1999). Cannabis. *Policing Issues and Practice Journal* 7, 1-9.
- 415. Dolan, K.** (1999). Injecting rooms in Switzerland. *NSW Public Health Bulletin* 10(6), 59-60.
- 416. Dolan, K. & Wodak, A.** (1999). HIV transmission in a prison system in an Australian state. *Medical Journal of Australia* 171(1), 14-17.
- 417. Dolan, K., Wodak, A. & Hall, W.** (1999). HIV risk behaviour and prevention in prison: A bleach programme for inmates in NSW. *Drug and Alcohol Review* 18(2), 139-144.
- 418. Hall, W.** (1999). Patient matching in the treatment of alcohol dependence: is the null hypothesis still alive and well? *Addiction* 94, 52-54.
- 419. Hall, W.** (1999) Reducing the toll of opioid overdose deaths in Australia. *Drug and Alcohol Review* 18, 219-226.
- 420. Hall, W.** (1999) Reducing the toll of opioid overdose deaths in Australia. *Drug and Alcohol Review* 18(2), 213-220.
- 421. Hall, W.** (1999) Appraisals of the health effects of cannabis: Ideology and evidence. *FAS Drug Policy Analysis Bulletin* 7, June.
- 422. Hall, W.** (1999). Opium in Britain: conflicting and converging interests. *Lancet* 353, 1449-1450.
- 423. Hall, W.** (1999). Appraisals of the health effects of cannabis: ideology and evidence. *FAS Drug Policy Analysis Bulletin* June, Number 7.
- 424. Hall, W., Degenhardt, L. & Lynskey, M.** (1999). Opioid overdose mortality in Australia, 1964-1997: birth-cohort trends. *Medical Journal of Australia* 171(1), 34-37.
- 425. Hall, W., Degenhardt, L. & Lynskey, M.** (1999). Cohort trends in overdose mortality in Australia 1964-1966: A window on post-war trends in heroin use. *Medical Journal of Australia* 171, 34-37.
- 426. Hall, W., Teesson, M., Lynskey, M. & Degenhardt, L.** (1999). The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: Findings from the National Survey of Mental Health and Well-Being. *Addiction* 94(10), 1541-1550.
- 427. Hall, W. & Wodak, A.** (1999). Is naltrexone a cure for heroin dependence? (Editorial). *Medical Journal of Australia* 171(1), 9-10.
- 428. Issakidis, C., Sanderson, K., Teesson, M., Johnston, S. & Buhrich, N.** (1999) Intensive case management in Australia: a randomized controlled trial. *Acta Psychiatrica Scandinavica* 99, 360-367.
- 429. Issakidis, C. & Teesson, M.** (1999). Measurement of need for care: A trial of the Camberwell Assessment of Need (CAN) and the HoNOS. *Australian and New Zealand Journal of Psychiatry* 33, 754-760.

430. **Lynskey, M. & Hall, W.** (1999). A reply to Caplehorn. *Drug and Alcohol Review* 18, 488.
431. **Lynskey, M., White, V., Hill, D., Letcher, T. & Hall, W.** (1999). Prevalence of illicit drug use among youth: Results from the Australian School Students' Alcohol and Drugs Survey. *Australian and New Zealand Journal of Public Health* 23(5), 1519-524.
432. **MacDonald, M. & Wodak, A.** (1999). Preventing transmission of hepatitis C. *Australian Family Physician* 28 (suppl 2), 1-5.
433. **McKetin, R.** (1999). Use of RAM to monitor illicit drug use in developed countries: Can rapid assessment result in a rapid response? (Comment on Stimson et al). *Drug and Alcohol Review* 18, 333-335.
434. **McKetin, R. & Solowij, N.** (1999). Event-related potential indices of auditory selective attention in dependent amphetamine users. *Biological Psychiatry* 45, 1488-1497.
435. **McKetin, R., Ward, P.B., Catts, S.V., Mattick, R.P. & Bell, J.** (1999). Changes in auditory selective attention and event-related potentials following oral administration of D-amphetamine in humans. *Neuropsychopharmacology* 21(3), 380-390.
436. **Maher, L. & Dixon, D.** (1999). Policing and public health: Law enforcement and harm minimization in a street-level drug market. *British Journal of Criminology* 39(4), 488-512.
437. **Maher, L. & Johnson, B.D.** (1999). Heroin, HIV and harm in New York and Sydney. *Medical Journal of Australia* 171(3), 163-165.
438. **Mattick, R.P.** (1999). Cognitive-behavioural strategies to prevent relapse. *Medicine* 27(2), 20-21.
439. **Peters, R., Copeland, J. & Dillon, P.** (1999). Anabolic-androgenic steroid use: User characteristics, motivations and deterrents. *Psychology of Addictive Behaviours* 13(3), 232-242.
440. **Richmond, R.L., Kehoe, L., Hailstone, S., Wodak, A. & Uebel-Yan, M.** (1999). Quantitative and qualitative evaluations of brief interventions to change excessive drinking, smoking and stress in the police force. *Addiction* 94(10), 1509-1521.
441. **Spooner, C.** (1999). Causes of adolescent drug abuse and implications for treatment. *Drug and Alcohol Review* 18, 457-479.
442. **Teesson, M.** (1999). Drug education: Early education vital. *Directions in Education* 8(1), 2-3.
443. **Topp, L., Hando, J. & Dillon, P.** (1999). Sexual behaviour of ecstasy users in Sydney, Australia. *Culture Health and Sexuality* 1(2), 147-160.
444. **Wodak, A.** (1999). Responding to the epidemic of drug overdose deaths. *Current Therapeutics* 40, 9-11.
445. **Wodak, A.** (1999). What is this thing called harm reduction? (Editorial). *International Journal of Drug Policy* 10, 169-171.
446. **Wodak, A.** (1999). Regulating cannabis comparative perspectives: Summary and conclusions (Editorial). *International Journal of Drug Policy Special Issue*, 10, 277-280.
447. **Wodak, A.** (1999). Naltrexone for alcohol dependence (commentary). *Modern Medicine of Australia*, November, 128-129.
448. **Wodak, W. & Baume, P.** (1999). The New South Wales Drug Summit. *Medical Journal of Australia* 171, 12-13.
- 2000
449. **Boot, B., McGregor, I.S., & Hall, W.** (2000). MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. *Lancet* 355, 1818-1821.
450. **Buck, D.J., Richmond, R.L., & Mendelsohn, C.P.** (2000). Cost-effectiveness analysis of a family physician delivered smoking cessation program. *Preventive Medicine* 31, 6410648.
451. **Buhrich, N., Hodder, T., & Teesson, M.** (2000). Prevalence of cognitive impairment among homeless people in inner Sydney. *Psychiatric Services* 51, 520-521.
452. **Buhrich, N., Hodder, T., & Teesson, M.** (2000). Lifetime prevalence of trauma among homeless people in Sydney. *Australian and New Zealand Journal of Psychiatry* 34, 963-966.
453. **Coffey, C., Lynskey, M., Wolfe, R., & Patton, G.C.** (2000). Initiation and progression of cannabis use in a population-based Australian adolescent longitudinal study. *Addiction* 95, 1679-1690.
454. **Cooke, M., Mattick, R.P., & Campbell, E.** (2000). A description of the adoption of the 'Fresh Start' smoking cessation programme by antenatal clinic managers. *Australian Journal of Advanced Nursing* 18, 13-21.
455. **Copeland, J., Peters, R., & Dillon, P.** (2000). Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. *Drug and Alcohol Dependence* 60, 91-96.

456. Copeland, J., Swift, W., & Rees, V. (2000). Brief interventions for cannabis dependence. *DrugWise February*, 51-52.
457. Darke, S. & Ross, J. (2000). The use of antidepressants among injecting drug users in Sydney, Australia. *Addiction* 95, 407-417.
458. Darke, S. & Ross, J. (2000). Fatal heroin overdoses resulting from non-injecting routes of administration, NSW, Australia, 1992-1996. *Addiction* 95, 569-573.
459. Darke, S. & Ross, J. (2000). Heroin-related deaths in regional New South Wales. 1992-96. *Drug and Alcohol Review* 19, 35-40.
460. Darke, S., Ross, J., Zador, D., & Sunjic, S. (2000). Heroin-related deaths in New South Wales. 1992-96. *Drug and Alcohol Dependence* 60, 141-150.
461. Darke, S., Sims, J., McDonald, S., & Wickes, W. (2000). Cognitive impairment among methadone maintenance patients. *Addiction* 95, 687-696.
462. Davoli, M., Ferri, M., Ali, R., Auriacombe, M., Faggiano, F., Mattick, R.P., Farrell, M. & Ling, W. (2000). The Cochrane Review Group on drugs and alcohol. *Addiction* 95, 1143-1474.
463. Degenhardt, L. (2000). Interventions for people with alcohol use disorders and an intellectual disability: A review of the literature. *Journal of Intellectual & Developmental Disability* 25, 135-146.
464. Degenhardt, L., Hall, W., & Lynskey, M. (2000). Cohort trends in the age of initiation of drug use in Australia. *Australian and New Zealand Journal of Public Health* 24, 421-426.
465. Degenhardt, L., Hall, W., & Lynskey, M. (2000). Cohort trends in the age of initiation of drug use in Australia. *Australian and New Zealand Journal of Public Health* 24, 421-426.
466. Dolan, K., Kimber, J., Fry, C., Fitzgerald, J., McDonald, D., & Trautmann, F. (2000). Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. *Drug and Alcohol Review* 19, 337-346.
467. Donnelly, N., McManus, P., Dudley, J., & Hall, W. (2000). Impact of increasing the re-supply interval on the seasonality of subscribed prescription use in Australia. *Australian and New Zealand Journal of Public Health* 24, 503-506.
468. Donnelly, N., Hall, W., & Christie, P. (2000). Effects of the Cannabis Expiation Notice System on the prevalence of cannabis use in South Australia: Evidence from the National Drug Strategy Household Surveys 1985-1995. *Drug and Alcohol Review* 19, 267-271.
469. Gallagher, J. & Teesson, M. (2000). Measuring disability, need and outcome in Australian community mental health services. *Australian and New Zealand Journal of Psychiatry* 34, 850-855.
470. Hall, W. (2000) Transcending methadone. *Lancet* 355, 585.
471. Hall, W. (2000) Rolleston revisited. *Addiction* 95, 1273-1274.
472. Hall, W. (2000) UROD: an Antipodean therapeutic enthusiasm. *Addiction* 95, 1765-1766.
473. Hall, W. (2000). The cannabis policy debate: Finding a way forward. *Canadian Medical Association Journal* 162, 1690-1692.
474. Hall, W. & Babor, T. (2000) Cannabis and public health: assessing the burden. *Addiction* 95, 485-490.
475. Hall, W. & Degenhardt, L. (2000). Cannabis and psychosis. *Australian and New Zealand Journal of Psychiatry* 34, 26-34.
476. Hall, W., Degenhardt, L., & Lynskey, M. (2000). Trends in methadone overdose death in Australia and the United Kingdom 1985-1995. *Drug and Alcohol Dependence* 57, 247-254.
477. Hall, W., Lynskey, M., & Degenhardt, L. (2000) Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995. *Drug and Alcohol Dependence* 57, 247-254.
478. Hall, W. & Mattick, R.P. (2000). Is ultra-rapid opioid detoxification a viable option in the treatment of opioid dependence? *CNS Drugs* 14, 251-255.
479. Hall, W., Ross, J., Lynskey, M., Law, M., & Degenhardt, L. (2000). How many dependent heroin users are there in Australia? *Medical Journal of Australia* 173, 528-531.
480. Hall, W. & Swift, W. (2000). The THC content of cannabis in Australia: evidence and implications. *Australian and New Zealand Journal of Public Health* 24, 503-508.
481. Hall, W. & Zador, D. (2000) Challenge of reducing drug-related deaths. *The Lancet* 356, 7.
482. Henderson, S., Andrews, G., & Hall, W. (2000) Australia's mental health: an overview of the general population survey. *Australian and New Zealand Journal of Psychiatry* 34, 197-205.

483. **Kaye, S. & Darke, S.** (2000). Comparison of the harms associated with the injection of heroin and amphetamines. *Drug and Alcohol Dependence* 58, 189-195.
484. **Lynskey, M., Degenhardt, L. & Hall, W.** (2000). Cohort trends in youth suicide in Australia 1964-1997. *Australian and New Zealand Journal of Psychiatry* 34, 408-412.
485. **Lynskey, M. & Hall, W.** (2000). The effects of adolescent cannabis use on educational attainment: a review. *Addiction* 95, 1621-1630.
486. **MacDonald, M.A., Wodak, A.D., Dolan, K.A., van Beek, I., Cunningham, P.H., & Kaldor, J.M.** (2000). Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Medical Journal of Australia* 172, 57-61.
487. **Reid, A., Lynskey, M., & Copeland, J.** (2000) Cannabis use among Australian adolescents: findings of the 1998 National drug Strategy Household Survey. *Australian and New Zealand Journal of Public Health* 24, 596- 602.
488. **Ross, J. & Darke, S.** (2000). The nature of benzodiazepine dependence among heroin users in Sydney, Australia. *Addiction* 95, 1785-1793.
489. **Strang, J., Witton, J., & Hall, W.** (2000). Improving the quality of the cannabis policy debate: defining the different domains. *British Medical Journal* 320, 108-110.
490. **Swift, W., Copeland, J., & Lenton, S.** (2000). Cannabis and harm reduction. *Drug and Alcohol Review* 19, 101-112.
491. **Swift, W., Hall, W., & Copeland, J.** (2000). One year follow-up of cannabis dependence among long-term users in Sydney, Australia. *Drug and Alcohol Dependence* 59, 309-318.
492. **Taylor, S., Choucair, A., Shaw, J., & Copeland, J.** (2000) Assessment of need for information on illicit drugs in the Arabic, Chinese and Vietnamese languages. *Australian Family Physician* 29, 725-726.
493. **Teesson, M.** (2000) Management of Drug Users in the Community: a practical handbook (book review). *Addiction* 94, 1751.
494. **Teesson, M., Hall, W., Lynskey, M., & Degenhardt, L.** (2000) Alcohol and drug-use disorders in Australia: implications of the National Survey of Mental Health and Wellbeing. *Australian and New Zealand Journal of Psychiatry* 34, 206-213.
495. **Teesson, M., Hodder, T., & Buhrich, N.** (2000) Substance use disorders among homeless people in inner Sydney. *Social Psychiatry and Psychiatric Epidemiology* 35, 451-456.
496. **Topp, L., Hando, J., Dillon, P., Roche, A. & Solowij, N.** (2000) Ecstasy use in Australia: Patterns of use and associated harm. *Drug and Alcohol Dependence* 55, 105-115.
497. **Wickes, W.A., Darke, S. & Ross, J.** (2000). Clobazam maintenance among methadone maintenance patients with problematic benzodiazepine use: five case studies. *Drug and Alcohol Review* 19, 401-405.
498. **Wutzke, S.E., Conigrave, K.M., Kogler, B.E., Saunders, J.B., & Hall, W.D.** (2000). Longitudinal research: methods for maximising subject follow-up. *Drug and Alcohol Review* 19, 159-163.
- 2001**
499. **Bonomo, Y., Coffey, C., Wolfe, R., Lynskey, M., Bowes, G., & Patton, G.** (2001). Alcohol-related problem behaviours in 16-17 year old Australian students. *Addiction* 96, 1485-1496.
500. **Cooke, M., Mattick, R.P., & Walsh, R.A.** (2001). Differential uptake of a smoking cessation programme disseminated to doctors and midwives in antenatal clinics. *Addiction* 96, 495-506.
501. **Cooke, M., Mattick, R.P., Walsh, R.** (2001). Implementation of the 'fresh start' smoking cessation program in 23 antenatal clinics: a randomized controlled trial investigating two methods of dissemination. *Drug and Alcohol Review* 20, 19-28.
502. **Copeland, J.** (2001). Mothers and illicit drugs: transcending the myths (book review). *Addiction* 96, 783.
503. **Copeland, J.** (2001). Women's Perspectives on Drugs and Alcohol: The Vicious Circle (book review). *Addiction* 96, 1681-1685.
504. **Copeland, J.** (2001). Nursing interventions for cannabis use disorder: Part 1 Prevalence and harms. *Pulse: Information Sheet of the Royal College of Nursing Australia*. 1-2.
505. **Copeland, J.** (2001). Nursing interventions for cannabis use disorder: Part 2 Prevalence and harms. *Pulse: Information Sheet of the Royal College of Nursing Australia*, 1-2.
506. **Copeland, J. & Conroy, A.** (2001). Australian National Minimum Data Set for Clients of Alcohol and Other Drug Treatment Services: findings of the national pilot and developments in implementation. *Drug and Alcohol Review* 20(3), 295-298.

507. Copeland, J., Swift, W., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J. (2001). A randomised controlled trial of brief interventions for cannabis problems among young offenders. *Drug and Alcohol Dependence* 63(s1), s32.
508. Copeland, J., Swift, W., & Rees, V. (2001). Clinical profile of participants in a brief intervention program for cannabis use disorder. *Journal of Substance Abuse Treatment* 20, 45-52.
509. Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001). A randomised controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. *Journal of Substance Abuse Treatment* 21, 55-64.
510. Darke, S. (2001). The Impact of Harm Reduction Based Methadone Treatment on HIV Infection and Mortality (book review). *Addiction* 96, 1072.
511. Darke, S., Kaye, S. & Ross, J. (2001). Geographical injecting locations among injecting drug users in Sydney, Australia. *Addiction* 96, 241-246.
512. Darke, S. & Ross, J. (2001). The relationship between suicide and heroin overdose among methadone maintenance patients in Sydney, Australia. *Addiction* 96, 1443-1453.
513. Darke, S., Ross, J. & Kaye, S. (2001). Physical injecting sites among injecting drug users in Sydney, Australia. *Drug and Alcohol Dependence* 62, 77-82.
514. Degenhardt, L., Conigrave, K., Wutzke, S., & Saunders, J. (2001). The validity of an Australian modification of the AUDIT questionnaire. *Drug and Alcohol Review* 20, 143-153.
515. Degenhardt, L. & Hall, W. (2001). The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-Being. *Psychological Medicine* 31, 659-668.
516. Degenhardt, L. & Hall, W. (2001) The relationship between tobacco use, substance use disorders and mental health: results from the National Survey of Mental Health and Well-being. *Nicotine and Smoking Research* 3, 225-234.
517. Degenhardt, L. Hall, W., & Adelstein, B. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. *Australian and New Zealand Journal of Public Health* 27, 447-450.
518. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. *Australian and New Zealand Journal of Public Health* 25, 447-450.
519. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use and other substance use in the general population. *Drug and Alcohol Dependence* 64, 319-327.
520. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. *Addiction* 96, 1603-1614.
521. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Co-morbidity between alcohol, tobacco and cannabis use: reply to David Ferguson (letter to the editor). *Addiction* 96, 1862.
522. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use and other substance use in the general population. *Drug and Alcohol Dependence* 64, 319-327.
523. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. *Social Psychiatry and Psychiatric Epidemiology* 36, 219-227.
524. Digiusto, E., Mattick, R.P., Kimber, J., O'Brien, S., Doran, C., Henderson, N., & Breen, C. (2001). National evaluation of pharmacotherapies for opioid dependence - why have we done it? (Editorial) *Drug and Alcohol Review*, 20, 139-141.
525. Dillon, P. & Degenhardt, L. (2001). Ketamine and GHB: new trends in club drug use? *Journal of Substance Use* 6, 11-15.
526. Dolan, K. (2001). Can hepatitis C transmission be reduced in Australian prisons? *The Medical Journal of Australia*, 174, 378-379.
527. Edwards, G., West, R., Babor, T., & Hall, W. (2001). No switching off the camera: how *Addiction* will respond to infringements of ethical publishing expectation. *Addiction* 96, 1391-1392.
528. Hall, W. (2001). Reducing the harms of cannabis use: the policy debate in Australia. *Drug and Alcohol Dependence* 62, 163-174.

529. **Hall, W., Degenhardt, L., & Currow, D.** (2001). Allowing the medical use of cannabis. *Medical Journal of Australia* 175, 39-40.
530. **Hall, W., Kimber, J. & Lynskey, M.** (2001). Breaking the deadlock over an Australian trial of injectable opioid maintenance. *Medical Journal of Australia* 176, 72-73.
531. **Kimber, J. & Dolan, K.** (2001) A view from Australia (book review). *International Journal of Drug Policy* 12, 203.
532. **Law, M.G., Lynskey, M., Ross, J., & Hall, W.** (2001) Back-projection estimates of the number of dependent heroin users. *Addiction* 96, 433-443.
533. **Lenné, M., Lintzeris, N., Breen, C., Harris, S., Hawken, L., Mattick, R., & Ritter, A.** (2001). Withdrawal from methadone maintenance treatment: prognosis and participant perspectives. *Australian and New Zealand Journal of Public Health* 25, 121-125.
534. **Lee, A., Tan, S., Lim, D., Winslow, R.M., Wong, K.E., Allen, J., Hall, W., & Parker, G.** (2001). Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. *Drug and Alcohol Review* 20, 193-199.
535. **Lynskey, M. & Hall, W.** (2001). Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link? *Addiction* 96, 815-822.
536. **McGregor, C., Ali, R., Christie, P., & Darke, S.** (2001). Overdose among heroin users: evaluation of an intervention in South Australia. *Addiction Research and Theory* 9, 481-501.
537. **Maher, L., Swift, W., & Dawson, M.** (2001). Heroin purity and composition in Sydney. *Drug and Alcohol Review* 20, 439-448.
538. **Mattick, R.P., Ali, R., Auriacombe, M., Davoli, M., Faggiano, E., Farrell, M., Ferri, M., & Ling, W.** (2001). Cochrane Drugs and Alcohol Group: The development of systematic reviews of treatment outcome. *Alcohol & Alcoholism* 36, 109-111.
539. **Post, J.J., Dolan, K.A., Whybin, L.R., Carter, I.W.J., Haber, P.S., & Lloyd, A.R.** (2001). Acute hepatitis C virus infection on an Australian prison inmate: tattooing as a possible transmission route. *Medical Journal of Australia* 174, 183-184.
540. **Proudfoot, H. & Teesson, M.** (2001). Women and schizophrenia (Book review). *Australian and New Zealand Journal of Psychiatry* 35, 698.
541. **Rosen, A. & Teesson, M.** (2001). Does case management work? The evidence and the abuse of evidence-based medicine. *Australian and New Zealand Journal of Psychiatry* 35, 731-746. (A Corrigendum to this article has been published in the *Australian and New Zealand Journal of Psychiatry* 36, 288.)
542. **Rouen, D. & Dolan, K.** (2001). Supporting needle and syringe programs in Australia (letter to the editor). *Australian and New Zealand Journal of Public Health* 25, 187.
543. **Rubin, G.L., Schofield, W.N., Dean, M.G., & Shakeshaft, A.P.** (2001). Appropriateness of red blood cell transfusions in major urban hospitals and effectiveness of an intervention. *Medical Journal of Australia* 175, 354-358.
544. **Sannibale, C. & Hall, W.** (2001). Gender related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders. *Drug and Alcohol Review* 20, 369-383.
545. **Shearer, J., Wodak, A., Mattick, R.P., van Beek, I., Lewis, J., Hall, W., & Dolan, K.** (2001). Pilot randomised controlled study of dexamphetamine for amphetamine dependence. *Addiction* 96, 1289-1296.
546. **Spooner, C., Hall, W., & Mattick, R.** (2001). An overview of diversion strategies for drug-related offenders. *Drug and Alcohol Review* 20, 281-94.
547. **Spooner, C., Mattick, R., & Noffs, W.** (2001). A study of the patterns and correlates of substance use among adolescents applying for treatment. *Australia & New Zealand Journal of Public Health* 24, 492-502.
548. **Spooner, C., Mattick, R.P., & Noffs, W.** (2001). Outcomes of a comprehensive treatment program for adolescents with a substance-use disorder. *Journal of Substance Use Treatment* 20, 205-213.
549. **Swift, W., Copeland, J., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J.** (2001). Adolescent cannabis check-up and intervention trial. *Drug and Alcohol Dependence* 63(s1), s156.
550. **Swift, W., Hall, W., & Teesson, M.** (2001). Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. *Addiction* 96, 737-748.

551. **Swift, W., Hall, W., & Teesson, M.** (2001). Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. *Drug and Alcohol Dependence* 63, 147-153.
552. **Tabakoff, B., Helander, A., Conigrave, K.M., Martinez, L., Hoffman, P.L., Whitfield, J., Degenhardt, L., Saunders, J., Baron, A., Glanz, J., & Members of the WHO/ISBRA Study Group** (2001) WHO/ISBRA Study on State and Trait Markers in Alcoholism. *Alcoholism: Clinical and Experimental Research* 25, 99S-103S.
553. **Teesson, M.** (2001) Practical measures in psychiatry (book review). *Medical Journal of Australia* 175, 417.
554. **Warner-Smith, M., Darke, S., Lynskey, M.T., & Hall, W.** (2001). Heroin overdose: Causes and consequences. *Addiction* 96, 1113-1125.
555. **Warner-Smith, M., Lynskey, M., Hall, W., & Monteiro, M.** (2001). Challenges attributable to illicit drug use. *European Addiction Research* 7, 104-116.
556. **Williamson, A., Feyer, A.M., Mattick, R.P., Friswell, R., & Finlay-Brown, S.** (2001). Developing measures of fatigue using an alcohol comparison to validate the effects of fatigue on performance. *Accident Analysis & Prevention* 33, 313-326.
557. **Wodak, A. & Hall, W.** (2001). Buprenorphine: better late than never. *Medical Journal of Australia* 175, 349-350.
558. **Wodak, A., Hall, W., Mattick, R.P., & Saunders, J.B.** (2001) Naltrexone treatment for opioid dependence: Past, present and future. *Drug and Alcohol Review* 20, 349-350.
- 2002**
559. **Bonevski, B., Doran, C., Bailey, C., & Lowe, J.** (2002). Description of an early discharge post-acute care program: length of hospital stay, patient and carer needs and cost. *Australian Health Review* 25, 78-86.
560. **Burns, L. & Teesson, M.** (2002). Alcohol use disorders comorbid with anxiety, depression and drug use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. *Drug and Alcohol Dependence* 68, 299-308.
561. **Coffey, C., Carlin, J.B., Degenhardt, L., Lynskey, M., Sanci, L., & Patton, G.C.** (2002). Cannabis dependence in young adults: an Australian population study. *Addiction* 97, 187-194.
562. **Conigrave, K.M., Degenhardt, L.J., Whitfield, J.B., Saunders, J.B., Helander, A., & Tabakoff, B.** (2002). CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA Collaborative Project. *Alcoholism: Clinical and Experimental Research* 26, 332-339.
563. **Copeland, J.** (2002). Dealing: Women in the Drug Economy (book review). *Australian and New Zealand Journal of Public Health* 26(3), 292.
564. **Copeland, J.** (2002). Drug Misuse and Motherhood: H. Klee, M. Jackson & S. Lewis. *Addiction* 97(9), 1228.
565. **Darke, S., Kaye, S., & Topp, L.** (2002). Cocaine use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the illicit drug reporting system. *Drug and Alcohol Dependence* 67, 81-88.
566. **Darke, S., Hall, W., Kaye, S., Ross, J., & Dufflou, J.** (2002). Hair morphine concentrations of fatal heroin overdose cases and living heroin users. *Addiction* 97, 977-984.
567. **Darke, S. & Ross, J.** (2002). Suicide among heroin users: rates, risk factors and methods. *Addiction* 97, 977-984.
568. **Darke, S., Topp, L., Kaye, S., & Hall, W.** (2002). Heroin use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the Illicit Drug Reporting System. *Addiction* 97, 179-186.
569. **Darke, S., Topp, L., & Ross, J.** (2002). The injection of methadone and benzodiazepines among Sydney IDU 1996-2000: 5 year monitoring of trends from the Illicit Drug Reporting System (IDRS). *Drug and Alcohol Review* 21, 35-40.
570. **Degenhardt, L., Darke, S., & Dillon, P.** (2002). GHB use among Australians: characteristics, use patterns and associated harms. *Drug and Alcohol Dependence* 67, 89-94.
571. **Degenhardt, L., Gascoigne, M., & Howard, J.** (2002). Young people's drug use when heroin is less available. *Youth Studies Australia* 21, 11-16.
572. **Degenhardt, L. & Hall, W.** (2002). Cannabis and psychosis. *Current Psychiatry Reports* 4, 191-196.

573. **Degenhardt, L., Lynskey, M., Coffey, C., & Patton, G.** (2002). 'Diagnostic orphans' among young adult cannabis users: persons who report dependence symptoms but do not meet diagnostic criteria. *Drug and Alcohol Dependence* 67, 205-212.
574. **Dolan, K.** (2002). The Addicted Offender: Developments in British Policy and Practice (Book review). *Addiction* 97, 187-194.
575. **Doran, C.M., Shakeshaft, A.P., Gates, J., Fawcett, J.E., & Mattick, R.P.** (2002). Current prescribing patterns of bupropion in Australia (letter to the editor). *Medical Journal of Australia* 177, 162.
576. **Edwards, G., Babor, T., West, R., & Hall, W.** (2002). Another mirror shattered: industry origins of a book which claims that nicotine is not addictive. *Addiction* 97, 1-5.
577. **Henderson, N. & Huon, G.** (2002). Negative affect and binge eating in overweight women. *British Journal of Health Psychology* 7, 77-87.
578. **Kaye, S. & Darke, S.** (2002). Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. *Addiction* 97, 727-731.
579. **Lynskey, M., Heath, A.C., Nelson, E.C., Bucholz, K.K., Maddem, P.A.F., Slutske, W.S., Statham, D.J., & Martin, N.G.** (2002). Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. *Psychological Medicine* 32, 195-207.
580. **McGregor, C., Ali, R., Lokan, R., Christie, P., & Darke, S.** (2002). Accidental fatalities among heroin users in South Australia, 1994-1997: Toxicological findings and circumstances of death. *Addiction Research and Theory* 10, 335-346.
581. **Patton, G., Coffey, C., Carlin, J.B., Degenhardt, L., Lynskey, M., & Hall, W.** (2002). Cannabis use and mental health in young people: cohort study. *British Medical Journal* 325, 1195-1198.
582. **Proudfoot, H. & Teesson, M.** (2002). Who seeks treatment for alcohol dependence? Findings from the Australian National Survey of Mental Health and Wellbeing. *Social Psychiatry and Psychiatric Epidemiology* 37, 451-456.
583. **Rey, J., Sawyer, M.G., Raphael, B., Patton, G.C., & Lynskey, M.** (2002). The mental health of teenagers who use marijuana: Results of an Australian survey. *British Journal of Psychiatry* 180, 216-221.
584. **Rosen, A. & Teesson, M.** (2002). Does case management work? The evidence and the abuse of evidence-based medicine. *Australian and New Zealand Journal of Psychiatry* 35, 731-746.
585. **Rubin, G.L., Schofield, W.N., Dean, M.G., & Shakeshaft, A.P.** (2002). Appropriateness of red blood cell transfusions in major urban hospitals and effectiveness of an intervention. *Medical Journal of Australia* 175, 354-358.
586. **Shakeshaft, A.P., Bowman, J.A., Burrows, S., Doran, C., & Sanson-Fisher, R.W.** (2002). Community-based alcohol counseling: a randomized clinical trial. *Addiction* 97, 1449-1463.
587. **Shakeshaft, A.P., Bowman, J.A., & Sanson-Fisher, R.W.** (2002). Community-based drug and alcohol counselling: who attends and why? *Drug and Alcohol Review* 21, 153-162.
588. **Shand, F. & Mattick, R.P.** (2002). Results from the 4th National Clients of Treatment Service Agencies census: changes in clients' substance use and other characteristics. *Australian and New Zealand Journal of Public Health* 26, 352-357.
589. **Shearer, J.** (2002). Cocaine Addiction Theory, Research and Treatment (book review). *Drug and Alcohol Review* 21, 188-189.
590. **Shearer, J., Sherman, J., Wodak, A., & Van Beek, I.** (2002). Substitution therapy for amphetamine users. *Drug and Alcohol Review* 21, 179-185.
591. **Sibthorpe, B., Bailie, R., Brady, M., Ball, S., Sumnerdodd, P., & Hall, W.** (2002). The demise of a planned randomized controlled trial in an urban Aboriginal Medical Service. *Medical Journal of Australia* 176, 273-276.
592. **Simon, N.G. & Mattick, R.P.** (2002). The impact of regular ecstasy use on memory function. *Addiction* 97, 1523-1530.
593. **Solowij, N. & Grenyer, B.** (2002). Are the adverse consequences of cannabis use age-dependent? (Editorial). *Addiction* 97, 1083-1086.
594. **Solowij, N., Stephens, R.S., Roffman, R.A., Babor, T., Kadden, R., Miller, M., Christiansen, K., McRee, B., & Vendetti, J.** (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. *Journal of the American Medical Association* 287, 1123-1131.

595. **Spooner, C. & Hall, W.** (2002). Preventing drug misuse by young people: we need to do more than 'just say no' (Editorial). *Addiction* 97, 478-481.
596. **Spooner, C. & Hall, W.** (2002). Public policy and the prevention of substance-use disorders. *Current Opinion in Psychiatry* 15, 235-9.
597. **Teesson, M., Dietrich, U., Degenhardt, L., Lynskey, M., & Beard, J.** (2002). Substance use disorders in an Australian community survey. *Drug and Alcohol Review* 21, 275-280.
598. **Teesson, M., Lynskey, M., Manor, B., & Baillie, A.** (2002). The structure of cannabis dependence in the community. *Drug and Alcohol Dependence* 68, 255-262.
599. **Topp, L., Degenhardt, L., Kaye, S., & Darke, S.** (2002). The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system. *Drug and Alcohol Review* 21, 341-348.
600. **Warner-Smith, M., Darke, S., & Day, C.** (2002). Morbidity associated with non-fatal heroin overdose. *Addiction* 97, 963-968.



Books/book chapters/government reports/conference proceedings

1987

1. **Gladstone, W. & Greeley, J.** (1987). Methadone treatment: Principles policy and practice. In **J. Greeley & W. Gladstone** (eds) *Methadone Programs in Australia: Policy and Practice*. NDARC Monograph No 1. Sydney: National Drug & Alcohol Research Centre.
2. **Heather, N.** (1987). DRAMS for problem drinkers: The potential of a brief intervention by general practitioners and some evidence of its effectiveness. In **T. Stockwell & S. Clement** (eds) *Helping the Problem Drinker: New Initiatives in Community Care*. London: Croom Helm.
3. **Prescott, J.** (1987). Research issues in methadone maintenance. In **J. Greeley & W. Gladstone** (eds) *Methadone Programs in Australia: Policy and Practice*. NDARC Monograph No 1. Sydney: National Drug & Alcohol Research Centre.
8. **Elkins, L. & Richmond, R.** (1989). *Women and Smoking: The Choice is Yours*, Sydney: NSW Department of Health.
9. **Heather, N.** (1989). A fresh look at 'loss of control'. In **J. Greeley & N. Heather** (eds) *Perspectives on Drug and Alcohol Dependence*. NDARC Monograph No 6. Sydney: National Drug & Alcohol Research Centre.
10. **Heather, N.** (1989). Evaluation of intervention and outcome: How do we know if it works? In *Proceedings of the International Congress on Alcohol, Other Drugs and the Family*. Sydney: Alcohol and Drug Foundation.
11. **Heather, N.** (1989). Brief intervention strategies. In **R.K. Hester & W.R. Miller** (eds). *Handbook of Alcoholism Treatment Approaches*. New York: Pergamon Press.

1988

4. **Heather, N.** (1988). Research priorities at the National Drug and Alcohol Research Centre. In **J. Greeley & N. Heather** (eds) *Towards a National Drug and Alcohol Research Network*. NDARC Monograph No 3. Sydney: National Drug & Alcohol Research Centre.
12. **Heather, N.** (1989). Controlled drinking treatment: Where do we stand today? In **T. Loberg, W.R. Miller, P.E. Nathan, & G.A. Marlatt** (eds) *Addictive Behaviours: Prevention and Early Intervention*, Amsterdam: Swets and Zeitlinger.

1989

5. **Chesher, G. & Greeley, J.** (1989). The effect of alcohol on cognitive and psychomotor functioning. In **J. Greeley & E. Gladstone** (eds) *The Effects of Alcohol on Cognitive Psychomotor and Affective Functioning*. NDARC Monograph No 8. Sydney: National Drug & Alcohol Research Centre.
6. **Chesher, G. & Greeley, J.** (1989). The effects of alcohol on mood. In **J. Greeley & W. Gladstone** (eds) *The Effects of Alcohol on Cognitive, Psychomotor and Affective Functioning*. NDARC Monograph No 8. Sydney: National Drug & Alcohol Research Centre.
7. **Chesher, G., Greeley, J., & Saunders, J.B.** (1989). Tolerance to the effects of alcohol. In **J. Greeley & W. Gladstone** (eds) *The Effects of Alcohol on Cognitive, Psychomotor and Affective Functioning*. NDARC Monograph No 8. Sydney: National Drug & Alcohol Research Centre.
13. **Heather, N.** (1989). A fresh look at loss of control. In **P.F. Lovibond & P. Wilson** (eds) *Proceedings of the XXIV International Congress of Psychology, Vol 9: Clinical and Abnormal Psychology*. Amsterdam: Elsevier Science Publishers BV.
14. **Heather, N., Batey, R., Saunders, J.B., & Wodak, A.** (1989). *The effectiveness of treatment for drug and alcohol problems. An overview*. National Drug Strategy Monograph Series No. 11. Australian Government Publication Service, Canberra.
15. **Heather, N. & Greeley, J.** (1989). Cue exposure: An alternative model for the prevention of relapse in the addictive disorders. In **B.F.S. Grenyer & N. Solowij** (eds) *Cognitive-behavioural Approaches to the Treatment of Drug and Alcohol Problems*. NDARC Monograph No 7. Sydney: National Drug and Alcohol Research Centre.
16. **Heather, N., Richmond, R., Webster, I., & Wodak, A.** (1989). *A Guide to Healthier Drinking*. Sydney Clarendon Printing.
17. **Heather, N. & Robertson, I.** (1989). *Problem Drinking (Revised Edition)*. Oxford: Oxford University Press.

18. **Heather, N. & Stallard, A.** (1989). Does the Marlatt model underestimate the importance of conditioned craving in the relapse process? In **M. Gossop** (ed) *Relapse and Addictive Behaviour*. London: Croom Helm.
19. **Heather, N. & Tebbutt, J.** (eds) (1989). *The Effectiveness of Treatment for Drug and Alcohol Problems: An Overview*. NCADA Monograph Series, No 11. Canberra: Australian Government Publishing Service.
20. **Richmond, R.L. & Wakefield, D.** (eds) (1989). *Sexually Transmitted Diseases and the AIDS Epidemic*. New York: Harcourt Brace Jovanovich.
21. **Stallard, A. & Heather, N.** (1989). Relapse prevention and AIDS among intravenous drug users. In **M. Gossop** (ed) *Relapse and Addictive Behaviour*. London: Groom Helm.
22. **Wodak, A. & Gold, J.** (1989). AIDS and intravenous drug use. In **R. Richmond & D. Wakefield** (eds) *Sexually transmitted infections and the AIDS epidemic*. Harcourt, Brace and Jovanovich.
- 1990
23. **Greeley, J. & McDonald, D.** (eds) (1990). *Alcohol and Human Behaviour* (Research Paper No 14) Canberra: Royal Commission into Aboriginal Deaths in Custody.
24. **Hall, W.** (1990). A survey of early and brief intervention research in Australia. In **J. Carless & W. Hall** (eds) *Proceedings from the National Workshop into Early/Brief Interventions for Drug and Alcohol Problems*. NDARC Monograph No 9. Sydney: National Drug and Alcohol Research Centre.
25. **Heather, N.** (1990). Treatment of alcohol problems: With special reference to the behavioural approach. In **D.K. Balfour** (ed) *Psychotropic Drugs of Abuse*. London: Pergamon Press.
26. **Heather, N.** (1990). Antabuse treatment for alcohol problems: Is it effective and, if so, why? In **C. Brewer** (ed) *Effective Treatment Options in Addiction*. London: Gaskell Monograph, The Royal College of Psychiatrists.
27. **Mattick, R.P.** (1990). Social phobia: An overview of psychological concepts and treatments. In **N. McNaughton** and **G. Andrews** (eds.), *Anxiety*. Dunedin, New Zealand: Otago University Press.
28. **Richmond, R.L., Webster, I., & Heather, N.** (1990). *Drug Use Amongst Youth: Patterns, Psychological Factors and Prevention*. Document prepared for the Parliamentary Standing Committee on Social Issues.
29. **Smith, R., Hunter, E., Spargo, R., & Hall, W.** (1990). *A Summary of Research Findings on Health and Lifestyle Presented to Kimberley Aboriginal Communities* Canberra: CSIRO Division of Human Nutrition.
30. **Wodak, A.** (1990). AIDS and injecting drug use in Australia: A case study in policy development and implementation. In **J. Strang & G.V. Stimson** (eds) *AIDS and Drugs Misuse: The challenge for Policy and Practice in the early 1990's*. London: Routledge.
- 1991
31. **Baker, A.L. & Dixon, J.** (1991). Motivational interviewing for HIV risk-reduction. In **W.R. Miller, & S. Rollnick** (eds) *Motivational Interviewing: Preparing People to Change Addictive Behaviours*. New York: Guilford.
32. **Bell, J. & Hall, W.** (1991). Does methadone maintenance reduce the criminal activity of opiate addicts? In **J. Hando** (ed) *Evaluation Clients and Treatments* NDARC Monograph No 11. Sydney: National Drug & Alcohol Research Centre.
33. **Bell, J. & Wyndham, L.** (1991). Screening for drug abuse – a community challenge. *Clinical Biochemist Monograph No 5*.
34. **Darke, S., Ward, J., Hall, W., Heather, N., & Wodak, A.** (1991). Assessing opiate users: The Opiate Treatment Index (OTI). In **J. Hando** (ed) *Evaluating Clients and Treatments*. NDARC Monograph No 11. Sydney: National Drug & Alcohol Research Centre.
35. **Davidson, I., Rollnick, S., & MacEwan, I.** (1991). *Counselling the problem drinker*. London: Routledge.
36. **De Burgh, S.P.H.** (1991). Alcohol and heart disease and the question of causality. In *Proceedings of the Conference on Medicinal Virtues of Alcohol in Moderation, Sydney, 30 October-1 November 1991*. Victoria: The Medical Friends of Wine Society, 142-175.
37. **Elkins, L. & Richmond, R.** (1991). Outcome results of the Smokescreen programme after being conducted in a hospital clinic and onsite in the workplace. In *The Global War: Proceedings of the*

- Seventh World Conference on Smoking and Health, Perth, April 1990*, 639-644.
38. **Fox, G.A. & Fox, A.M.** (1991). A neuropsychological test for diffuse brain damage. In **W.R. Levick, B.G. Frost, M. Watson, & H.P. Pfister** (eds) *Brain Impairment: Advances in Applied Research, Proceedings of the 15th Annual Conference of the Australian Society for the Study of Brain Impairment, University of Newcastle*, 165-171.
 39. **Greeley, J. & Westbrook, F.** (1991). Associative learning, drug use and addictive behaviour. In **N. Heather, W.R. Miller & J. Greeley** (eds) *Self-control and the Addictive Behaviors*, Sydney: Maxwell MacMillan.
 40. **Hall, W. & Bird, K.D.** (1991). Statistical inference in psychiatric research. In **V.J. Carr, H. Eshkevari, R. Kalucy & R. Kosky** (eds) *Mental Health and Illness: A Textbook for Australasian Health Science Students*. Sydney: Butterworth-Heinemann.
 41. **Heather, N.** (1991). Foreword to **I. Davidson, S. Rollnick, & I. MacEwan** (eds) *Counselling the Problem Drinker*. London: Routledge.
 42. **Heather, N.** (1991). Impaired control over alcohol consumption. In **N. Heather, W.R. Miller & J. Greeley** (eds) *Self-control and the Addictive Behaviours*. Sydney: Maxwell MacMillan Publishing.
 43. **Heather, N., Miller, W.R., & Greeley, J.D.** (eds) (1991). *Self-control and the Addictive Behaviours*. Sydney: Pergamon Press.
 44. **Jarvis, T. & Duquemin, A.** (1991). Research into drug and alcohol issues for women: Where are the gaps? How can these best be addressed? *Changing the Research Story: Women and Drugs. Proceedings of the Women and Drugs Research Workshop, February*. Melbourne, 438-440.
 45. **Mant, A.** (1991). Women and substance abuse. In **D. Saltman** (ed). *Women and Health: An Introduction to Issues*. Sydney: Harcourt Brace Jovanovich.
 46. **Mattick, R.P.** (1991). *Approaches to the Evaluation of Treatment Services for Problems of Drug Abuse*. Commissioned Report to the World Health Organisation Project on Assessing Standards of Care in Drug Abuse Treatment. Geneva: WHO.
 47. **Mattick, R.P. & Franks, F.B.** (1991). Development and implementation of Australian standards of care for drug and alcohol treatment services. In **J. Orley** (ed) *National Perspectives on Quality Assurance in Mental Health Care*. Geneva: WHO, 71-78.
 48. **Mattick, R.P., Peters, L., & Clarke, J. C.** (1991). Exposure and cognitive restructuring for social phobia: A controlled study. In **K. M. McConkey and N. W. Bond** (eds.), *Readings in Australian Psychology*. Harcourt, Brace, Jovanovich, Sydney.
 49. **Miller, W.R. & Rollnick, S.** (1991). *Motivational Interviewing: Preparing People to Change Addictive Behaviours*. New York: Guildford.
 50. **Richmond, R.L.** (1991). Smokescreen: A decade of experience conducting research in general practice for smokers. In **J. Hando** (ed) *Evaluating Clients and Treatment*. NDARC Monograph No 11. Sydney: National Drug & Alcohol Research Centre.
 51. **Richmond, R.L., Elkins, L., Mendelsohn, C., & Rollnick, S.** (1991). *Smokers: You Have a Right to Know*. Sydney: NSW Department of Health.
 52. **Richmond, R.L., Elkins, L., Mendelsohn, C., & Rollnick, S.** (1991). *Smokers: The Choice is Yours*. Sydney: NSW Department of Health.
 53. **Richmond, R.L., Elkins, L., Mendelsohn, C., & Rollnick, S.** (1991). *Taking Action to Stop Smoking*. Sydney: NSW Department of Health.
 54. **Richmond, R.L., Elkins, L., Mendelsohn, C., & Rollnick, S.** (1991). *Self-help for Smokers*. Sydney: NSW Department of Health.
 55. **Richmond, R.L., Heather, N., Holt, P., & Hu, W.** (1991). A survey of policies and programmes for tobacco, alcohol and drugs in the top 600 companies in Australia. In *Proceedings of the Conference on Alcohol and Drugs in the Workplace - Reducing the Costs, Melbourne, April 18-19, 1991*. Canberra: Department of Health, Housing and Community Services.
 56. **Richmond, R.L., Makinson, R., Giugni, A., & Webster, I.** (1991). General practitioner smoking interventions in Australia: Results of studies over the past ten years. In *The Global War: Proceedings of the Seventh World Conference on Tobacco and Health, Perth, April 1990*. 657-660.
 57. **Richmond, R. L., Webster, I., Elkins, L., Mendelsohn, C., & Rollnick, S.** (1991). *Smokescreen for the 1990's: A Stop Smoking Programme for General Practitioners to Use with Smokers*. Sydney: NSW Department of Health.

58. **Rollnick, S. & Bell, A.** (1991). Brief motivational interviewing for the non-specialist. In **W.R. Miller & S. Rollnick**. *Motivational Interviewing: Preparing People to Change Addictive Behaviours*. New York: Guildford.
59. **Rollnick, S. & MacEwan, I.** (1991). Alcohol counselling in context. In **R. Davidson, S. Rollnick, & I. MacEwan** (eds) *Counselling the Problem Drinker*. London: Routledge.
60. **Solowij, N. & Lee, N.** (1991). *A survey of Ecstasy (MDMA) Users in Sydney*. Research Grant Report Series No. B91/1 Sydney, NSW Drug & Alcohol Directorate.
61. **Stewart, J.** (1991). Evaluation of a specialist drug and alcohol service for women. In **J. Hando** (ed) *Evaluating Clients and Treatment*. NDARC Monograph No 11. Sydney: National Drug & Alcohol Research Centre.
62. **Stewart, J.** (1991). Gender-sensitive treatment services? An evaluation *Pro-Ed (No3)*, 5-9.
63. **Stewart, J.** (1991). Evaluation of a specialist drug and alcohol treatment service for women. In *Proceedings of the 1991 National Women and Drugs Conference, Melbourne, February 10-12, 1991*. Melbourne, Addiction Research Institute of Victoria, 214-226.
64. **Stewart, J.** (1991). The Jarrah House evaluation research experience. *Changing the Research Story: Women and Drugs, Proceedings of the Women and Drugs Research Workshop, February 1991, Melbourne*. Melbourne, Addiction Research Institute of Victoria) 45-46.
65. **Ward, J., Mattick, R., & Hall, W.** (1991). *Assessment of Opioid Dependence and Suitability for Methadone Maintenance*. Report prepared for the Drug & Alcohol Directorate, NSW Department of Health.
66. **Ward, J., Mattick, R., & Hall, W.** (1991). *Duration of Methadone Maintenance*. Report prepared for the Drug & Alcohol Directorate, NSW Department of Health.
67. **Ward, J., Mattick, R., & Hall, W.** (1991). *Methadone Maintenance and Pregnancy*. Report prepared for the Drug & Alcohol Directorate, NSW Department of Health.
68. **Webster, P. & Jarvis, T.** (1991). The Quality Assurance Project: Implications for Women. *Changing the Research Story: Women and Drugs. Proceedings of the Women and Drugs Research Workshop, February 1991 Melbourne*, Melbourne, Addiction Research Institute of Victoria, 45-46.
69. **Webster, P., Mattick, R.P., & Baillie, A.J.** (1991). *Clients of Treatment Service Agencies: March 1990 Census Findings*. Canberra: Australian Government Printing Service.
70. **Wodak, A.** (1991). Alcoholism. In **R.E. Rakel** (ed) *Conn's Current Therapy*. Section 16: Psychiatric Disorders. W B Saunders Company, 1035-1040.
71. **Wodak, A.** (1991). To shun the Heaven that leads man to this hell: AIDS and drug injection. Chapter AIDS and Drug Use. In **I. Glass** (ed) *Handbook in Addiction Behaviour*. Routledge: London.
72. **Wodak, A.** (1991). To take up arms against a ser of drugs: AIDS, Injecting drug users and drug policy. HIV Infection and AIDS. *Present Status and Future Prospects for Prevention, Treatment and Cure. Proceedings of the 1991 Annual General Meeting of the Australian Academy of Science, 3 May 1991 Canberra*. Canberra, Australian Academy of Science. 61-70.
73. **Wodak, A., Richmond, R..L, Webster, I.W., Scanlon, K., & Solomon, M.** (1991). Alcoholscreen: Detection, assessment and minimal intervention for problem drinkers in general practice. In **J. Bell & L. Wyndham** (eds). *Screening for Drug Abuse – A Community Challenge*, Clinical Biochemist Monograph No. 5 (Marylands, WA, Australian Association of Clinical Biologists) 22-26.
74. **Wodak, A., Shaw, J.M., Gaughwin, M.D., Ross, M.W., Miller, M.E., & Gold, J.** (1991). Behind bars: HIV risk-taking behaviour of Sydney male drug injectors while in prison. In **J. Norberry, M. Gaughwin & S.A. Gerrull** (eds) *HIV/AIDS and Prisons: Proceedings of the Conference on AIDS in Prisons, 21 November 1990, Melbourne*. Canberra: Australian Institute of Criminology, 239-44.
- 1992
75. **Baker, A.L, Heather, N & Wodak, A.** (1992). The application of self-control strategies to reducing HIV risk-taking behaviour in intravenous drug users. In **N. Heather, W.R. Miller & J. Greeley** (eds) *Self-control and the Addictive Behaviours*. Sydney: Maxwell MacMillan Publishing.
76. **Chesher, G., Fox, A., Greeley, J., Lemon, J., & Nabke, C.** (1992). *Investigation of the 'Hangover' Effects of An Acute Dose of Alcohol on Psychomotor Performance*. Final report of results from

- Consultancy 89/175, Federal Office of Road Safety.
77. **Hall, W., Ward, J., & Hando, J.** (1992). The effectiveness of methadone maintenance treatment: Implications for a proposed trial of injectable heroin maintenance. In **G. Brammer & G. Gerrard** (eds) *Heroin Treatment – New Alternatives*. Canberra: National Centre for Epidemiology and Population Health.
 78. **Mant, A.** (1992). Intervention. In **L. Price** (ed) *Staff Development Manual*. Committee for International Day Against Drug Abuse and Illicit Trafficking, June 26 1991, Sydney.
 79. **Mant, A.** (1992). Prescribing and the Use of Psychotropic Drugs: Ideal, ideology and rationally In **TRANX National Conference on Benzodiazepine (Minor Tranquilliser) Use, October 25, 1991**, La Trobe University Union.
 80. **Mant, A., Hall, W., Hu, W., & Whicker, S.D.** (1992). *A Drug and Alcohol Educational Network for Doctors*. Report to the NCADA April 1992.
 81. **Mattick, R.P.** (1992). Psychoactive substance dependence and associated states. In **S. Schwartz** (ed) *Case Studies in Abnormal Psychology*. Brisbane: John Wiley and Sons.
 82. **Mattick, R.P. & Baillie, A.J.** (eds) (1992). *An outline for approaches to smoking cessation: Quality Assurance Project*. NCADA Monograph Series No 19, Australian Government Publishing Service, Canberra.
 83. **Oldenberg, B. & Lemon, J.** (1992). *Drug Use Among a Cohort of Sydney Teenagers in 1985, 1986 & 1988*. A Report from the University of Sydney, Department of Public Health.
 84. **Ross, M.W., Wodak, A., Miller, M.E., & Gold, J.** (1992). Attitudes towards termination of pregnancy and associated risk behaviours in drug-injecting women. **F. Melica** (ed) in *AIDS and Reproduction: Proceedings of the First International Conference, Genoa*. Basel, Karger. 55-60.
 85. **Ward, J., Mattick, R., & Hall, W.** (1992). *Counselling Psychotherapy and Psychopathology*. Report prepared for the Drug & Alcohol Directorate, NSW Department of Health.
 86. **Ward, J., Mattick, R., & Hall, W.** (1992). *Methadone Maintenance and Pregnancy*. Report prepared for the Drug & Alcohol Directorate, NSW Department of Health.
 87. **Ward, J., Mattick, R., & Hall, W.** (1992). *Withdrawal Regimens at the End of Methadone Maintenance*. Report prepared for the Drugs & Alcohol Directorate, NSW Department of Health.
 88. **Ward, J., Mattick, R.P., & Hall, W.** (1992). *Key Issues in Methadone Maintenance Treatment* Sydney: New South Wales University Press.
 89. **Ward, J., O'Connor, D., Mattick, R., & Hall, W.** (1992). Translating research into policy: Methadone maintenance in New South Wales. In **J. White** (ed.), *Drug problems in society: Dimensions and perspectives* (pp.51-56). Drug and Alcohol Services Council, Parkside, South Australia.
 90. **Wodak, A.** (1992). Beyond the prohibition of heroin: The development of a controlled availability policy in Australia. In **P.A. O'Hare, R. Newcombe, A. Mathews, E.C. Buning, & E. Drucker** (eds). *The Reduction of Drug-Related Harm*. Routledge: London pp 49-61.
 91. **Wodak, A.** (1992). Emergency presentations of alcohol and drugs. In **G.W.O. Fulde** (ed) *Emergency Medicine: The Principles of Practice*. Williams and Wilkins: Sydney pp 359-372.
 92. **Wodak, A., Dwyer, R., Ross, M.W., Drury, M.J., Gold, J., & Miller, M.E.** (1992). *Life at the Epicentre: Sex and drug using behaviour in Sydney*. Australian National AIDS and Injecting Drug Use Study, Sydney.
- 1993**
93. **Bell, J. & O'Connor, D.** (1993). *Methadone Prescribers Manual*. AMPSAD, Sydney.
 94. **Chen, R., Mattick, R.P., & Baillie, A.** (1993). *Clients of Treatment Service Agencies: March 1992 Census Findings*. Australian Government Publishing Service, Canberra.
 95. **Copeland, J.** (1993). Issues for consideration in the treatment of women with alcohol and other drug problems. In *Women: Alcohol and Other Drugs – An Update on Health and Social Issues. Proceedings of an Eastern Area Health Service Workshop*, 13-14.
 96. **Fox, A.M., Nabke, C., Chesher, G., Greeley, J., & Lemon, J.** (1993). Acute and hangover effects of alcohol on event-related potentials (ERPs). In **H.D. Utzermann, G. Berghaus & G. Kroj,** (eds), *Alcohol, Drugs and Traffic Safety – T92, Proceedings of the 12th International Conference on Alcohol, Drugs and Traffic Safety*, Cologne, 649-652.

97. **Greeley, J., Swift, W., & Heather, N.** (1993). Desire to drink or not to drink in alcohol-dependent patients in treatment. In **L. Harris** (ed), *Problems of drug dependence 1991: Proceedings of the 53rd Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc* (NIDA Research Monograph No. 132, 212). Rockville, MD: National Institute on Drug Abuse.
98. **Greeley, J., Swift, W., Prescott, J., & Heather, N.** (1993). Cue reactivity in heavy and light drinkers. In **L. Harris** (ed) *Problems of drug dependence 1991: Proceedings of the 53rd Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc* (NIDA Research Monograph No. 119, 325). Rockville, MD: National Institute on Drug Abuse.
99. **Hall, W., & Hando, J.** (1993). Patterns of illicit psychostimulant use in Australia. In **D. Burrows, B. Faherty, & M. MacAvoy** (eds) *Illicit Psychostimulant Use in Australia*. Canberra: National Campaign Against Drug Abuse.
100. **Hando, J., & Hall, W.** (1993). *Amphetamine Use Among Young Adults in Sydney, Australia*. Research Grant Report Series No. B93/2 Sydney, NSW Drug & Alcohol Directorate.
101. **Harris, K., Richmond, R., & Holt, P.** (1993). Smoking cessation rates: the hospital clinic versus the worksite program. *Proceedings of the 8th World Conference on Tobacco or Health*. Buenos Aires.
102. **Heather, N.** (1993). Antabuse treatment for alcohol problems: is it effective and, if so, why? In **C. Brewer** (ed). *Medical Management of Alcohol and Opiate Abuse*. London: Gaskell Monographs, The Royal College of Psychiatrists.
103. **Heather, N.** (1993). Application of harm-reduction principles to the treatment of alcohol problems. In **N. Heather, A. Wodak, E. Nadelmann, & P. O'Hare** (eds). *Psychoactive Drugs and Harm Reduction: From Faith to Science* London: Whurr Publications.
104. **Heather, N.** (1993). "No Quick Fix" and the Australian drug and alcohol research agenda: a reply to Pederson, Montague and Webster. In **M. Balzer** (ed). *Drug and Alcohol Research and Evaluation: Concepts and Priorities. A Report on AMPSAD's National Conference 1992*. Sydney: Australia Medical and Professional Society on Alcohol and Other Drugs.
105. **Heather, N.** (1993). The role of research in the National Drug Strategy. In **M. Balzer** (ed). *Drug and Alcohol Research and Evaluation: Concepts and Priorities. A Report on AMPSAD's National Conference 1992*. Sydney: Australian Medical and Professional Society on Alcohol and Other Drugs.
106. **Heather, N., Wodak, A., Nadelmann, E., & O'Hare, P.** (eds) (1993). *Psychoactive Drugs and Harm Reduction: From Faith to Science*. London: Whurr Publications.
107. **Heather, N., Wodak, A., Nadelmann, E., & O'Hare, P.** (1993). Preface to **N. Heather, A. Wodak, E. Nadelmann, & P. O'Hare** (eds) *Psychoactive Drugs and Harm Reduction: From Faith to Science*. London
108. **Lemon, J., Greeley, J., Fox, A., Chesher, G., & Nabke, C.** (1993). The effects of 'hangover' on psychomotor performance twelve hours after drinking. In **H.D. Utzelmann, G. Berghaus & G. Kroj** (eds) *Alcohol, Drugs and Traffic Safety - T92 Proceedings of the 12th International Conference on Alcohol, Drugs and Traffic Safety*, Cologne, 653-656.
109. **Mattick, R.P., Baillie, A., Grenyer, B., Hall, W., Hando, J., Jarvis, T., Ward, J. & Webster, P.** (1993). *A treatment outline for approaches to opioid dependence: quality assurance project*. National Drug Strategy Monograph Series No 21. Australian Government Publishing Service, Canberra.
110. **Mattick, R.P., Baillie, A., Grenyer, B., Hall, W., Jarvis, T., & Webster, P.** (1993). *An outline for the management of alcohol problems: quality assurance project*. National Drug Strategy Monograph Series, No 20. Australian Government Publishing Service, Canberra.
111. **Mattick, R.P., & Hall, W.** (1993). *A treatment outline for approaches to opioid dependence: Quality assurance in the treatment of drug dependence project*, National Campaign Against Drug Abuse Monograph No. 21. Australian Government Publishing Service, Canberra.
112. **Mattick, R.P., & Jarvis, T.** (1993). *An outline for the management of alcohol problems: Quality assurance in the treatment of drug dependence project*. National Campaign Against Drug Abuse Monograph No. 20. Australian Government Publishing Service, Canberra.
113. **Nabke, C.** (1993). *The chronic and acute effects of alcohol on memorising strategies, free-recall and event-related potentials in heavy and light male social drinkers*. (Research thesis, Master of Psychology) (Clinical), UNSW.

1994

114. **Donnelly, N. & Hall, W.** (1994). *Patterns of cannabis use in Australia*. National Drug Strategy Monograph Series No. 27. Australian Government Publication Service, Canberra.
115. **Hall, W., Solowij, N. & Lemon, J.** (1994). *The health and psychological effects of cannabis use*. National Drug Strategy Monograph Series No. 25. Australian Government Publication Service, Canberra.
116. **Mattick, R.P. & Andrews, G.** (1994). Social phobia. In **M. Hersen & R. T. Ammerman** (eds.) *Handbook of prescriptive treatments for adults* (pp.157-178). Plenum Press, New York.
117. **Mattick, R.P., Bell, J., & Hall, W.** (1994). Psychiatric morbidity, antisocial personality disorder, and treatment response in methadone maintenance patients. In **L. S. Harris** (ed.), *Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting - The College on Problems of Drug Dependence Volume II: Abstracts* (332). National Institute on Drug Abuse Research Monograph 141. Rockville, MD: National Institutes of Health.
118. **Pead, J., Greeley, J.D., Ritter, A., Murray, T., Felstead, B., Mattick, R., & Heather, N.** (1994). A clinical trial of cue exposure combined with cognitive-behavioural treatment for alcohol dependence. In **L.S. Harris** (ed.), *Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting - The College on Problems of Drug Dependence Volume II: Abstracts* (332). National Institute on Drug Abuse Research Monograph 141. Rockville, MD: NIH.
- II: Abstracts* (153). National Institute on Drug Abuse Research Monograph 153. Rockville, MD: National Institutes of Health.
122. **Greeley, J. D., Pead, J., Murray, T., Pahoki, S., Ritter, A., Felstead, B., Mattick, R.P., & Heather, N.** (1995). Preliminary outcome of cue exposure treatment for alcohol dependence. In **L. S. Harris** (ed.), *Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting - The College on Problems of Drug Dependence Volume II: Abstracts* (233). National Institute on Drug Abuse Research Monograph 153. Rockville, MD: National Institutes of Health.
123. **Hall, W.** (1995). Substance abuse. In **A. Jorm**, (ed) *Men and Mental Health*. National Health and Medical Research Council, Australian Government Publishing Service, Canberra.
124. **Hall, W. & Nelson, J.** (1995). *Public perceptions of the health and psychological consequences of cannabis use*. National Drug Strategy Monograph Number 29. Australian Government Publishing Service, Canberra.
125. **Jarvis, T., Tebbutt, J., & Mattick, R.P.** (1995). *Treatment approaches for alcohol and drug dependence*. John Wiley and Sons. Sussex, England.
126. **Loxley, W., Carruthers, S., Wodak, A., Crofts, N., Dolan, K., Gaughwin, M. & Kaldor, J.** (1995). Patterns of infection. *National AIDS Bulletin* 9(2), 26-27.
127. **Mattick, R.P., Page, A., & Lampe, L.** (1995). Cognitive and behavioural aspects of social phobia. In **M. B. Stein** (Ed.) *Social phobia: Clinical and research perspectives* (pp.189-228). American Psychiatric Press, Washington, D.C.

1995

119. **Bell, J., Ward, J., Mattick, R.P., Hay, A., Chan, J., & Hall, W.** (1995). *An evaluation of private methadone clinics*. NDS Research Report Series No. 4. AGPS, Canberra.
120. **Copeland, J.** (1995). Women and Substance Abuse. In *Update in Women's Health: Strategies to Reduce Morbidity and Mortality*. Alpha Biomedical Communications: Sydney, 183-190.
121. **Darke, S., Cohen, J., Ross, J., Hando, J., & Hall, W.** (1995). Transitions between routes of administration of regular amphetamine users. In **L. S. Harris** (ed.), *Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting - The College on Problems of Drug Dependence Volume*
128. **Cooke, M.** (1996). Barriers to brief intervention. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 104-118.
129. **Dolan, K.** (1996). HIV prevalence and transmission in prisons. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 126-139.
130. **Hall, W.** (1996). What have populations surveys revealed about substance use disorders and their comorbidity with other mental disorders? In *Substance Use and Mental Illness: Proceedings of the*

Fourth Lingard Symposium. Hunter Institute of Mental Health, Newcastle.

131. **Hando, J.** (1996). Treatment needs of regular amphetamine users in Sydney. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 1-30.
132. **Hando, J. & Hall, W.** (1996). *Patterns of amphetamine misuse in Australia*. In **H. Klee** (ed.) *Amphetamine misuse - International perspectives on current trends*. Chur, Switzerland: Harwood Academic Publishers.
133. **McKetin, R., Mattick, R., Ward, P., Catts, S., & Bell, J.** (1996). Amphetamine use: Changes in mood, memory and attention. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 31-45.
134. **Mattick, R.P.** (1996). Substance dependence and abuse. In **P.R. Martin and J.S. Birnbrauer** (eds.) *Clinical Psychology Profession and Practice in Australia*. MacMillan, Melbourne.
135. **Mattick, R.P., Oliphant, D.A., Bell, J., & Hall, W.** (1996). Psychiatric morbidity in methadone maintenance patients: prevalence, effect on drug use and detection. In *Substance Use and Mental Illness: Proceedings of the Fourth Lingard Symposium*. Hunter Institute of Mental Health, Newcastle.
136. **Ross, J., Darke, S., & Hall, W.** (1996). Benzodiazepine injecting among heroin users. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 140-150.
137. **Spooner, C.** (1996). Bridging the gap between research and practice: A case study. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 1-30.
138. **Swift, W., Copeland, J., & Hall, W.** (1996). *Characteristics and Treatment Needs of Women with Alcohol and Other Drug Problems: Results from an Australian Survey*. National Drug Strategy Research Report Series, Number 7. Australian Government Publishing Service, Canberra.
139. **Swift, W., Hall, W., & Copeland, J.** (1996). Patterns and consequences of long term cannabis use. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 80-103.
140. **Topp, L.** (1996). Cue reactivity in amphetamine users. In *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney, 46-79.
- 1997
141. **Copeland, J. & Howard, J.** (1997). Substance abuse and juvenile crime. In **A. Borowski and I. O'Connor** (eds.) *Juvenile Crime, Juvenile Justice and Juvenile Corrections*. Longman Cheshire: Melbourne, 167-189.
142. **Copeland, J. & Jarvis, T.J.** (1997). Childhood sexual assault and the subsequent development of substance abuse among women. In **L.S. Harris**, *Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting, The College on Problems of Drug Dependence Inc.* NIDA Research Monograph 174, 112.
143. **Dawe, S. & Mattick, R.P.** (1997). *Review of diagnostic screening instruments for alcohol and other psychiatric disorders*. Australian Government Publishing Service, Canberra.
144. **Dolan, K.** (1997). AIDS drugs and risk behaviour in prison: State of the art. In **J. Nelles & A. Fuhrer** *Harm Reduction in Prison* (pp 213-238). Swiss Federal Office of Public Health, Bern.
145. **Dolan, K.** (1997). Why is there conflicting evidence of HIV transmission in prison? In *Report of the 3rd European Conference on Drug and HIV/AIDS Services in Prison*. O. O'Brien (Ed.) Cranstoun Drug Services, London, 19-21.
146. **Hall, W., Ward, J., & Mattick, R.P.** (1997). The role of drug maintenance treatment in the management of drug dependence. In **D. Sellman, G. Robinson, R. McCormick, & G. Dore** (eds.) *The Long and the Short of Treatment for Alcohol and Drug Disorders*, Department of Psychological Medicine, Christchurch School of Medicine, Christchurch.
147. **Hando, J. & Hall, W.** (1997). Drug availability and crime among amphetamine users in Australia: Implications for law enforcement. In **Australian Bureau of Criminal Intelligence**. *Australian Illicit Drug Report 1996-1997*. Australian Bureau of Criminal Intelligence, Canberra.
148. **Hando, J. & Hall, W.** (1997). Patterns of ampheta-

- mine misuse in Australia. In **H. Klee** (ed) *Amphetamine Misuse: International Perspectives on Current Trends*. Harwood Academic Publishers, Reading.
149. **McGregor, C., Ali, R., Darke, S., & Christie, P.** (1997). Benzodiazepine use among heroin users in Adelaide, Australia: patterns and preferences. In **K. Dyer & D. Addy** (Eds.), *New Perspectives: Proceedings of the 1997 NCETA Research Seminar Program*. National Centre for Education and Training on Addiction, Adelaide.
150. **Maher, L.** (1997). *Sexed work: Gender, race and resistance in a Brooklyn drug market*. Oxford: Oxford University Press.
151. **Maher, L., Dixon, D., Swift, W., & Nguyen, T.** (1997). *Ann hai: Young Asian background people's perceptions and experiences of policing*. Research Monograph Series: UNSW Faculty of Law.
- 1998
152. **Abeni, D., Perucci, C.A., Dolan, K., & Sangali, S.** (1998). Prison and HIV-1 infection among injecting drug users. In **G. Stimson, D.C. Des Jarlias & A. Ball** (eds.) *Drug Injecting and HIV infection: Global Dimensions and Local Responses* (pp 168-182). London, University College London Press.
153. **Ali, R., Christie, P., Lenton, S., Hawks, D., Sutton, A., Hall, W., & Allsop, S.** (1998). *The Social Impacts of the Cannabis Expiation Notice Scheme in South Australia*. Report to the Ministerial Council on Drug Strategy, 4 May 1998. Department of Health and Family Services, Canberra.
154. **Bell, J.** (1998). Delivering effective methadone treatment. In **J. Ward, R.P. Mattick & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Therapies*. Harwood Academic Publishers, Amsterdam.
155. **Bell, J.** (1998). Staff training in methadone clinics. In **J. Ward, R.P. Mattick & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Therapies*. Harwood Academic Publishers, Amsterdam.
156. **Daly, K. & Maher, L.** (1998). *Criminology at the crossroads: Feminist readings of crime and justice*. New York: Oxford University Press.
157. **Darke, S.** (1998). The effectiveness of methadone maintenance treatment 3: Moderators of treatment outcome. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp. 75-90). Amsterdam: Harwood Academic Publishers.
158. **De Burgh, S.** (1998). The distribution of alcohol consumption. In **M. Grant & J. Lifvak** (eds.) *Drinking Patterns and their Consequences*. Washington D.C., Taylor and Francis.
159. **Dillon, P., Peters, R., Copeland, J., & Beel, A.** (1998). The quest for the body beautiful: Male anabolic-androgenic steroid use in NSW. In *Conference Proceedings: 2nd National Men's Health Conference 1997*. Men's Health Teaching and Research Unit, School of Public Health, Curtin University of Technology, Perth, 100-105.
160. **Dolan, K., Hall, W., & Wodak, A.** (1998). The provision of methadone within prison settings. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp. 379- 396). Amsterdam: Harwood Academic Publishers.
161. **Donoghoe, M., Hall, W., Ball, A., & Lopez, A.** (1998). *Opioid Overdose: Trends, risk factors, interventions and priorities for action*. Substance Abuse Department, World Health Organization, Geneva.
162. **Hall, W.** (1998). Cannabis use and psychosis. In *Having It Both Ways: Problematic drug and alcohol use and mental illness. Conference Proceedings*. Tehan, M. & Chong, D. (Eds), 9-29.
163. **Hall, W., Ward, J. & Mattick, R.** (1998). The effectiveness of methadone maintenance treatment 1: Heroin use and crime. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp. 17-58). Amsterdam: Harwood Academic Publishers.
164. **Hall, W., Ward, J., & Mattick, R.** (1998). The future of opioid replacement therapy. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp. 443-462). Amsterdam: Harwood Academic Publishers.
165. **Hall, W., Ward, J. & Mattick, R.P.** (1998). The role of drug maintenance in the treatment of drug dependence. In **D. Sellman, G. Robinson, R. McCormick & G. Dore** (eds) *The Long and the Short of Treatment for Alcohol and Drug Disorders*. Department of Psychological Medicine, Christchurch School of Medicine, Christchurch.
166. **Hando, J., Topp, L., & Dillon, P.** (1998). Associated harms and risk-taking behaviour. In **P. Dillon, L. Topp, & W. Swift**, (1998) *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre*

- Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
167. **Hunter, E.M., Brady, M., Hall, W., Arlidge, L., & Eltringham, A.** (1998). *Services relating to Alcohol in Indigenous Communities: A Report to the office of Aboriginal and Torres Strait Islander Health Services*. Department of Social and Preventive Medicine, University of Queensland.
 168. **Lynskey, M.** (1998). A longitudinal study of cannabis use during adolescence. In **P. Dillon, L. Topp, & W. Swift**, (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
 169. **Mattick, R.P., Oliphant, D., Ward, J., & Hall, W.** (1998). The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine, naltrexone and injectable maintenance. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.123-157). Amsterdam: Harwood Academic Publishers.
 170. **Mattick, R.P., Ward, J., & Hall, W.** (1998). The role of counselling and psychological therapy. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp. 265-304). Amsterdam: Harwood Academic Publishers.
 171. **Maxwell, J., Davey, J., & Dillon, P.** (1998). *Comparison of patterns of illicit drug use in Australia and the United States*. Texas Commission on Alcohol and Drug abuse, Austin, Texas.
 172. **Peters, R., Copeland, J., & Dillon, P.** (1998). Patterns and correlates of anabolic-androgenic steroid use. In **P. Dillon, L. Topp, & W. Swift**, (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
 173. **Rees, V., Copeland, J., & Swift, W.** (1998). Brief cognitive behavioural interventions for cannabis dependence. In **P. Dillon, L. Topp, & W. Swift**, (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
 174. **Ross, J. & Darke, S.** (1998). Benzodiazepine dependence and psychopathology among heroin users. In **P. Dillon, L. Topp, & W. Swift**, (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
 175. **Solowij, N.** (1998). *Cannabis and Cognitive Functioning*. Cambridge, UK: Cambridge University Press.
 176. **Spooner, C.** (1998). *Primary prevention of psychoactive substance-related harm: A review*. Report prepared for the World Health Organization, Sydney.
 177. **Swift, W., Hall, W., & Copeland, J.** (1998). One year on: A follow-up of long-term cannabis smokers. In **P. Dillon, L. Topp, & W. Swift**, (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
 178. **Teesson, M., Hodder, T., & Buhrich, N.** (1998). Drug dependence among the homeless in Sydney, Australia. In **L.S. Harris, (ed)** *Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc.* NIDA Research Monograph 179, US Department of Health and Human Services.
 179. **Topp, L., Hando, J., & Dillon, P.** (1998). Ecstasy I: Patterns and context of use. In **P. Dillon, L. Topp, & W. Swift**, (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Monograph No 37, Sydney: National Drug and Alcohol Research Centre.
 180. **Ward, J., Mattick, R.P., & Hall, W.** (1998). *Methadone Maintenance Treatment and Other Opioid Replacement Therapies*, Harwood Academic Publishers, Amsterdam.
 181. **Ward, J., Mattick, R.P., & Hall, W.** (1998). The effectiveness of methadone maintenance treatment 2: HIV and infectious hepatitis. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.59-74). Harwood Academic Publishers, Amsterdam.

182. **Ward, J., Mattick, R.P., & Hall, W.** (1998). Assessment for opioid replacement therapy. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.177-203). Harwood Academic Publishers, Amsterdam.
183. **Ward, J., Mattick, R.P. & Hall, W.** (1998). The use of methadone during maintenance treatment: Pharmacology, dosage and treatment outcome. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.205-238). Harwood Academic Publishers, Amsterdam.
184. **Ward, J., Mattick, R.P., & Hall, W.** (1998). The use of urinalysis during opioid replacement therapy. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.239-264). Harwood Academic Publishers, Amsterdam.
185. **Ward, J., Mattick, R.P., & Hall, W.** (1998). How long is long enough? Answers to questions about the duration of methadone maintenance treatment. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.305-336). Harwood Academic Publishers, Amsterdam.
186. **Ward, J., Mattick, R.P., & Hall, W.** (1998). Making the transition from maintenance to abstinence: Detoxification from methadone maintenance treatment. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.337-358). Harwood Academic Publishers, Amsterdam.
187. **Ward, J., Mattick, R.P., & Hall, W.** (1998). Methadone maintenance during pregnancy. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.397-418). Harwood Academic Publishers, Amsterdam.
188. **Ward, J., Mattick, R.P., & Hall, W.** (1998). Psychiatric comorbidity among the opioid dependant. In **J. Ward, R.P. Mattick, & W. Hall** (eds.) *Methadone Maintenance Treatment and Other Opioid Replacement Therapies* (pp.419-440). Harwood Academic Publishers, Amsterdam.
189. **Wodak, A.** (1998). Harm reduction as an approach to treatment. In **A.W. Graham & T.K. Schultz** (eds.) *Principles of Addiction Medicine, second edition.* (pp. 395-404). American Society of Addiction Medicine.
- 1999
190. **Andrews, G., Hall, W., Teesson, M. & Henderson, S.** (1999). *The Mental Health of Australians.* National Survey of Mental Health & Well-being Report No 2. Canberra: Mental Health Branch, Commonwealth Department of Aged Care.
191. **Bell, J., Kimber, J., Mattick R.P.** (1999). *Interim clinical guidelines: Use of naltrexone in relapse prevention for opioid dependence.* Commonwealth Department of Health and Aged Care, Canberra.
192. **Channabasavanna, S., Paes, M. & Hall, W.** (1999). Mental and behavioural disorders due to cannabis. In: **H. Kalant, W. Corrigal, W. Hall & R. Smart** (eds) (1999) *The Health Effects of Cannabis.* (pp ix-xi). Addiction Research Foundation, Toronto.
193. **Chesher, G. & Hall, W.** (1999). The effects of cannabis on the cardiovascular and gastrointestinal systems. In: **H. Kalant, W. Corrigal, W. Hall & R. Smart** (eds) (1999) *The Health Effects of Cannabis.* (pp ix-xi). Addiction Research Foundation, Toronto.
194. **Copeland, J.** (1999). Women and alcohol: Implications for road safety. In *Proceedings of the National Road Safety Summit 1998.* Federal Office of Road Safety: Canberra, 121-127.
195. **Dixon, D. & Maher, L.** (1999) Walls of silence. In: **G. Hage and R. Couch** (eds) *The future of Australian multiculturalism.* Sydney: Research Institute for Humanities and Social Sciences.
196. **Dolan, K. & Crofts, N.** (1999) A review of risk behaviours, transmission and prevention of blood borne viral infections in Australian prisons. In: **D. Shewan & J.B. Davies** (eds) *Drug Use and Prisons. An International Perspective.* (pp 215-232). Harwood Academic Publishers, London.
197. **Donnelly, N., Hall, W., & Christie, P.** (1999). *Effects of the Cannabis Expiation Notice Scheme on levels and patterns of cannabis use in South Australia: Evidence from the National Drug Strategy Household Surveys 1985-1995.* National Drug Strategy Research Monograph Number 37. Australian Government Publishing Service, Canberra.
198. **Fry, A. & Teesson, M.** (1999) *Blacktown Youth Suicide Prevention Project: Hospital and Health Services Protocols 1.2.1 Final Report.* University of Western Sydney, Sydney.
199. **Hall, W.** (1999). Assessing the health and psychological effects of cannabis use. In: **H. Kalant, W. Corrigal, W. Hall & R. Smart** (eds) (1999) *The*

- Health Effects of Cannabis*. (pp ix-xi). Addiction Research Foundation, Toronto.
200. **Hall, W.** (1999) Heroin and other opioid overdose deaths in Australia. In: *Heroin Crisis*. (pp 170-176). Bookman Press, Melbourne.
201. **Hall, W., Johnston, L. & Donnelly, N.** (1999) The epidemiology of cannabis use and its consequences. In: **H. Kalant, W. Corrigal, W. Hall, & R. Smart** (eds) (1999) *The Health Effects of Cannabis*. (pp ix-xi). Addiction Research Foundation, Toronto.
202. **Hall, W., Room, R. & Bondy, S.** (1999) Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In: **H. Kalant, W. Corrigal, W. Hall, & R. Smart** (eds) (1999) *The Health Effects of Cannabis*. (pp ix-xi). Addiction Research Foundation, Toronto.
203. **Hall, W. & Teesson, M.** (1999) Alcohol use disorders: Who should be treated and how? In: **G. Andrews & A.S. Henderson** (eds) *Unmet need in psychiatry: Problems, resources, responses*. (pp 290-301). Cambridge University Press.
204. **Hando, J., Hall, W., Rutter, S. & Dolan, K.** (1999). *Current state of research on illicit drugs in Australia: An information document*. National Health and Medical Research Council, Commonwealth of Australia.
205. **Howe, D., Temple, L., Mackson, C. & Teesson, M.** (1999). *'Catch Us If U Can!' Young People and Psychiatric Illness – Intervention & Assessment (YPPI-IA) Final Report*. YPPI Centre, Sydney.
206. **Kalant, H., Corrigal, W., Hall, W. & Smart, R.** (eds) (1999). *The Health Effects of Cannabis*. Addiction Research Foundation, Toronto.
207. **Kalant, H., Corrigal, W., Hall, W. & Smart, R.** (1999). Introduction. In: **H. Kalant, W. Corrigal, W. Hall, & R. Smart** (eds) *The Health Effects of Cannabis*. (pp ix-xi). Addiction Research Foundation, Toronto.
208. **McGregor, C., Hall, K., Ali, R., Christie, P., Braithwaite, R., & Darke, S.** (1999). It's rarely just the 'h': addressing overdose among South Australian heroin users through a process of intersectoral collaboration. *Drug and Alcohol Services Council of South Australia Monograph No. 2*. Drug and Alcohol Services Council, Parkside, South Australia.
209. **Maher, L., Nguyen, T. & Le, T.** (1999) Wall of silence: Stories of Cabramatta street youth. In: **R. White** (ed) *Australian youth subcultures*. Hobart: National Clearinghouse for Youth Studies.
210. **Rees, V., Copeland, J., Swift, W., Roffman, R. & Stephens, R.** (1999) Brief cognitive behavioural interventions for cannabis dependence. In: **L.S. Harris** (ed) *Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting, The College on Problems of Drug Dependence Inc*. NIDA Research Monograph 179, 79.
211. **Robertson, S., Kellehear, K., Teesson, M. & Miller, V.** (eds) (1999) *Making History: Shaping the Future. Contemporary THEMHS in Mental Health Services*. Standard Publishing House, Rozelle.
212. **Solowij, N.** (1999) Long-term effects of cannabis on the central nervous system. I Brain function and neurotoxicity. II Cognitive functioning. In: **H. Kalant, W. Corrigal, W. Hall, & R. Smart** (eds) (1999) *The Health Effects of Cannabis*. (pp 195-265). Addiction Research Foundation, Toronto.
213. **Spooner, C., Mattick, R., & Hall, W.** (1999). *Suspended sentences with treatment orders: A proposed framework for diversion pilot projects*. Report prepared for NSW Intersectoral Taskforce on Recidivism of Drug & Alcohol Offenders. CJ Spooner: Planning Research & Evaluation & NDARC, Sydney, 1999.
214. **Swift, W., Hall, W., & Copeland, J.** (1999). Cannabis dependence: a one year follow-up of long-term cannabis users. In **L.S. Harris** (ed) *Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting, The College on Problems of Drug Dependence Inc*. NIDA Research Monograph 179, 79.
- 2000
215. **Conroy, A. & Copeland, J. (Eds)** (2000). *Data Dictionary for Alcohol and Other Drug Treatment Services in New South Wales: Data guidebook for the NSW Minimum Data Set*. NSW Department of Health/National Drug and Alcohol Research Centre: Sydney.
216. **Conroy, A., Copeland, J., & Reid, A.** (2000). *AIHW National Survey of Alcohol and Other Drug Treatment Services: Report on NSW Findings*. National Drug and Alcohol Research Centre Report to NSW Department of Health.

217. **Copeland, J. & Taylor, S.** (2000). *An overview of attitudes, knowledge and use patterns of alcohol, tobacco and other drugs in culturally and linguistically diverse communities in New South Wales: a DAMEC perspective*. Proceedings of The Second Statewide Conference of the Drug and Alcohol Multicultural Education Centre - Community Partnerships: Sydney, 3-10.
218. **Darke, S. & Hall, W.** (2000) *Drug Trends Bulletin July 2000*. Sydney: National Drug and Alcohol Research Centre.
219. **Darke, S. & Kaye, S.** (2000). *Drug Trends Bulletin December 2000*. Sydney: National Drug and Alcohol Research Centre.
220. **Darke, S., Ross, J., Hando, J., Hall, W., & Degenhardt, L.** (2000). *Illicit Drug Use in Australia: Epidemiology, Use Patterns and Associated Harm*. National Drug Strategy Monograph Number 43. Commonwealth Department of Health and Aged Care, Canberra.
221. **Dillon, P. & Dolan, K.** (2000). *Needle and syringe programs: your questions answered*. National Drug and Alcohol Research Centre, Sydney.
222. **Dolan, K., Topp, L., & MacDonald, M.** (2000). *Needle and syringe programs: a review of the evidence*. National Drug and Alcohol Research Centre, Sydney.
223. **Hall, W.** (2000). The mental health effects of cannabis use. (pp 550-553) **M. Gelder, J.J. Lopez-Ibor & N. Andreasen** (eds) *New Oxford Textbook of Psychiatry*. Oxford University Press, 2000.
224. **Hall, W. (Chair)** (2000) *Report of the Working Party on the Use of Cannabis for Medical Purposes*. Volume 1: Executive Summary; Volume 2: Full Report. NSW Government, Sydney, 2000.
225. **Hall, W. & Teesson, M.** (2000) Alcohol-use disorders: who should be treated and how? In: **Andrews, G. & Henderson, S.** (eds) *Unmet Need in Psychiatry. Problems, Resources, Responses*. (pp 290-301). Cambridge University Press, Cambridge.
226. **Henry-Edwards, S., Ali, R., Bisshop, P., Gordon, S., & Hall, W.** (2000). *Options for Control of Performance and Image Enhancing Drugs*. Prepared on Behalf of the National Expert Advisory Committee on Illicit Drugs. Ministerial Council on Drug Strategy, July 2000.
227. **Humeniuk, R., Ali, R., White, J., Hall, W., & Farrell, M.** (2000). *Proceedings of Expert Workshop on the Induction and Stabilisation of Patients onto Methadone*. National Drug Strategy Monograph Series No. 39. Australian Government Publication Service, Canberra.
228. **Hunter, E.M., Brady, M., & Hall, W.** (2000). *National Recommendations for the Clinical Management of Alcohol-related Problems of Indigenous Primary Health Care Settings*. Commonwealth Department of Health and Aged Care, Canberra.
229. **Hunter, E.M., Brady, M., & Hall, W.** (2000). *An analysis of needs for services for alcohol-related problems in Indigenous communities in Far North Queensland*. Department of Social and Preventive Medicine, University of Queensland.
230. **Lynskey, M. & Hall, W.** (2000). *Educational outcomes and adolescent cannabis use*. NSW Department of Education and Training, Sydney.
231. **MacDonald, M. & Topp, L.** (2000) *Drug Trends Bulletin October 2000*. Sydney: National Drug and Alcohol Research Centre.
232. **McKetin, R. & Darke, S.** (2000) *Drug Trends Bulletin April 2000*. Sydney: National Drug and Alcohol Research Centre.
233. **Miller, V., Robertson, S., Kellehear, K., Teesson, M., Farhall, J., Issakidis, C., Peters, J., Swensdon, C., Bland, R., & Epstein, M.** (eds) (2000) *Whose Dreams? Whose Realities? Proceedings of the 9th Annual THEMHS Conference, Melbourne, Australia*, Standard Publishing House, Rozelle.
234. **Penrose-Wall, J., Copeland, J., & Harris, M.** (2000) *Shared care of illicit drug problems by general practitioners and primary health care providers: A literature review*, A report for the National Illicit Drug Strategy. Centre for Integration Studies and National Drug and Alcohol Research Centre, UNSW: Sydney.
235. **Penrose-Wall, J., Harris, M., & Copeland, J.** (2000) *Program Guide: Sharing Mental Health Care Vol 2 Alcohol and Other Drug Problems. A Guide for Divisions of General Practice*. Integration Studies and National Drug and Alcohol Research Centre, UNSW: Sydney.
236. **Teesson, M., Hall, W., Lynskey, M., & Degenhardt, L.** (2000). The epidemiology of drug dependence in Australia: findings from the National Survey of Mental Health and Wellbeing. In **Harris, L.S.** (ed) *Problems of Drug Dependence, 1999: Proceedings of the 61st Annual Scientific*

Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph 180, US Department of Health and Human Services.

237. **Trauer, T., Rosen, A., Cummins, R., & Teesson, M.** (2000). What's new in outcome measurement. In **Miller, V., et al** (eds) *Whose Dreams? Whose Realities? Proceedings of the 9th Annual THEMHS Conference, Melbourne, Australia*, Standard Publishing House, Rozelle, 235-243.

2001

238. **Burns, L. & Teesson, M.** (2001). Comorbidity between mental health and substance use disorders. In: **G. Meadows & B. Singh** (eds) *Mental Health in Australia*. Oxford University Press.
239. **Copeland, J., Swift, W., Clement, N., & Reid, A.** (2001). *Young cannabis users' attitudes and beliefs about cannabis and school drug education. Report prepared for the NSW Department of Education and Training*. NSW Department of Education and Training, Student Services and Equity Programs.
240. **Copeland, J., Swift, W., & Matalon, E.** (2001). *What's the Deal on Quitting Cannabis?* National Drug and Alcohol Research Centre: Sydney.
241. **Copeland, J., Swift, W., & Matalon, E.** (2001). *Quitting Cannabis?* Commonwealth Department of Health and Aged Care: Canberra.
242. **Darke, S., Topp, L., & Kaye, S.** (2001). *Illicit Drug Reporting System Drug Trends Bulletin December 2001*. National Drug and Alcohol Research Centre, Sydney.
243. **Day, C. & Dolan, K.** (2001). Characteristics of Indigenous Injecting Drug Users in Sydney: gender, prison history and treatment experiences. *Best Practice Interventions in Corrections for Indigenous People*. Australian Institute of Criminology, Canberra.
244. **Degenhardt, L.** (2001). *Opioid Overdose Deaths in Australia*. Sydney: National Drug and Alcohol Research Centre.
245. **Dickerson, M., Wodak, A., Mattick, R., & Hill, S.** (2001). *Problem Drinking/Problem Gambling: A Study of Co-morbid Individuals in NSW*. University of Western Sydney, Sydney.
246. **Gowing, L., Proudfoot, H., Henry-Edwards, S., & Teesson, M.** (2001). *Evidence supporting treatment: the effectiveness of interventions for illicit drug use*. ANCD Research Paper 3. Australian National Council on Drugs, Canberra.
247. **Hall, W., Lynskey, M., & Teesson, M.** (2001) What is comorbidity and why does it matter? **Teesson, M. & Burns, L.** (eds) *National Comorbidity Project*. Commonwealth Department of Health and Aged Care, Canberra.
248. **Lintzeris, N., Clark, N., Ritter, A., Ali, R., Bell, J., Gowing, L., Hawken, L., Henry-Edwards, S., Mattick, R.P., Monheit, B., Newton, I., Quigley, A., Whicker, S., White, J.** (2001). *National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence*. Commonwealth Department of Health and Aged Care, Canberra.
249. **Lynskey, M.** (2001). Alcohol use and violent behaviour among youth: results from a longitudinal study. In **P. Williams** (ed) *Alcohol, Young Persons and Violence*. Australian Institute of Criminology Research and Public Policy Series No. 35, Canberra.
250. **Lynskey, M. & Sussman, S.** (2001). Pilot Studies. In **S. Sussman** (ed) *Handbook of Program Development for Health Behavior Research and Practice*. Sage Publications, California.
251. **MacDonald, M., Robotin, M., & Topp, L.** (2001). Drug use trends among injecting drug users (IDU): Findings from the Australian Needle and Syringe Program (NSP) Survey, 1995-2000. *Drug Trends Bulletin, October 2001*. Sydney: National Drug and Alcohol Research Centre.
252. **Mitchell, P., Spooner, C., Copeland, J., Vimpani, G., Toumbourou, J., Howard, J., & Sanson, A.** (2001). *The role of families in the development, identification, prevention and treatment of illicit drug problems*. NH&MRC, Commonwealth of Australia: Canberra.
253. **Spooner, C., Hall, W., & Lynskey, M.** (2001). *Structural determinants of youth drug use*. ANCD Research Paper 2, Australian National Council on Drugs, Canberra.
254. **Swift, W., Clement, N., Copeland, J., Martin, G., Roffman, R.A., Berghuis, J., Stephens, R.S., & Howard, J.** (2001). *What's The Deal On Grass? Talking with a young person about cannabis*. National Drug and Alcohol Research Centre: Sydney.
255. **Swift, W., Clement, N., Copeland, J., Martin, G., Roffman, R.A., Berghuis, J., Stephens, R.S., & Howard, J.** (2001). *What's The Deal On Grass? Cannabis facts for young people*. National Drug and Alcohol Research Centre: Sydney.

256. **Swift, W., Clement, N., Copeland, J., Martin, G., Roffman, R.A., Berghuis, J., Stephens, R.S., & Howard, J.** (2001). *What's The Deal On Grass? Cannabis facts for parents*. National Drug and Alcohol Research Centre: Sydney.
257. **Swift, W. & Hall, W.** (2001). Dependence. In **Franjo Grotenhermen** (ed) *Cannabis and Cannabinoids: Pharmacology and Therapeutic Potential*. pp. 283-294, Verlag Hans Huber, Bern (German Edition).
258. **Teesson, M.** (2001) Background: causes, prevention and treatment of comorbidity. **Teesson, M. & Burns, L.** (eds) *National Comorbidity Project*. Commonwealth Department of Health and Aged Care, Canberra.
259. **Teesson, M. & Burns, L.** (eds) (2001) *National Comorbidity Project*. Commonwealth Department of Health and Aged Care, Canberra.
260. **Teesson, M. & Hall, W.** (2001). Substance-related disorders. In **G. Meadows and B. Singh** (eds) *Mental Health in Australia: A Collaborative Community Practice*. pp 363-373. Oxford University Press.
261. **Topp, L., McKetin, R., Hando, J., & Hando, J.** (2001). *A Users' Guide To Speed*. National Drug and Alcohol Research Centre: Sydney.
262. **Warner-Smith, M., Lynskey, M., Darke, S., & Hall, W.** (2001). *Heroin overdose: prevalence, correlates, consequences and interventions*. Australian National Council on Drugs, Commonwealth Department of Health and Aged Care, Canberra.
263. **Warner-Smith, M., Lynskey, M., Hall, W. & Montiero, M.** (2001). Challenges and first approaches to estimating the burden of disease attributable to illicit drug use. In **J. Rehm and G. Gmel** (eds) *Alcohol, Illicit Drugs and Global Burden of Disease*. Karger, Zurich.
- 2002
264. **Dietze, P., Richards, J., Rumbold, G., Aitken, C., Day, C., McGregor, C., & Ritter, A.** (2002). *Treatment utilisation by heroin dependent persons in Australia: Implications for treatment service systems*. Turning Point Alcohol and Drug Centre Inc., Melbourne.
265. **Dillon, P.** (2002). Foreword. In **T. McGill** *Facing Drugs a guide for parents*. Griffin Press, Sydney.
266. **Dolan, K., Day, C., Southgate, E., & Jenkins, C.** (2002). Effectiveness of interventions for marginalized and particularly vulnerable IDUs including prisoners, indigenous, MSM, and sex workers. *2001 Global Research Network Meeting on HIV Prevention in Drug-Using Populations. Fourth Annual Meeting Report. October 11-12, 2001 Melbourne, Australia* (pp 33-35). National Institutes of Health, US Department of Health and Human Services.
267. **Dwyer, R., Fry, C., Carruthers, S., Bolleter, A., Dolan, K., Donald, A., Byrne, J., & Loxley, W.** (2002). *The Australian Blood-borne virus Risk and Injecting Drug Use Study (ABRIDUS): A national study of hepatitis C risk practices and contexts in Melbourne, Perth and Sydney*. Fitzroy: Turning Point Alcohol & Drug Centre Inc.
268. **Hall, W.** (2002). Gewohnheitsmaiger cannabiskonsum und Telnahme am Straenverkehr. In **F. Grotenhermen and M. Karus** (eds) *Cannabis, Straenverkehr und Arbeitswelt*. Springer, Berlin.
269. **Hall, W., Degenhardt, L., & Lynskey, M.** (2002). *The health and psychological effects of cannabis use*. Monograph Series No 44. Canberra: Commonwealth of Australia.
270. **Hallett, J., Indig, D., Aloï, A., Byrne, G., Copeland, J., Crocker, C., Doyle, S., Hanley, E., Holmes, J., Lawrinson, P., Leary, J., Manzie, R., Nesire, V., Pierce, L., Tynan, M. & Young, M.** (2002). *NSW Minimum Dataset for Alcohol and Other Drug Treatment Service: Data Dictionary and Collection Guidelines 2002-2003. Version 2 July*. New South Wales Department of Health and the National Drug and Alcohol Research Centre, University of New South Wales; Sydney.
271. **Lawrinson, P. & Copeland, J.** (2002). Measuring treatment outcomes for clients of alcohol and other drug treatment services. In: **J. Sansoni & L. Tilley** (eds) *Health Outcomes 2002: Current Challenges and Future Frontiers. Proceedings of the 8th Annual National Health Outcomes Conference*. Canberra: Australian Health Outcomes Collaboration.
272. **Shand, F. & Mattick, R.P.** (2002). *Clients of treatment service agencies: May 2001 census findings*. National Drug Strategy Monograph No. 47. Australian Government Publishing Service, Canberra.
273. **Solowij, N. & Grenyer, B.F.S.** (2002). Long-term effects of cannabis on psyche and cognition. In **F. Grotenhermen & E. Russo** (eds), *Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential*. New York, HawothPress.

274. **Swift, W. & Hall, W.** (2002). Tolerance, withdrawal and dependence. **F. Grotenhermen and E. Russo** (eds) *Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential*. New York: Haworth Press.
275. **Teesson, M., Degenhardt, L., & Hall, W.** (2002). *Addictions*, Psychology Press, Taylor & Francis Group, London.
276. **Teesson, M. & Proudfoot, H.** (2002). Interventions for alcohol dependence, abuse and excessive drinking. *National Alcohol Research Agenda*, Commonwealth Department of Health and Ageing, Canberra.



Technical Reports

1989

1. **Keats, J., Webster, R., & O'Brien, S.** (1989). *Social processes in alcohol dependence: An analysis of the Australian Inventory of Alcohol Usage*. Sydney: National Drug and Alcohol Research Centre.
2. **Westbrook, R.F. & Greeley, J.** (1989). *Some effects of the opioid antagonist, Naloxone, upon the rat's reactions to a heat stressor*. Sydney: National Drug and Alcohol Research Centre.
3. **Chesher, G., Lemon, J., Gomel, M., & Murphy, G.** (1989). *The effects of methadone as used in a methadone maintenance program, on driving-related skills*. Sydney: National Drug and Alcohol Research Centre.

1990

4. **Pedic, F.** (1990). *A review of the National Drug Poisonings Case Reporting System*. Sydney: National Drug and Alcohol Research Centre.
5. **Pedic, F. & Flaherty, B.** (1990). *Early warning indicators of changes in drug use: A New South Wales perspective*. Sydney: National Drug and Alcohol Research Centre.
6. **Heather, N.** (1990). *Assisted spontaneous remission from alcohol problems: Effects of a controlled drinking self-help manual with and without added telephone contact*. Sydney: National Drug and Alcohol Research Centre.
7. **Pedic, F.** (1990). *Drug use in prisons: Data collection procedures. A review and recommendations*. Sydney: National Drug and Alcohol Research Centre.
8. **Murray, T.** (1990). *Craving for alcohol: An information-processing analysis. Winning essay, 1989 Syd Lovibond Prize*. Sydney: National Drug and Alcohol Research Centre.
9. **Lemon, J.** (1990). *The Rozelle Test Battery: A computerized testing instrument for visumotor and cognitive performance*. Sydney: National Drug and Alcohol Research Centre.
10. **Ward, J., Darke, S., & Hall, W.** (1990). *The HIV Risk-taking Behaviour Scale (HRBS) Manual*. Sydney: National Drug and Alcohol Research Centre.

1991

11. **Darke, S., Ward, J., Hall, W., Heather, N., & Wodak, A.** (1991). *The Opiate Treatment Index (OTI) Researcher's Manual*. Sydney: National Drug and Alcohol Research Centre.

12. **Fox, A.M., Michie, P.T., Coltheart, M., & Solowij, N.** (1991). *An event-related potential study of memory functioning: Effects of alcohol*. Sydney: National Drug and Alcohol Research Centre.
13. **Saunders, J.B., Sitharthan, T., McGrath, D., & Cairns, D.** (1992). *The development of an instrument to assess the severity of opiate dependence*. Sydney: National Drug and Alcohol Research Centre.
15. **Heather, N., Gold, R., & Rollnick, S.** (1991). *Readiness to Change Questionnaire: User's manual*. Sydney: National Drug and Alcohol Research Centre.

1992

16. **Darke, S., Tebbutt, J., Ross, J., Thomas, G., Larson, I., & Hall, W.** (1992). *The Australian National AIDS and Injecting Drug Users Questionnaire (ANAIIDUSQ)*. Sydney: National Drug and Alcohol Research Centre.

1993

17. **Copeland, J., Hall, W., Didcott, P., & Biggs, V.** (1993). *Evaluation of a specialist drug and alcohol treatment service for women: Jarrah House*. Sydney: National Drug and Alcohol Research Centre.
18. **Hall, W., Chen, R., & Evans, B.** (1993). *Clients admitted to 'The Buttery', a therapeutic community 1980-1992*. Sydney: National Drug and Alcohol Research Centre.
19. **Heather, N. & Rollnick, S.** (1993). *Readiness to Change Questionnaire: User's manual (revised version)*. Sydney: National Drug and Alcohol Research Centre.
20. **Darke, S., Hall, W.D., & Swift, W.** (1993). *Geographical differences in risk-taking among Sydney methadone maintenance patients: A comparison of inner city and outer south western clinics*. Sydney: National Drug and Alcohol Research Centre.

1994

21. **Richmond, R., Heather, N., Wodak, A., Kehoe, L., & Webster, I.** (1994). *Controlled evaluation of a general practice-based brief intervention for excessive alcohol consumption: The Alcoholscreen Project*. Sydney: National Drug and Alcohol Research Centre.

1995

22. **Dolan, K., Hall, W., & Wodak, A.** (1995). *Bleach availability and risk behaviours in prison in New South Wales*. Sydney: National Drug and Alcohol Research Centre.

24. **Copeland, J.** (1995). *A qualitative study of self-managed change in substance dependence among women*. Sydney: National Drug and Alcohol Research Centre.
26. **Grenyer, B., Luborsky, L., & Solowij, N.** (1995). *Treatment manual for supportive-expressive dynamic psychotherapy: Special adaption for treatment of cannabis (marijuana) dependence*. Sydney: National Drug and Alcohol Research Centre.
27. **Ross, J., Darke, S., & Hall, W.** (1995). *Benzodiazepine use among heroin users in Sydney: Patterns, availability and preferences*. Sydney: National Drug and Alcohol Research Centre.
- 1996**
37. **Rutter, S., Dolan, K., & Wodak, A.** (1996). *Sex, drugs and viruses in Sin City Sydney, 1994. Report on Australian Study of HIV and Injecting Drug Use*. Sydney: National Drug and Alcohol Research Centre.
38. **O'Brien, S., Darke, S., & Hando, J.** (1996). *Drug trends: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
39. **Darke, S., Sunjic, S., Zador, D., & Prolov, T.** (1996). *A comparison of blood toxicology of heroin-related deaths and current heroin users in South Western Sydney*. Sydney: National Drug and Alcohol Research Centre.
- 1997**
40. **Darke, S., Zador, D., & Sunjic, S.** (1997). *Toxicological findings and circumstances of heroin related deaths in South Western Sydney, 1995*. Sydney: National Drug and Alcohol Research Centre.
41. **Ward, J., van Beek, I., Mattick, R.P., Hill, P., & Kaldor, J.** (1996). *A controlled study of methadone maintenance in a primary health care setting with young 'at-risk' injecting opiate users*. Sydney: National Drug and Alcohol Research Centre.
42. **Swift, W., Maher, L., Sunjic, S., & Doan, V.** (1997). *Transitions between routes of administrations among caucasian and indochinese heroin users in South-West Sydney*. Sydney: National Drug and Alcohol Research Centre.
43. **Mattick, R.P., Oliphant, D., Ward, J., Hall, W., & White, J.** (1997). *The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine and naltrexone*. Sydney: National Drug and Alcohol Research Centre.
43. **Hall, W.** (1997). *Swiss scientific studies of medically prescribed narcotics*. Sydney: National Drug and Alcohol Research Centre.
44. **Hall, W.** (1997). *The role of legal coercion in the treatment of offenders with alcohol and heroin problems*. Sydney: National Drug and Alcohol Research Centre.
45. **Rankin, J., & Mattick, R.P.** (1997). *Review of the effectiveness of methadone maintenance treatment and analysis of St Mary's Clinic, Sydney*. Sydney: National Drug and Alcohol Research Centre.
46. **Rankin, J., & Copeland, J.** (1997). *The national minimum data set project for alcohol and other drug treatment services*. Sydney: National Drug and Alcohol Research Centre.
47. **Swift, W., Hall, W., & Copeland, J.** (1997). *Cannabis dependence among long-term users in Sydney*. Sydney: National Drug and Alcohol Research Centre.
48. **Peters, R., Copeland, J., Dillon, P., & Beel, A.** (1997). *Patterns and correlates of anabolic-androgenic steroid use*. Sydney: National Drug and Alcohol Research Centre.
49. **Hall, W. & Darke, S.** (1997). *Trends in opiate overdose deaths in Australia 1979-1995*. Sydney: National Drug and Alcohol Research Centre.
50. **Ross, J. & Darke, S.** (1997). *Benzodiazepine dependence and psychopathology among heroin users in Sydney*. Sydney: National Drug and Alcohol Research Centre.
51. **Topp, L., Hall, W., & Hando, J.** (1997). *Is there a dependence syndrome for ecstasy?* Sydney: National Drug and Alcohol Research Centre.
52. **Darke, S. & Ross, J.** (1997). *Heroin-related deaths in South Western Sydney: 1992-1996*. Sydney: National Drug and Alcohol Research Centre.
53. **Teesson, M., Gallagher, J., & Ozols, S.** (1997). *The Gemini Project: An evaluation of a treatment program for persons with serious mental illness and substance misuse*. Sydney: National Drug and Alcohol Research Centre.
54. **Lynskey, M. & Hall, W.** (1997). *Jurisdictional trends in opioid overdose deaths, 1988-1996*. Sydney: National Drug and Alcohol Research Centre.
- 1998**
55. **Hall, W.** (1998). *Cannabis use and psychosis*. Sydney: National Drug and Alcohol Research Centre.


56. **Hando, J. & Darke, S.** (1998). *NSW Drug Trends 1997: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
57. **Cormack, S., Faulkner, C., Foster, P., & Greaves, H.** (1998). *South Australian Drug Trends 1997: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
58. **Darke, S., Hall, W., Weatherburn, D., & Lind, B.** (1998). *Fluctuations in heroin purity and the incidence of fatal heroin overdose in south western Sydney, 1993-1995*. Sydney: National Drug and Alcohol Research Centre.
59. **Rumbold, G. & Fry, C.** (1998). *Victorian Drug Trends 1997: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
60. **Darke, S., Kaye, S., & Ross, J.** (1998). *Transitions between the injection of heroin and amphetamines*. Sydney: National Drug and Alcohol Research Centre.
61. **Lynskey, M. & Hall, W.** (1998). *Age of initiation to heroin use: Cohort trends and consequences of early initiation for subsequent adjustment*. Sydney: National Drug and Alcohol Research Centre.
62. **Mattick, R.P., O'Brien, S., & Dodding, J.** (1998). *Outcome evaluation of the Woolshed Program*. Sydney: National Drug and Alcohol Research Centre.
63. **Hall, W., Teesson, M., Lynskey, M. & Degenhardt, L.** (1998). *The prevalence in the past year of substance use an ICD-10 substance use disorders in Australian adults: Findings from the National Survey of Mental Health and Well-Being*. Sydney: National Drug and Alcohol Research Centre.
64. **Rees, V., Copeland, J. & Swift, W.** (1998). *A brief cognitive-behavioural intervention for cannabis dependence: Therapists treatment manual*. Sydney: National Drug and Alcohol Research Centre.
65. **Conroy, A. & Copeland, J.** (1998). *The National Minimum Data Set Project for Alcohol and Other Drug Treatment Services: Report on the pilot study and recommended set of data definitions*. Sydney: National Drug and Alcohol Research Centre.
66. **Lynskey, M. & Hall, W.** (1998). *Cannabis use among Australian youth*. Sydney: National Drug and Alcohol Research Centre.
- 1999
67. **Hall, W., Degenhardt, L., & Lynskey, M.** (1999). *Trends in opioid overdose & suicide mortality in young adults in Australia 1964-1997*. Sydney: National Drug and Alcohol Research Centre.
68. **Darke, S., Ross, J., Zador, D. & Sunjic, S.** (1999). *Heroin-related deaths in New South Wales 1992-1996*. Sydney: National Drug and Alcohol Research Centre.
69. **Hall, W., Lynskey, M., & Degenhardt, L.** (1998). *Trends in methadone-related deaths in the UK and Australia 1985-1995*. Sydney: National Drug and Alcohol Research Centre.
70. **Darke, S. & Ross, J.** (1999). *The use of antidepressants among injecting drug users*. Sydney: National Drug and Alcohol Research Centre.
71. **Hayes, A., Farrington, D., Faulkner, C., Greaves, H. & Cormack, S.** (1999). *South Australian Drug Trends 1998: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
72. **McKetin, R., Darke, S., & Godycka-Cwirko, K.** (1999). *NSW Drug Trends 1998: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
73. **Rumbold, G. & Fry, C.** (1999). *Victorian Drug Trends 1998: Finding from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
74. **Hall, W. & Swift, W.** (1999). *The THC content of cannabis in Australia: evidence and implications*. Sydney: National Drug and Alcohol Research Centre.
75. **Shearer, J., Wodak, A., Mattick, R.P., van Beek, I., Lewis, J., Hall, W. & Dolan, K.** (1999). *A randomised controlled trial of the feasibility of monitoring controlled prescribing of dexamphetamine*. Sydney: National Drug and Alcohol Research Centre.
76. **Hall, W.** (1999). *Assessing the population level impact of the Swiss model of heroin prescription*. Sydney: National Drug and Alcohol Research Centre.
77. **Darke, S., Ross, J., & Kaye, S.** (1999). *Physical and geographical injecting sites among injecting drug users*. Sydney: National Drug and Alcohol Research Centre.
78. **Swift, W., Hall, W., & Teesson, M.** (1999). *Cannabis use disorders among Australian adults: results from the National Survey of Mental Health and Wellbeing*. Sydney: National Drug and Alcohol Research Centre.

79. **Swift, W., Maher, L., & Dawson, M.** (1999). *Heroin purity and composition: an analysis of street level samples in Cabramatta*. Sydney: National Drug and Alcohol Research Centre.
80. **Degenhardt, L. & Hall, W.** (1999). *The relationship between tobacco use, substance use disorders and mental disorders: results from the National Survey of Mental Health and Well-Being*. Sydney: National Drug and Alcohol Research Centre.
- 2000
81. **Rysavy, P., O'Reilly, B., & Moon, C.** (2000). *Northern Territory Drug Trends 1999: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
82. **Fleming, J., Cooke, B., & Williams, P.** (2000). *Australian Capital Territory Drug Trends 1999: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
83. **Degenhardt, L., Lynskey, M., & Hall, W.** (2000). *Cohort trends in the age of initiation of drug use in Australia*. Sydney: National Drug and Alcohol Research Centre.
84. **Bruno, R., & McLean, S.** (2000). *Tasmanian Drug Trends 1999: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
85. **Hargreaves, K., & Lenton, S.** (2000). *West Australian Drug Trends 1999: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
86. **McKetin, R., Darke, S., & Kaye, S.** (2000). *NSW Drug Trends 1999. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
87. **Kinner, S., & Roach, A.** (2000). *Queensland Drug Trends 1999. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
88. **Humeniuk, R.** (2000). *South Australian Drug Trends 1999. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
89. **Dwyer, R., & Rumbold, G.** (2000). *Victorian Drug Trends 1999. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
90. **Darke, S., Hall, W., Kaye, S., Ross, J., DuFlou, J.** (2000). *Hair morphine concentrations of fatal heroin overdose cases and living heroin users*. Sydney: National Drug and Alcohol Research Centre.
91. **Proudfoot, H. & Teesson, M.** (2000). *Investing in drug and alcohol treatment*. Sydney: National Drug and Alcohol Research Centre.
92. **Teesson, M., Clement, N., Copeland, J., Conroy, A., & Reid, A.** (2000). *The measurement of outcome in alcohol and other drug treatment: a review of available instruments*. Sydney: National Drug and Alcohol Research Centre.
93. **Degenhardt, L., & Hall, W.** (2000). *The association between psychosis and problematic drug use among Australian adults: Findings from the National Survey of Mental Health and Well-Being*. Sydney: National Drug and Alcohol Research Centre.
94. **Degenhardt, L., Hall, W., & Adelstein, B.A.** (2000). *Ambulance calls to suspected drug overdoses: Analysis of New South Wales patterns - July 1997 to June 1999*. Sydney: National Drug and Alcohol Research Centre.
95. **Dolan, K.** (2000). *Surveillance and prevention of Hepatitis C infection in Australian prisons: A discussion paper*. Sydney: National Drug and Alcohol Research Centre.
96. **Spooner, C., Hall, W., & Mattick, R.P.** (2000). *A strategic overview of the diversion of drug-related offenders in NSW*. Sydney: National Drug and Alcohol Research Centre.
97. **Degenhardt, L., Hall, W. & Lynskey, M.** (2000). *Alcohol use disorders in Australia: Findings from the National Survey of Mental Health and Well-Being*. Sydney: National Drug and Alcohol Research Centre.
98. **Degenhardt, L., Hall, W. & Lynskey, M.** (2000). *Cannabis use and mental health among Australian adults: Findings from the National Survey of Mental Health and Well-Being*. Sydney: National Drug and Alcohol Research Centre.
99. **Kaye, S., Darke, S., & McKetin, R.** (2000). *The prevalence, patterns and harms of cocaine use among injecting and non-injecting drug users in Sydney*. Sydney: National Drug and Alcohol Research Centre.

100. **Darke, S. & Ross, J.** (2000). *The relationship between suicide and overdose among methadone maintenance patients*. Sydney: National Drug and Alcohol Research Centre.
101. **Darke, S. Hall, W. & Topp, L.** (2000). *The Illicit Drug Reporting System (IDRS) 1996-2000*. Sydney: National Drug and Alcohol Research Centre.
- 2001
102. **Rouen, D. & Dolan, K.** (2001). *An evaluation of a Needle and Syringe Information Kit*. Sydney: National Drug and Alcohol Research Centre.
111. **Dillon, P., Copeland, J., & Jansen, K.** (2001). *Patterns of use and harms associated with non-medical ketamine use*. Sydney: National Drug and Alcohol Research Centre.
112. **Rutter, S., Dolan, K., Wodak, A., & Heilpern, H.** (2001). *Prison-based syringe exchange: a review of international research and program development*. Sydney: National Drug and Alcohol Research Centre.
113. **Topp, L. & Darke, S.** (2001). *NSW Party Drug Trends 2000. Findings from the Illicit Drug Reporting System (IDRS) Party Drugs Module*. Sydney: National Drug and Alcohol Research Centre.
114. **McAllister, R., Topp, L., Dawes, L., Watt, K., & Shuttlewood, G.** (2001). *Queensland Party Drug Trends 2001. Findings from the Illicit Drug Reporting System (IDRS) Party Drugs Module*. Sydney: National Drug and Alcohol Research Centre.
116. **Kaye, S., Darke, S., & Topp, L.** (2001). *An examination of cocaine dependence among injecting and non-injecting drug users in Sydney*. Sydney: National Drug and Alcohol Research Centre.
117. **Darke, S., Topp, L., & Kaye, S.** (2001). *NSW Drug Trends 2000. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
118. **Burns, L., Teesson, M., & Lynskey, M.** (2001). *The epidemiology of comorbidity between alcohol use disorders and mental disorders in Australia*. Sydney: National Drug and Alcohol Research Centre.
119. **Rouen, D., Dolan, K., Day, C., Topp, L., Darke, S., & Hall, W.** (2001). *Changes in heroin availability in Sydney Australia in early 2001*. Sydney: National Drug and Alcohol Research Centre.
120. **Rouen, D., Dolan, K., & Kimber, J.** (2001). *A review of drug detection testing and examination of urine, hair, saliva and sweat*. Sydney: National Drug and Alcohol Research Centre.
121. **Degenhardt, L., Hall, W., & Lynskey, M.** (2001). *Comorbidity between cannabis use and psychosis: Modelling some possible relationships*. Sydney: National Drug and Alcohol Research Centre.
122. **Proudfoot, H. & Teesson, M.** (2001). *Who seeks treatment for alcohol dependence?* Sydney: National Drug and Alcohol Research Centre.
123. **Spooner, C. & McPherson, M.** (2001). *In what ways do police contribute to the prevention and management of alcohol-related problems in NSW? An overview*. Sydney: National Drug and Alcohol Research Centre.
124. **Mattick, R.P., Kimber, J., Kaldor, J., MacDonald, M., Weatherburn, D., & Lapsley, H.** (2001). *Six-month process evaluation report on the Medically Supervised Injecting Centre (MSIC)*. Sydney: National Drug and Alcohol Research Centre.
125. **Darke, S., Kaye, S., & Topp, L.** (2002). *Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
126. **Kimber, J., Dolan, K., & Wodak, A.** (2002). *International survey of supervised injecting centres (1999-2000)*. Sydney: National Drug and Alcohol Research Centre.
128. **Williams, P., & Rushforth, C.** (2002). *ACT Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
129. **Fry, C., & Miller, P.** (2002). *Victorian Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
130. **Longo, M., Humeniuk, R., Christie, P., & Ali, R.** (2002). *SA Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
131. **Longo, M., Humeniuk, R., Christie, P., Topp, L., & Ali, R.** (2001). *SA Party Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS) Party Drugs Module*. Sydney: National Drug and Alcohol Research Centre.

2002

132. **Rose, G.M., & Najman, J.M.** (2002). *QLD Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
134. **Hargreaves, K., & Lenton, S.** (2002). *WA Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
135. **Bruno, R., & McLean, S.** (2002). *Tasmanian Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
137. **O'Reilly, B.** (2002). *Northern Territory Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
138. **Day, C., Topp, L., Swift, W., Kaye, S., Breen, C., Kimber, J., Ross, J., & Dolan, K.** (2002). *Interviewer safety in the drug and alcohol field: a safety protocol and training manual for staff of the National Drug and Alcohol Research Centre*. Sydney: National Drug and Alcohol Research Centre.
139. **Ross, J., Teesson, M., Darke, S., Lynskey, M., Hetherington, K., Mills, K., Williamson, A., & Fairbairn, S.** (2002). *Characteristics of heroin users entering three treatment modalities in NSW: Baseline findings from the Australian Treatment Outcome Study (ATOS)*. Sydney: National Drug and Alcohol Research Centre.
140. **Hall, W. & Carter, L.** (2002). *Ethical issues in trialling and using a cocaine vaccine to treat and prevent cocaine dependence*. Sydney: National Drug and Alcohol Research Centre.
141. **Degenhardt, L., Adelstein, B.A., Darke, S., & Hodda, A.** (2002). *Early indicators of trends in opioid overdose deaths*. Sydney: National Drug and Alcohol Research Centre.
142. **Breen, C., Topp, L., & Longo, M.** (2002). *Adapting the IDRS methodology to monitor trends in party drug markets: Findings of a two-year feasibility trial*. Sydney: National Drug and Alcohol Research Centre.



Monographs

1987

1. **Greeley, J., & Gladstone, W. (ed)** (1987). *Methadone Programs in Australia: Policy and Practice. Proceedings from the National Methadone Workshop, 30th-31st March, 1987.* Sydney: National Drug and Alcohol Research Centre.
2. **Prescott, J.** (1987). *Issues and Priorities in Methadone Research.* Sydney: National Drug and Alcohol Research Centre.
3. **Greeley, J., & Heather, N. (eds)** (1987). *Towards a National Drug and Alcohol Research Network: Proceedings from the First Annual NDARC Research Symposium, November, 1987.* Sydney: National Drug and Alcohol Research Centre.

1988

4. **Swift, W., & Greeley, J. (eds)** (1988). *The future of the Addiction Model: Proceedings from a Seminar at Prince of Wales Hospital, August, 1988.* Sydney: National Drug and Alcohol Research Centre.
5. **Prescott, J., & McCall, G. (eds)** (1988). *Kava: Use and Abuse in Australia and South Pacific: Proceedings from the Symposium on Kava, UNSW, November, 1988.* Sydney: National Drug and Alcohol Research Centre.

1989

6. **Greeley, J., & Heather, N. (eds)** (1989). *Perspectives on Drug and Alcohol Dependence: Proceedings from a Symposium held during the XXIV International Congress of Psychology, Sydney, August, 1988.* Sydney: National Drug & Alcohol Research Centre.
7. **Grenyer B. F., & Solowij, N. (eds)** (1989). *Cognitive-Behavioural Approaches to the Treatment of Drug and Alcohol Problems: Proceedings from the Second National Drug and Alcohol Research Annual Symposium, December, 1988.* Sydney: National Drug & Alcohol Research Centre.

1990

8. **Greeley, J., & Gladstone, W. (eds)** (1990). *The effects of alcohol on cognitive, psychomotor and affective functioning.* Sydney: National Drug & Alcohol Research Centre.
9. **Carless, J. & Hall, W. (eds)** (1990). *Proceedings from the National Workshop on Research into Early/Brief Intervention for Drug and Alcohol Problems.* Sydney: National Drug and Alcohol Research Centre.

10. **Hando, J., & Carless, J. (eds)** (1990). *Controlled Availability: Wisdom or Disaster? Proceedings from the Third National Drug and Alcohol Research Centre Annual Symposium, February, 1990.* Sydney: National Drug and Alcohol Research Centre.

1991

11. **Hando, J. (ed)** (1991). *Evaluating Clients and Treatment: Proceedings from the Fourth National Drug and Alcohol Research Centre Annual Symposium, November, 1990.* Sydney: National Drug and Alcohol Research Centre.
12. **Hunter, E., Hall, W., & Spargo, R. (1991).** *The distribution and correlates of alcohol consumption in a remote Aboriginal population.* Sydney: National Drug and Alcohol Research Centre.
13. **Tebbutt, J., Muir, C., & Heather, N. (1991).** *Drug use trends in New South Wales.* Sydney: National Drug and Alcohol Research Centre.

1992

14. **Mattick, R.P. & Baillie, A. (1992).** *An outline for approaches to smoking cessation: Quality Assurance Project.* Sydney: National Drug and Alcohol Research Centre.
15. **Swift, W. (ed)** (1992). *The Consequences of Alcohol and Drug Use: Implications for Policy. Proceedings of the Fifth NDARC Annual Symposium, Melbourne, March, 1992.* Sydney: National Drug and Alcohol Research Centre.
16. **Moore, D. (1992).** *From psychological description to sociological explanation: Ethnographic comments on the concept of 'dependence'. Winning essay, 1991 Syd Lovibond Prize.* Sydney: National Drug and Alcohol Research Centre.

1993

17. **Howard, K. (1993).** *Measuring drug use in methadone maintenance programs. Winning essay, 1992 Syd Lovibond Prize.* Sydney: National Drug and Alcohol Research Centre.

1994

18. **Ross, J., Cohen, J., Darke, S., Hando, J., & Hall, W. (1994).** *Transitions between routes of administration and correlates of injecting amongst regular amphetamine users.* Sydney: National Drug and Alcohol Research Centre.

19. **Oliphant, D. & Mattick, R.P.** (1994). *Correlates and consequences of excessive drug use: Proceedings of the Fifth Anniversary NDARC Annual Symposium*. Sydney: National Drug and Alcohol Research Centre.
20. **Darke, S., Ross, J., Cohen, J., & Hall, W.** (1994). *Context and correlates of non-fatal overdose among heroin users in Sydney*. Sydney: National Drug and Alcohol Research Centre.
21. **Ross, J.** (1994). *Health for all? Social justice issues in the alcohol and other drug field: Proceedings from the Seventh National Drug and Alcohol Research Centre Annual Symposium, December 1993*. Sydney: National Drug and Alcohol Research Centre.
22. **Zador, D., Sunjic, S., & Darke, S.** (1994). *Toxicological findings and circumstances of heroin caused deaths in New South Wales, 1992*. Sydney: National Drug and Alcohol Research Centre.
- 1995**
23. **Copeland, J. & Hall, W.** (1995). *Women and drug dependence: An overview for clinicians, policy makers and researchers*. Sydney: National Drug and Alcohol Research Centre.
- 1996**
26. **Spooner, C., Mattick, R., & Howard, J.** (1996). *The nature and treatment of adolescent substance abuse*. Sydney: National Drug and Alcohol Research Centre.
27. **Dillon, P.** (1996). *National Drug Strategy: the first ten years and beyond. Proceedings of the Eighth Annual Symposium of the National Drug and Alcohol Research Centre*. Sydney: National Drug and Alcohol Research Centre.
28. **Baker, A., Heather, N., Stallard, A., O'Neill, K., & Wodak, A.** (1996). *A manual of cognitive behavioural techniques aimed at reducing HIV risk-taking behaviour in injecting drug users*. Sydney: National Drug and Alcohol Research Centre.
29. **Topp, L. & Dillon P.** (1996). *Looking to the future: A second generation of drug research. Proceedings from the Tenth National Drug and Alcohol Research Centre Annual Symposium*. Sydney: National Drug and Alcohol Research Centre.
- 1997**
30. **Didcott, P., Reilly, D., Swift, W., & Hall, W.** (1997). *Long-term cannabis users on the New South Wales North Coast*. Sydney: National Drug and Alcohol Research Centre.
31. **Hando, J., O'Brien, S., Darke, S., Maher, L., & Hall, W.** (1997). *The Illicit Drug Reporting System (IDRS) Trial: Final Report*. Sydney: National Drug and Alcohol Research Centre.
32. **Kaye, S., Darke, S., Finlay-Jones, R., & Hall, W.** (1997). *The relationship between Antisocial Personality Disorder, psychopathy, and injecting heroin use*. Sydney: National Drug and Alcohol Research Centre.
33. **Maher, L. & Swift, W.** (1997). *Heroin use in Sydney's Indo-Chinese communities: a review of NDARC research*. Sydney: National Drug and Alcohol Research Centre.
34. **Mattick, R.P., Bell, J., Daws, L.C., White, J.M., O'Brien, S., & Harris, S.J.** (1997). *Review of the evidence on the effectiveness of antagonists in managing opioid dependence*. Sydney: National Drug and Alcohol Research Centre.
35. **Hall, W.** (1997). *Proceedings of an International Opioid Overdose Symposium, Sydney, Australia, 14-15 August 1997*. Sydney: National Drug and Alcohol Research Centre.
- 1998**
36. **Hando, J., Darke, S., Degenhardt, L., Cormack, S., & Rumbold, G.** (1998). *Drug Trends 1997. A comparison of drug use and trends in three Australian states: Results from a national trial of the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
37. **Dillon, P., Topp, L., & Swift, W.** (1998). *Illicit Drugs: Current Issues and Responses. Proceedings from the Eleventh National Drug and Alcohol Research Centre Annual Symposium, November 1997*. Sydney: National Drug and Alcohol Research Centre.
38. **Maher, L., Dixon, D., Lynskey, M., & Hall, W.** (1998). *Running the risks: Heroin, health and harm in south west Sydney*. Sydney: National Drug and Alcohol Research Centre.
39. **Topp, L., Hando, J., Degenhardt, L., Dillon, P., Roche, A., & Solowij, N.** (1998). *Ecstasy Use in Australia*. Sydney: National Drug and Alcohol Research Centre.
- 1999**
40. **Spooner, C., Mattick, R.P., & Noffs, W.** (1999). *The nature and treatment of adolescent substance abuse (Supplement to Monograph 26)*. Sydney: National Drug and Alcohol Research Centre.
41. **McKetin, R., Darke, S., Hayes, A., & Rumbold, G.** (1999). *A comparison of drug use and*

trends in three Australian states: Findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Research Centre.

42. **Hall, W., Lynskey, M., & Degenhardt, L.** (1999). *Heroin use in Australia: its impact on public health and public order*. Sydney: National Drug and Alcohol Research Centre.

2000

43. **McKetin, R., Darke, S., Humeniuk, R., Dwyer, R., Bruno, R., Fleming, J., Kinner, S., Hargreaves, K., & Rysavy, P.** (2000). *Australian Drug Trends 1999. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
44. **Hall, W., Ross, J., Lynskey, M., Law, M. & Degenhardt, L.** (2000). *How many dependent opioid users are there in Australia?* Sydney: National Drug and Alcohol Research Centre.
46. **Warner-Smith, M., Lynskey, M., Darke, S., & Hall, W.** (2000). *Heroin overdose: prevalence, correlates, consequences and interventions*. Sydney: National Drug and Alcohol Research Centre.

2001

47. **Topp, L., Darke, S., Bruno, R., Fry, C., Hargreaves, K., Humeniuk, R., McAllister, R., O'Reilly, B., & Williams, P.** (2001). *Australian Drug Trends 2000. Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.

2002

48. **Topp, L., Kaye, S., Bruno, R., Hargreaves, K., Longo, M., Williams, P., O'Reilly, B., Fry, C., Rose, G. & Darke, S.** (2002). *Australian Drug Trends 2001: Findings from the Illicit Drug Reporting System (IDRS)*. Sydney: National Drug and Alcohol Research Centre.
49. **Henderson, N., Ross, J., Darke, S., Teesson, M. & Lynskey, M.** (2002). *Longitudinal studies of dependent heroin users in Australia: Feasibility and benefits*. Sydney: National Drug and Alcohol Research Centre.



Staff Lists

1998

Wayne Hall	Director, Professor of Drug and Alcohol Studies
Richard P. Mattick	Deputy Director and Associate Professor
Shane Darke	Senior Lecturer
Jan Copeland	Lecturer
Michael Lynskey	Lecturer
Maree Teesson	Lecturer
Paul Adamson	Technical Officer
Eva Congreve	Archivist
Andrew Conroy	Senior Research Assistant
Erol Digiusto	Senior Co-ordinator
Paul Dillon	Information Officer
Kate Dolan	Research Officer
Lisa Maher	Research Fellow
Rebecca McKetin	Senior Research Assistant
Vaughan Rees	Clinical Trial Co-Ordinator
Nadia Solowij	Principal Research Officer
Heli Wolk	Professional Officer
Wendy Swift	Doctoral Student
Libby Topp	Doctoral Student
Courtney Breen	Research Assistant
Louisa Degenhardt	Research Assistant
Kasia Godycka	Research Assistant
Simon Harris	Research Assistant
Sharlene Kaye	Research Assistant
Jo Kimber	Research Assistant
Susannah O'Brien	Research Assistant
Heather Proudfoot	Research Assistant
Joanne Ross	Research Assistant
James Shearer	Research Assistant
Seija Wolk	Research Assistant
Gail Pickering	Centre Secretary

Conjoint Appointments

Andrea Mant	Associate Professor
Alex Wodak	Senior Lecturer
James Bell	Lecturer
Robyn Richmond	Lecturer

Visiting and Honorary Staff

Greg Chesher	Honorary Research Fellow
Sharon Dawe	Honorary Research Fellow
Simon De Burgh	Honorary Research Fellow
Janet Greeley	Honorary Research Fellow
John Howard	Honorary Research Fellow
Ernest Hunter	Honorary Research Fellow
Katy O'Neill	Honorary Research Fellow
Catherine Spooner	Honorary Associate
Petra Staiger	Honorary Research Fellow
Deborah Zador	Honorary Research Fellow

1999

Wayne Hall	Director, Professor of Drug and Alcohol Studies
Richard P. Mattick	Deputy Director and Associate Professor
Shane Darke	Senior Lecturer
Jan Copeland	Lecturer
Michael Lynskey	Lecturer
Maree Teesson	Lecturer
Paul Adamson	Technical Officer
Eva Congreve	Archivist
Andrew Conroy	Senior Research Assistant
Erol Digiusto	Senior Coordinator
Paul Dillon	Information Officer
Kate Dolan	Research Officer
Rebecca McKetin	Senior Research Assistant
Wendy Swift	Senior Research Assistant
Nadia Solowij	Principal Research Officer
Heli Wolk	Professional Officer
Lucy Burns	Doctoral Student
Amanda Reid	Doctoral Student
Amanda Willemyns	Doctoral Student
Courtney Breen	Research Assistant
Louisa Degenhardt	Research Assistant
Sharlene Kaye	Research Assistant
Jo Kimber	Research Assistant
Susannah O'Brien	Research Assistant

Heather Proudfoot	Research Assistant	Heli Wolk	Professional Officer
Joanne Ross	Research Assistant	Lucy Burns	Doctoral Student
James Shearer	Research Assistant	Carolyn Day	Doctoral Student
Seija Wolk	Research Assistant	Amanda Reid	Doctoral Student
Gail Pickering	Centre Secretary	Amanda Willemyns	Doctoral Student
Conjoint Appointments		Neil Simon	Honours Student
Andrea Mant	Associate Professor	Courtney Breen	Research Assistant
Alex Wodak	Senior Lecturer	Nicole Clement	Research Assistant
James Bell	Lecturer	Louisa Degenhardt	Research Assistant
Robyn Richmond	Lecturer	Aylza Donald	Research Assistant
Visiting and Honorary Staff		Mary Ellen Harrod	Research Assistant
Greg Chesher	Honorary Research Fellow	Sharlene Kaye	Research Assistant
Sharon Dawe	Honorary Research Fellow	Jo Kimber	Research Assistant
Simon De Burgh	Honorary Research Fellow	Peter Lawrinson	Senior Research Assistant
Janet Greeley	Honorary Research Fellow	Nicky Henderson	Research Assistant
John Howard	Honorary Research Fellow	Susannah O'Brien	Research Assistant
Ernest Hunter	Honorary Research Fellow	Etty Matalon	Research Assistant
Katy O'Neill	Honorary Research Fellow	Joanne Ross	Research Assistant
Catherine Spooner	Honorary Associate	James Shearer	Research Assistant
Petra Staiger	Honorary Research Fellow	Matthew Warner-Smith	Research Assistant
Deborah Zador	Honorary Research Fellow	Evelyn Wilhelm	Research Assistant
		Heather Proudfoot	Research Assistant
2000		Joanne Ross	Research Assistant
Wayne Hall	Director, Professor of Drug and Alcohol Studies	Libby Topp	Research Assistant
Richard P. Mattick	Deputy Director and Associate Professor	Pat Ward	On Secondment from NSW Health
Shane Darke	Senior Lecturer	Gail Pickering	Centre Secretary
Jan Copeland	Senior Lecturer	Conjoint Appointment	
Kate Dolan	Senior Lecturer	Andrea Mant	Associate Professor
Erol Digiusto	Lecturer	Alex Wodak	Senior Lecturer
Michael Lynskey	Lecturer	James Bell	Lecturer
Maree Teesson	Lecturer	Robyn Richmond	Lecturer
Paul Adamson	IT Officer	Visiting and Honorary Staff	
Eva Congreve	Archivist	Greg Chesher	Honorary Research Fellow
Andrew Conroy	Senior Research Assistant	Sharon Dawe	Honorary Research Fellow
Paul Dillon	Information Officer	Simon De Burgh	Honorary Research Fellow
Chris Doran	Health Economist	Janet Greeley	Honorary Research Fellow
Rebecca McKetin	Senior Research Assistant	John Howard	Honorary Research Fellow
Wendy Swift	Senior Research Assistant	Ernest Hunter	Honorary Research Fellow
Nadia Solowij	Principal Research Officer	Katy O'Neill	Honorary Research Fellow

Catherine Spooner	Honorary Associate	Sharlene Kaye	Research Assistant
Petra Staiger	Honorary Research Fellow	Jo Kimber	Research Assistant
Deborah Zador	Honorary Research Fellow	Greg Martin	Research Assistant
		Etty Matalon	Research Assistant
		Katherine Mills	Research Assistant
		Heather Proudfoot	Research Assistant
		David Rouen	Research Assistant
		Fiona Shand	Research Assistant
		James Shearer	Research Assistant
		Aaron Silver	Research Assistant
		Matthew Warner-Smith	Research Assistant
		Anne Maree Weatherall	Research Assistant
		Bethany White	Research Assistant
		Evelyn Wilhelm	Research Assistant
		Gail Pickering	Admin Asst to Professors
		Julie Hodge	Centre Receptionist
		Conjoint Appointment	
		Andrea Mant	Associate Professor
		Alex Wodak	Senior Lecturer
		James Bell	Senior Lecturer
		Visiting and Honorary Staff	
		Robert Ali	Honorary Visiting Fellow
		Sharon Dawe	Honorary Visiting Fellow
		Linda Gowing	Honorary Visiting Fellow
		Ernest Hunter	Honorary Visiting Professor
		Jim Rankin	Honorary Visiting Professor
		Nadia Solowij	Honorary Visiting Fellow
		Catherine Spooner	Honorary Visiting Fellow
		Ingrid Van Beek	Honorary Visiting Fellow
		Deborah Zador	Honorary Visiting Fellow
Wayne Hall	Director , Professor of Drug and Alcohol Studies		
Richard P. Mattick	Deputy Director and Associate Professor		
Shane Darke	Associate Professor		
Jan Copeland	Senior Lecturer		
Kate Dolan	Senior Lecturer		
Maree Teesson	Senior Lecturer		
Erol Digiusto	Lecturer		
Michael Lynskey	Lecturer		
Wendy Swift	Lecturer		
Joanne Ross	Lecturer		
Paul Adamson	IT Officer		
Eva Congreve	Archivist		
Paul Dillon	Information Officer		
Chris Doran	Health Economist		
Peter Lawrinson	Senior Research Assistant		
Barry Manor	Senior Research Assistant		
Greg Martin	Senior Research Assistant		
Susannah O'Brien	Senior Research Assistant		
Kathryn Oowler	Senior Research Assistant		
Andrew Shakeshaft	Senior Research Assistant		
Libby Topp	Senior Research Assistant		
Pat Ward	On Secondment from NSW Health		
Heli Wolk	Professional Officer		
Lucy Burns	Doctoral Student		
Carolyn Day	Doctoral Student		
Amanda Reid	Doctoral Student		
Courtney Breen	Research Assistant		
Nicole Clement	Research Assistant		
Julius Cordell	Research Assistant		
Louisa Degenhardt	Research Assistant		
Jenny Gates	Research Assistant		
Nicky Henderson	Research Assistant		
Kate Hetherington	Research Assistant		

• Please see p. 11 for 2002 staff list

Appearances of personnel as key speakers at conferences both nationally and internationally

2000

1. **Burns, L.** *Comorbidity with alcohol disorders in Australia: epidemiology and policy responses.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
2. **Burns, L.** *Problem drinking and mental health.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
3. **Clement, N.** *Non-injecting routes of administration of drug use – a clinical trial.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
4. **Copeland, J.** *A randomised controlled trial of brief interventions for cannabis dependence.* Paper presented at 11th International Conference on the Reduction of Drug Related Harm, Jersey, Channel Islands, 9-13 April.
5. **Copeland, J.** *Nurses and brief interventions: findings of a randomised controlled trial for cannabis use disorder.* Gave an invited address to the Drug and Alcohol Nurses Association Annual Conference, Sydney, 18 May.
6. **Copeland, J.** *A brief, multi-dimensional instrument designed to measure outcomes for clients receiving methadone maintenance treatment.* Paper presented at National Methadone Conference, Melbourne, 1 December.
7. **Copeland, J.** *A brief multi-dimensional instrument designed to measure outcome for clients receiving methadone maintenance treatment.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
8. **Copeland, J.** *Alcohol and other drug issues amongst NSW juvenile detainees.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
9. **Darke, S.** *History and harm reduction.* Was a discussant at the 10th Anniversary Conference, Centre for Drugs and Health Behaviours, London, 7 April.
10. **Darke, S.** *Drug trends in NSW.* Paper presented at 2000 Illicit Drug Trends Conference, Sydney, 30 November.
11. **Day, C.** *The experience of Hepatitis C related discrimination within a NSW community sample of people living with hepatitis C.* Paper presented at Hepatitis C Everyday People Conference (working for change), Melbourne, 17 November.
12. **Degenhardt, L.** *The epidemiology of alcohol dependence in Australia.* Poster presentation at the 10th Congress of the International Society for Biomedical Research on Alcoholism, Yokohama, Japan, 2-8 July.
13. **Degenhardt, L.** *Persons with an intellectual disability and an alcohol use problem: Issues and treatment possibilities.* Paper presented at 2000 Annual Conference of Psychologists in Developmental Disability Services, Sydney, 13 December.
14. **Degenhardt, L.** *The epidemiology of fatal opioid overdose in Australia.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
15. **Degenhardt, L.** *Psychosis and problematic drug use in Australia.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
16. **Digiusto, E.** *Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).* Paper presented at 11th International Conference on the Reduction of Drug Related Harm, Jersey, Channel Islands, 9-13 April.
17. **Digiusto, E.** *Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
18. **Dillon, P.** *Australian street drugs and current trends.* Paper presented at Western Cluster Field Conference, Dubbo, 23 March.
19. **Dillon, P.** *Ketamine, GHB and the club scene.* Paper presented at Gearing up for the Millenium, Cardiff, Wales, 6 April.
20. **Dillon, P.** *GHB: a community based-approach to the*

- problem. Paper presented at 11th International Conference on the Reduction of Drug Related Harm, Jersey, Channel Islands, 9-13 April.
21. **Dillon, P.** *What's going on? Reviewing the research.* Paper presented at the Young and the Rest Of Us, Perth, 31 August.
 22. **Dillon, P.** *Club drugs.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 23. **Dolan, K.** *A randomised controlled trial of the NSW Prison Methadone Program.* Paper presented at 11th International Conference on the Reduction of Drug Related Harm, Jersey, Channel Islands, 9-13 April.
 24. **Dolan, K.** *A randomised controlled trial of the NSW Prison Methadone Program.* Paper presented at Injecting Drugs: the Prevention of Blood Borne Viruses and Overdose, The National Drug Research Institute, Perth, 4 August.
 25. **Dolan, K.** *A Randomised Control Trial of the New South Wales Prison Methadone Program* at Encouraging Health Conference, Hamburg, Germany, 22-25 November.
 26. **Doran, C.** *Buprenorphine vs methadone maintenance: a cost-effectiveness analysis.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 27. **Hall, W.** *What is comorbidity?* Paper presented at National Comorbidity Workshop, Canberra, 6 March.
 28. **Hall, W.** *An overview of the research activities of the National Drug and Alcohol Research Centre.* Paper presented at Annual Conference of the Australian and New Zealand Association for Psychiatry, Psychology and the Law, Melbourne, 28 April.
 29. **Hall, W.** *Patterns and trends in illicit drug use.* Paper presented at the Drug and Alcohol Nurses Association Annual Conference, Sydney, 19 May.
 30. **Hall, W.** *The Report of the Working Party on the Medical Use of Cannabis.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 31. **Hall, W.** *Estimating the number of heroin dependent users in Australia?* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 32. **Hall, W.** *Estimating the number of dependent heroin users in Australia.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
 33. **Hall, W.** *The rationale for the Illicit Drug Reporting System.* Paper presented at 2000 Illicit Drug Trends Conference, Sydney, 30 November.
 34. **Kaye, S.** *The prevalence, patterns and harms of cocaine use among injecting and non-injecting drug users in Sydney.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
 35. **Kimber, J.** *International survey of supervised injecting centres: preliminary findings.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 36. **Kimber, J.** *International survey of supervised injecting centres: preliminary findings.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
 37. **Mattick, R.** *Treatment approaches in opiate abuse – where do we go from here?* Paper presented at Buprenorphine – Progress in Partnership, London, UK, 23-24 March.
 38. **Mattick, R.** *Buprenorphine – treatment models.* Workshop presented at Buprenorphine – Progress in Partnership, London, UK, 23-24 March.
 39. **Proudfoot, H.** *Who gets treatment for alcohol use disorders in Australia?* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
 40. **Reid, A.** *The prevalence of adolescent cannabis use and the exploration of dependence, comorbidity and risk perception among heavy users.* Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
 41. **Shearer, J.** *Monitoring dexamphetamine prescribing: a randomised controlled study.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 42. **Spooner, C.** *The role of police in the prevention and management of alcohol problems.* Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
 43. **Swift, W.** *A randomised controlled trial of brief interventions for cannabis use disorder.* Keynote address given to Cutting Edge 2000, Rotorua, New Zealand, 31 August – 2 September.

44. **Swift, W.** *Putting research into practice: the case of cannabis*. Keynote address given to Cutting Edge 2000, Rotorua, New Zealand, 31 August – 2 September.
45. **Teesson, M.** *Prevention, promotion and politics*. Paper presented at The Mental Health Services Summer Forum, Sydney, 25 January.
46. **Teesson, M.** *The political abuse of evidence based medicine: The case of case management*. Keynote address presented at Getting Better Conference, Sydney, 19 February.
47. **Teesson, M.** *National Comorbidity Project*. Keynote address presented at National Comorbidity Workshop, Canberra, 6 March.
48. **Teesson, M.** *Case management and evidence based medicine*. Paper presented at The Mental Health Services Conference, Adelaide, 29-31 August.
49. **Teesson, M.** *Measuring need for care*. Paper presented at The Mental Health Services Conference, Adelaide, 29-31 August.
50. **Teesson, M.** *Alcohol and other drug use disorders in Australia*. Paper presented at The Mental Health Services Conference, Adelaide, 29-31 August.
51. **Teesson, M.** *The National Comorbidity Project*. Paper presented at The Mental Health Services Conference, Adelaide, 29-31 August.
52. **Teesson, M.** *The Australian Treatment Outcome Study*. Paper presented at the Combined APSAD and National Methadone Conference, Melbourne, 20-22 November.
53. **Topp, L.** *National drug trends*. Paper presented at 2000 Illicit Drug Trends Conference, Sydney, 30 November.
54. **Topp, L.** *Designer drug trends in NSW*. Paper presented at 2000 Illicit Drug Trends Conference, Sydney, 30 November.
55. **Ward, P.** *Health care utilisation under the Commonwealth Medicare Benefits Scheme by methadone patients*. Paper presented at 2000 NDARC Annual Symposium, Sydney, 29 November.
- 2001
56. **Burns, L.** *Comorbidity between alcohol use, depression and anxiety in an outpatient setting and the impact on treatment outcomes*. Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
57. **Copeland, J.** *Profiles of culturally and linguistically diverse clients from the NSW Minimum Dataset of Clients of Alcohol and Other Drug Treatment Services*. Invited paper to the Diversity in Health: Sharing Global Perspectives Conference: Sydney, May 30.
58. **Copeland, J.** *Clients of NSW alcohol and other drug treatment services: findings of the inaugural Minimum Data Set*. 2001. Presentation to Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
59. **Copeland, J., Swift, W., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J.** *A randomized controlled trial of brief interventions for cannabis problems among young offenders*. Poster presentation at the Sixty-third Annual Scientific Meeting of the College on Problems of Drug Dependence, June 16-21, Scottsdale, Arizona, USA.
60. **Copeland, J., Swift, W., & Martin, G.** *Cannabis interventions for young people*. Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
61. **Darke, S.** *The relationship between suicide and overdose among methadone maintenance patients*. Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
62. **Darke, S.** *Drug trends in NSW*. Paper presented at National Drug Trends Conference 2001, Sydney, 29 November.
63. **Day, C.** *Indigenous male and female injecting drug users*. Best Practice Interventions in Corrections for Indigenous People, Sydney, 8-9 October.
64. **Day, C.** *Drug treatment utilisation by Sydney heroin users*. Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
65. **Degenhardt, L.** *Characteristics of a sample of GHB users in Australia: preliminary findings*. Paper presented at the 12th International Conference on the Reduction of Drug Related Harm. Ashok Hotel, New Delhi, India, 1-5 April.
66. **Degenhardt, L.** *Birth cohort trends in the age of initiation of drug use in Australia*. Paper presented at the 12th International Conference on the Reduction of Drug Related Harm. Ashok Hotel, New Delhi, India, April 1-5 April.

67. **Degenhardt, L.** *The gender gap in drug use. Is it closing?* Paper presented at the 12th International Conference on the Reduction of Drug Related Harm. Ashok Hotel, New Delhi, India, 1-5 April.
68. **Degenhardt, L.** *GHB users in Australia: Who are they, how do they use it and what are the risks?* Paper presented at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
69. **Degenhardt, L.** *Crystal meth use in Sydney.* Paper presented at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
70. **Degenhardt, L.** *GHB users: their characteristics, use patterns and the associated harms of GHB use.* Paper presented at 2001 NDARC Annual Symposium, Sydney, 28 November.
71. **Digiusto, E.** *Treatment retention and drug use outcomes in the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).* Paper presented at 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
72. **Digiusto, E.** *National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): All treatments work, but some work better and are more cost effective than others.* Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
73. **Dillon, P.** *Cannabis: What's the story?* Keynote address at 'Innovation For Change', NSW PDHPE Teachers' Association Conference, Sydney, 20 October.
74. **Dillon, P.** *The media: manipulator or manipulated?* Workshop presented at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
75. **Dillon, P.** *Why is no-one talking to me? Media frustration with the d&a field.* Invited paper presented at the Australasian Medical Writers Association Conference – Testing the Limits ... Challenges for Medical Writers, Brisbane, Queensland, 2-3 November.
76. **Dolan K.** *Prisons and harm reduction.* Invited presentation at the 12th International Conference on the Reduction of Drug Related Harm, New Delhi, India, 1-5 April.
77. **Dolan, K.** *Effectiveness of interventions for marginalized and particularly vulnerable IDUs.* Paper presented at the Fourth Global Research Network Meeting, Melbourne, 11 October.
78. **Doran C.** *Buprenorphine vs. methadone maintenance: a cost-effectiveness analysis.* Presentation to the International Health Economic Association Conference, University of York, 23 July.
79. **Doran C.** *NEPOD: a focus on the health economic evaluation.* Presentation to the Centre for Health Economic Research and Evaluation, University of Sydney 17 October.
80. **Doran, C.** *Understanding economic evaluations: methods and practical application in clinical research.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
81. **Doran, C.** *NEPOD health economic evaluation: costs and cost-effectiveness of opioid detoxification and maintenance treatments.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
82. **Hall, W.** *The epidemiology of opioid overdose death in Australia 1964-1999.* Annual Conference of the Royal Australasian College of Physicians, Sydney, 15 May.
83. **Kaye, S.** *Non-injecting cocaine users in Sydney: patterns of use and associated harms.* Paper presented at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
84. **Kimber J.** *International Survey of Supervised Injecting Centres: preliminary findings.* Paper presented at the 12th International Conference on the Reduction of Drug Related Harm. Ashok Hotel, New Delhi, India, 1-5 April.
85. **Kimber, J.** *Evaluation of the Medically Supervised Injecting Centre (MSIC).* Paper presented at 2001 NDARC Annual Symposium, Sydney, 28 November.
86. **Lawrinson, P.** *Measuring treatment outcomes for clients of alcohol and other drug treatment services.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
87. **Lawrinson, P.** *Measuring treatment outcomes of clients of alcohol and other drug treatment services.* Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
88. **Martin, G.** *Adolescent Cannabis Check-Up.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.

89. **Matalon, E.** *A brief intervention for cannabis use disorders.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
90. **Mattick, R.** *Drug use in Australia: patterns of use, harms and responses.* Paper presented at the 4th National Conference on Alcohol and other Drugs in the Workplace, 2 May.
91. **Mattick, R.** *Buprenorphine versus methadone maintenance therapy: a randomised double-blind trial with 405 opioid dependent patients.* Paper presented at 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
92. **Mattick, R., Breen, C., & Kimber, J.** *Efficacy of methadone maintenance therapy versus no methadone maintenance therapy for opioid dependence: a meta-analytic review.* Poster presentation at 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
93. **Mattick, R.** *National Evaluation of Pharmacotherapies for Opioid Dependence.* Paper presented at 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
94. **Mattick, R., Kimber, J., MacDonald, M., Kaldor, J., Weatherburn, D., Lapsley, H., & van Beek, I.** *Methodology of the evaluation of the Medically Supervised Injecting Centre (MISC) and latest results of process evaluation.* Poster presentation at 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
95. **Mattick, R.** *Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence: a meta-analytic review.* Paper presented to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
96. **O'Brien, S.** *National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): project methodology and characteristics of the clients entering the trials.* Paper presented to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
97. **Proudfoot, H.** *Effective treatments for alcohol problems and treatment-seeking for alcohol dependence in Australia.* TheMHS 11th Annual Mental Health Services Conference, Wellington, New Zealand, 30 August.
98. **Proudfoot, H.** *Interventions for Common Chronic Disease Risk Factors - Alcohol.* The Royal Australian College of General Practitioners (RACGP) 44th Scientific Convention, Sydney, 29 September.
99. **Proudfoot, H.** *Interventions for alcohol dependence, abuse and excessive drinking.* Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
100. **Ross, J.** *Treatment of Alcoholism: What works?* Hanoi-Sydney Collaborative Mental Health Conference, Hanoi, 27-29 September.
101. **Shakeshaft, A.** *Appropriateness of red blood cell transfusions in major urban hospitals.* Presented at the 4th International Conference on the Scientific Basis of Health Services, Sydney, Australia, 27 September.
102. **Shakeshaft, A.** *National evaluation of pharmacotherapies for opioid dependence (NEPOD): criminal behaviour, expenditure on illicit drugs and serious adverse events.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
103. **Shand, F.** *Characteristics of the Clients in Treatment: the COTSA Census 2001.* Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
104. **Shearer, J.** *Pilot randomised double-blind placebo controlled study of dexamphetamine for cocaine dependence.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
105. **Shearer, J.** *Replacement therapy for stimulant users.* Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
106. **Shearer, J.** *The future of amphetamine.* National Chemical Diversion Conference, Australian Bureau of Criminal Intelligence, Canberra, 5 December.
107. **Spooner, C.** *Youth and drugs: the why and what do we do.* Presentation to 2001 NDARC Annual Symposium, Sydney, 28 November.
108. **Swift, W.** *Can it work? Does it work? Is it worth it? Cannabis.* Presentation to 2001 Combined APSAD and National Methadone Conference, Sydney, 29-31 October.

- 109. Swift, W., Copeland, J., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J.** *Adolescent Cannabis Check-up and Intervention Trial*. Poster presentation at the Sixty-third Annual Scientific Meeting of the College on Problems of Drug Dependence, June 16-21, Scottsdale, Arizona, USA.
- 110. Swift, W., Copeland, J., & Howard, J.** *A trial of two brief interventions for cannabis problems among young offenders in New South Wales*. Poster presentation at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
- 111. Teesson, M.** *Bridging the gap between research and practice*. Paper presented at the Mental Health Services Conference Summer Forum, 25 January.
- 112. Teesson, M.** *National Comorbidity Project*. Poster presentation at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
- 113. Teesson, M.** *National Comorbidity Project*. Paper presentation at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
- 114. Teesson, M.** *Managing scarcity in Australia: Discussant*. Paper presented at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
- 115. Topp, L.** *Patterns of ecstasy use in Australia, 1990-2001*. Paper presented at the Sixty-third Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, Arizona, USA, 16-21 June.
- 116. Topp, L.** *Prevalence & patterns of ecstasy use in Australia*. Paper presented at Combined APSAD and National Methadone Conference, Sydney, 29-31 October.
- 117. Topp, L.** *History and methodology of the IDRS*. Paper presented at National Drug Trends Conference 2001, Sydney, 29 November.
- 118. Topp, L.** *An overview of national drug trends*. Paper presented at National Drug Trends Conference 2001, Sydney, 29 November.
- 119. Topp, L.** *Australian Drug Trends 2001*. Keynote presentation at Drugs: National Problem, Local Solutions, Brisbane, 4 December.
- 2002**
- 120. Barker, B.** *Neuropsychological performance of ecstasy users*. Poster at the Annual Conference of the Australian Psychological Society, Royal Pines Resort, Gold Coast, 27 September – 9 October.
- 121. Barker, B.** *Neuropsychological performance in human ecstasy users – A test of the ecstasy-induced serotonin neurotoxicity hypothesis*. Paper to the Combined Australian Professional Society for Alcohol and Other drugs (APSAD) National Methadone Conference, Hilton Hotel, Adelaide, 18-20 November .
- 122. Barker, B.** *Neuropsychological performance in human ecstasy users – A test of the ecstasy-induced serotonin neurotoxicity hypothesis*. Paper to the NDARC Annual Symposium, Sydney, 27 November.
- 123. Breen, C.** *Examining party drug use in NSW*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Hilton Hotel, Adelaide, 18-20 November.
- 124. Breen, C.** *Australian drug trends: findings of the Illicit Drug Reporting System 2002*. Paper to the National Drug Trends Conference, Sydney, 28 November.
- 125. Copeland, J.** *Treatment of cannabis dependence*. Invited address to the International Scientific Conference on Cannabis, Brussels, Belgium, 25 February.
- 126. Copeland, J.** *Adolescent Cannabis Use: Issues and Interventions*. Invited paper to the Australasian Drug and Alcohol Nurses Conference, Sydney, 10 May.
- 127. Copeland, J.** *Patterns of Use, Harms and Brief Interventions for Cannabis*. Invited paper to the Australasian Drug and Alcohol Nurses Conference, Sydney, 10 May.
- 128. Copeland, J.** *Adolescent Cannabis Check-up and Intervention Trial*. Paper presented at the 64th College on Problems of Drug Dependence Meeting, Quebec City, Canada, 13 June.
- 129. Copeland, J.** *A RCT of Brief Interventions for Cannabis Problems Among Young Offenders in Australia*. Seventh NIDA International Forum: Building International Research on Drug Abuse Treatment Innovations. Quebec City, Canada, 15 June.
- 130. Copeland, J.** *A RCT of Brief Cannabis Interventions Among Young Offenders in NSW*. Invited paper to the National Crime Prevention Conference, Sydney, 13 September.

131. **Copeland, J.** *The Adolescent Cannabis Check-Up: Preliminary findings*. Paper to the 2002 Australian Professional Society of Alcohol and Drugs (APSAD) National Conference, Adelaide, 20 November.
132. **Darke, S.** *Suicide and depression among entrants to treatment for heroin dependence in Sydney, Australia. Preliminary findings from the Australian Treatment Outcome Study (ATOS)*. Seventh NIDA International Forum: Building International Research on Drug Abuse Treatment Innovations. Quebec City, Canada, 15 June.
133. **Day C.** *Discrimination of heroin users in Sydney: Is it based on drug use status or hepatitis C status?* 3rd Australasian Conference on Hepatitis C, Melbourne, 25-27 March.
134. **Day C.** *Changes in the patterns of drug use following a reduction in heroin availability in Sydney: The Heroin Drought*. 13th International Conference on the Reduction of Drug Related Harm, Ljubljana, Slovenia, 3-7 March.
135. **Day C.** *Female injecting drug users in Sydney Australia: Aboriginal and non-aboriginal*. 2nd International Harm Reduction Congress on Women and Drugs, Ljubljana, Slovenia, 3 March 2002.
136. **Day, C.** *Discrimination of heroin users in Sydney: is it based on drug user status or hepatitis C status?* Paper to the NDARC Annual Symposium, Sydney, 27 November.
137. **Degenhardt, L.** *Ambulance callouts to suspected drug overdoses*. Paper presented at the 13th International Conference on the Reduction of Drug Related Harm. Lubljana, Slovenia, 3-7 March.
138. **Dillon, P.** *New drugs, new risks: current state of play*. Invited presentation to the 2nd International Conference on Night-Life, Substance Use and Related Health Issues, Rimini, Italy, 24-27 March.
139. **Dillon, P.** *NDARC perspectives*. Invited presentation at Initiatives, Innovation and Practice: Drug Treatment Service Providers Conference, Preston, Victoria, 9 August.
140. **Dillon, P.** *Party drugs*. Workshop presented at Initiatives, Innovation and Practice: Drug Treatment Service Providers Conference, Preston, Victoria, 9 August.
141. **Dillon, P.** *The media: manipulated or manipulator?*. Paper presented at the 12th Mental Health Services Conference, Sydney, 20-22 August.
142. **Dolan, K.** *A follow-up study of subjects in a randomised controlled trial in NSW prisons*. Paper presented at the 13th International Conference on the Reduction of Drug-Related Harm, Ljubljana, Slovenia, 3-7 March.
143. **Dolan, K.** *A follow-up study of subjects in a randomised controlled trial in NSW prisons*. Paper presented at the 3rd Australasian Conference on Hepatitis C, Melbourne, 26 March.
144. **Doran, C.** *Buprenorphine versus methadone maintenance: a cost-effectiveness analysis*. Presentation made at the 24th Australian Conference of Health Economists, Sydney, 19 July.
145. **Doran, C.** Discussant on the paper entitled *The use of comparative standards in consumer evaluation of mental health service attributes* by Dr Duane Pennebaker. Presentation made at the 24th Australian Conference of Health Economists, Sydney, 19 July.
146. **Gates, J.** *Zyban and nicotine dependence: current patterns of usage and costs*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
147. **Kaye, S.** *Injecting and non-injecting cocaine use in Sydney, Australia*. Paper presented at the 13th International Conference on the Reduction of Drug-Related Harm, Ljubljana, Slovenia, 3-7 March.
148. **Kelly, E.** *Illicit drug use and driving: epidemiology, accident involvement and risk perceptions*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
149. **Kimber, J.** *Methodology of the Evaluation of the Sydney Medically Supervised Injecting Centre (MSIC) and latest process evaluation results*. Paper presented at the 13th International Conference on the Reduction of Drug-Related Harm, Ljubljana, Slovenia, 3-7 March.

150. **Kimber, J.** *Konsumraumen: Die Australischen Ergebnisse (Consumption rooms: The Australian experience)*. Paper to 7. Internationaler akzept-Drogenkongress, Jena, Germany, 27 October.
151. **Lawrinson, P.** *Measuring treatment outcomes for clients of alcohol and other drug treatment services*. Paper presented at Health Outcomes 2002: Current Challenges and Future Frontiers. 8th Annual National Health Outcomes Conference, Canberra, 17-18 July 2002.
152. **Lawrinson, P.** *Measuring treatment outcomes for clients of alcohol and other drug treatment services*. Paper presented at Cutting Edge 2002, Annual Treatment Conference on Alcohol Drug and Other Addictive Disorders. Nelson, New Zealand. 29-31 August 2002.
153. **Lawrinson, P.** *Implementation of Routine Outcome Measures in Alcohol and Drug Services: What this could mean for clinicians in practice?* Plenary paper presented at Cutting Edge 2002, Annual Treatment Conference on Alcohol Drug and Other Addictive Disorders. Nelson, New Zealand. 29-31 August 2002.
154. **Lawrinson, P.** *Measuring treatment outcomes for clients of alcohol and other drug treatment services*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
155. **Matalon, E.** *Brief Interventions for Cannabis Dependence*. An invited clinical workshop to the Australasian Drug and Alcohol Nurses Conference, Sydney, 10 May.
156. **Mattick, R.** *Buprenorphine maintenance treatment*. Invited presentation at the Buprenorphine Treatment Program Special Lecture, Jakarta, Indonesia, 6 April.
157. **Mills, K.** *Alcohol consumption among university students*. 3rd International Conference on Drugs and Young People, Randwick, 14 May.
158. **Mills, K.** *Post traumatic stress disorder (PTSD) among heroin users: prevalence, stressful life events, and associated harms*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
159. **O'Brien, S.** *Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)*. Paper presented at the 13th International Conference on the Reduction of Drug Related Harm in Ljubljana, Slovenia, 3-7 March.
160. **Shakeshaft, A.** *Using computers to reduce alcohol problems among general practice patients: is systems change the thing?* Paper to the NDARC Annual Symposium, Sydney, 27 November.
161. **Shanahan, M.** *Cost-effectiveness analysis of the NSW Adult Drug Court Program*. Paper presented at the 24th Australian Health Economics Society Conference, Sydney 18 - 19 July.
162. **Shanahan, M.** *The cost-effectiveness analysis of the NSW Adult Drug Court*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
163. **Shanahan, M.** *Prescription heroin – rhetoric versus evidence*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
164. **Shearer, J.** *Research into dexamphetamine substitution for psycho-stimulant dependence*. Paper presented at Drug and Alcohol Nurses of Australasia Conference, Sydney, 9 May.
165. **Shearer, J.** *Pilot randomised double blind placebo controlled study of dexamphetamine for cocaine dependence*. Paper presented at College of Problems of Drug Dependence, Quebec City, Canada, 12th June.
166. **Spooner, C.** *Youth drug use and harms*. 3rd International Conference on Drugs and Young People, Randwick, 13 May.
167. **Spooner, C.** *The role of police in illicit drug harm minimisation: An overview*. Keynote presentation 2nd Australasian Conference on Drug Strategy, Perth, 9 May.
168. **Spooner, C.** *The police and illicit drug harm minimization: identifying and addressing the harms*. Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.

169. **Spooner, C.** *The role of police in preventing and minimising illicit drug use and its harms.* Paper to the NDARC Annual Symposium, Sydney, 27 November.
170. **Swift, W.** *Young people and cannabis use: A Check-Up Approach.* 3rd International Conference on Drugs and Young People, Randwick, 14 May.
171. **Teesson, M.** *Cannabis and psychosis.* Paper to the 12th Mental Health Services (THEMHS) Conference, Sydney, 20-22 August.
172. **Teesson, M.** *The structure of cannabis dependence in the community.* Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
173. **Teesson, M.** *Australian Treatment Outcome Study (ATOS): Heroin.* Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.
174. **Topp, L.** *Tracking the emergence of potent forms of methamphetamine in Sydney, Australia.* Paper presented at the 13th International Conference on the Reduction of Drug-Related Harm, Ljubljana, Slovenia, March 3-7.
175. **Topp, L.** *Australia's dynamic methamphetamine markets.* Paper to Paper to the Combined Australian Professional Society for Alcohol and Other Drugs (APSAD) National Methadone Conference, Adelaide, 18-20 November.



Appearances of personnel as key speakers at seminars and workshops both nationally and internationally

2000

176. **Breen, C.** *Opiate treatment – pharmacotherapies: buprenorphine.* Presentation at South Eastern Sydney Area Health Service Drug and Alcohol Clinical Skills Update, Sutherland Hospital, 24 May.
177. **Burns, L.** *Alcohol and anxiety/depression.* Presentation to Co-morbidity, a CEIDA and NDARC Seminar, Sydney, 15 August.
178. **Copeland, J.** *A randomised controlled trial of brief interventions for cannabis dependence.* Presentation at The National Addiction Centre, Institute of Psychiatry, London, 10 April.
179. **Copeland, J.** *Brief interventions for cannabis use disorder.* The European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 12 April.
180. **Copeland, J.** *The epidemiology and aetiology of substance use disorders.* Presentation to Masters of Psychological Medicine Seminar Series, St Vincent's Hospital, 30 May.
181. **Copeland, J.** *Prevalence and treatment of cannabis use disorders.* Presentation to ACT Community Care Seminar Series for Treatment Works Week, Canberra, 28 June.
182. **Darke, S.** *Hair morphine concentrations of fatal heroin overdose cases and living heroin users.* National Addiction Centre, London, 6 April.
183. **Darke, S.** *Heroin overdoses in Australia.* Queensland Department of Health Seminar, Brisbane, 2 May.
184. **Darke, S.** *Hair morphine concentrations of fatal heroin overdose cases and living heroin users.* Presentation to We Help Ourselves Seminar, Sydney, 2 August.
185. **Darke, S.** *Hair morphine concentrations of fatal heroin overdose cases and living heroin user.* Presentation to Central Coast Area Health Service Drug and Alcohol Service Seminar, Gosford, 15 August.
186. **Darke, S.** *Using the Opiate Treatment Index as a clinical tool.* Presentation to Wentworth Area Health Service Drug and Alcohol Service Seminar, Sydney, 29 August.
187. **Darke, S.** *Hair morphine concentrations of fatal heroin overdose cases and living heroin users.* Presentation to Department of Psychology Seminar, Sydney, 7 September.
188. **Degenhardt, L.** *Cannabis and psychosis.* Presentation to Co-morbidity, a CEIDA and NDARC Seminar, Sydney, 15 August.
189. **Dillon, P.** *Australian street drugs and current trends.* Presentation at Pfizer Clinical Meeting, Sydney, 22 March.
190. **Dillon, P.** *Australian street drugs and current trends.* Presentation at Dubbo Medical Society's Post-Graduate Weekend, Dubbo, 26 March.
191. **Dillon, P.** *Current drug trends.* Presentation to Diocesan Drug Education Adviser Workshop, Catholic Education Commission, 25 May.
192. **Dillon, P.** *Current trends in party drug use.* Presentation to HIV Prescribers Course, Sydney, 6 August.
193. **Dillon, P.** *Party drugs.* Presentation to Kirketon Road Seminar, Sydney, 9 August.
194. **Dillon, P.** *Club drugs.* Presentation to Pfizer GP Seminar, Perth, 30 August.
195. **Dillon, P.** *Club drugs.* Presentation to Pfizer GP Seminar, Perth, 31 August.
196. **Hall, W.** *A summary of the Institute of Medicine Report: Marijuana and Medicine.* Presentation at the Meeting of the Working Party on the Use of Cannabis for Medical Purposes, Sydney, 15 February.
197. **Hall, W.** *Making causal inferences in the health sciences.* Presentation at the Psychology Honours Seminar on Health Statistics, School of Psychology, UNSW, Sydney, 9 March.
198. **Hall, W.** *Trends in opioid overdose in Australia 1964-1998.* Presentation at the Research Seminar, School of Physiology and Pharmacology, UNSW, Sydney, 14 March.

199. **Hall, W.** *Estimating the number of dependent heroin users in Australia.* Presentation at the Workshop, Drug and Alcohol Services Council of South Australia, Adelaide, 16 March.
200. **Hall, W.** Was a discussant at the Launch of National School Drug Education Policy, Sydney, 22 March.
201. **Hall, W.** *The logic of causal inference.* Presentation at Human Behaviour Course, Second Year Medicine, Sydney, 23 March.
202. **Hall, W.** *Trends in opioid overdose deaths 1964-1998.* Presentation at School of Psychology and Psychiatry, James Cook University, Townsville, 31 March.
203. **Hall, W.** *Policy analysis in the health sciences; The case of medical uses of cannabis.* Presentation at Seminar, Psychology Honours Seminar on Health Statistics, School of Psychology, UNSW, Sydney, 6 April.
204. **Hall, W.** Briefing for International Narcotics Control Board Delegation, Canberra, 10 April.
205. **Hall, W.** *What can be done to reduce heroin overdose deaths?* Presentation at Grand Rounds, St Vincent's Hospital, Sydney, 9 May.
206. **Hall, W.** *How many opioid dependent people are there in Australia?* Presentation at Meeting of Australian National Council on Drugs, Darwin, 11 May.
207. **Hall, W.** *Briefing on trends in opioid overdose deaths.* Presentation at Premier's Expert Advisory Group on Drugs, Sydney, 19 May.
208. **Hall, W.** *Patterns and trends in alcohol and other drug use and drug-related harm in Australia.* Presentation to Briefing to House of Representatives Standing Committee on Family and Community Affairs Committee Inquiry into Drug Abuse: How are we handling it? Canberra, 9 June.
209. **Hall, W.** *Trends in illicit drug use in Australia.* Presentation to Community Forum, Fairfield, Sydney, 21 June.
210. **Hall, W.** *Briefing on report of Working Party on the Use of Cannabis for Medical Purposes.* Presentation to Premier's Expert Advisory Group on Drugs, Sydney, 22 June.
211. **Hall, W.** *Estimating the number of dependent heroin users in Australia.* Presentation to National Addiction Centre, Institute of Psychiatry, London, 12 July.
212. **Hall, W.** *Estimating the number of dependent heroin users in Australia.* Presentation to the Centre for Drugs and Health Behaviour, London, 13 July.
213. **Hall, W.** *Performance indicators for drug law enforcement.* Seminar given to NSW Police Centre, Sydney, 27 July.
214. **Hall, W.** *Reducing the harms of cannabis use; the Australian policy debate.* Presentation to Master of Public Health Course, University of Sydney, Sydney, 2 August.
215. **Hall, W.** Gave Evidence to House of Representatives Standing Committee on Family and Community Affairs Committee Inquiry into Drug Abuse: How are we handling it?, Canberra, 14 August.
216. **Hall, W.** *Co-morbidity: why does it matter?* Presentation to Co-morbidity, a CEIDA and NDARC Seminar, Sydney, 15 August.
217. **Hall, W.** *Reducing the harms of heroin use: the Australian policy debate.* Presentation to Masters of Public Health Lecture, Sydney, 16 August.
218. **Hall, W.** *Briefing on findings and recommendations of Working Party on the use of cannabis for medical purposes.* Presentation to NSW Expert Advisory Group on Drugs, Sydney, 17 August.
219. **Hall, W.** *How many dependent heroin users are there in Australia?* Presentation to NSW Bureau of Crime Statistics and Research, Attorney General's Department, Sydney, 17 August.
220. **Hall, W.** *Assessing the public health impact of heroin prescribing.* Presentation to NSW Branch, Public Health Association of Australia, Sydney, 23 August.
221. **Hall, W.** *Trends in opioid overdose death in Australia.* Presentation to King County Heroin Overdose Task Force, King County Department of Public Health, Seattle, Washington, 12 September.
222. **Hall, W.** *Reducing the harm of cannabis use: The Australian policy debate.* Presentation to Alcohol and Drug Abuse Institute, University of Washington, Seattle, Washington, 13 September.
223. **Hall, W.** *Heroin use in Australia: lessons for social policies towards biotechnologies.* Presentation to Institute of Molecular Bioscience, University of Queensland, 17 October.

224. **Hall, W.** *Reducing the harms of cannabis use: the Australian policy debate.* Presentation to School of Psychiatry, University of New South Wales, 3 November.
225. **Hall, W.** *The Report of the Working Party on the Medical Uses of Cannabis.* Presentation to Australian National Council on Drugs, Hobart, 15 December.
226. **Kimber, J.** *Overview of European Experience of Supervised Injecting Centres.* Presentation to ACT Community Care Seminar Series for Treatment Works Week, Canberra, 28 June.
227. **Lynskey, M.** *Epidemiology of heroin use and dependence.* Presentation to Public Health Lecture, Sydney, 9 August.
228. **O'Brien, S.** *The Woolshed Study.* Presentation to ATCA National Workshop -Towards Better Practice in the New Millennium, Gold Coast, 5 November.
229. **Swift, W.** *Cannabis.* Presentation to Annual General Meeting of the Employee Assistance Professional Association, NSW Branch, Sydney, 2 November.
230. **Teesson, M.** *The Australian Treatment Outcome Study: Heroin.* Presentation to Reference Group Meeting, Adelaide, 14 June.
231. **Teesson, M.** *Treatment of alcohol disorders: Assessing the evidence.* Presentation to Masters of Public Health Lecture, Sydney, 26 July.
232. **Teesson, M.** *How common is co-morbidity?* Presentation to Co-morbidity, a CEIDA and NDARC Seminar, Sydney, 15 August.
233. **Teesson, M.** *Evaluation of a treatment program for persons with substance use and mental disorders in inner Sydney.* Presentation to Co-morbidity, a CEIDA and NDARC Seminar, Sydney, 15 August.
234. **Teesson, M.** *A national response to comorbidity.* Presentation to Co-morbidity, a CEIDA and NDARC Seminar, Sydney, 15 August.
235. **Teesson, M.** *Comorbidity.* Presentation to European Association of Cognitive Behaviour Therapy, Spain, 26 September.
236. **Teesson, M.** *Compliance therapy in alcohol dependence.* Presentation to European Association of Cognitive Behaviour Therapy, Spain, 26 September.
- 2001
237. **Copeland, J.** *Young offenders, substance use, depression and suicidal behaviour' and 'Alcohol and other drug use issues among NSW juvenile detainees.* Presentation to 1st Forensic Psychology Conference, Sydney, 11 February.
238. **Copeland, J.** *The why and how of two cannabis interventions with young people.* Video-link presentation to 8 Queensland sites for health workers: Sydney, 6 June.
239. **Copeland, J. & Swift, W.** *Cannabis Use and Young People in Australia: Patterns of Use, Harms and Responses.* Invited paper to the Alcohol and Drug Institute, University of Washington and the Innovative Programs Research Groups University of Washington School of Social Work: Seattle, Washington, 25 June.
240. **Copeland, J.** *Adolescent cannabis use: harms and responses.* Seminar to the Faculty of Applied Psychology, Griffith University, Gold Coast Campus, 7 September.
241. **Darke, S.** *Suicide and overdose among methadone maintenance patients.* Central Sydney Area Health Service, 29 January.
242. **Darke, S.** *Suicide and overdose among methadone maintenance patients.* South Western Sydney Area Health Service, 30 January.
243. **Darke, S.** *Suicide and overdose among methadone maintenance patients.* Wentworth Area Health Service, 12 February.
244. **Darke, S.** *Depression, suicide and antidepressant use among injecting drug users.* Brisbane Drug and Alcohol Services, Brisbane, 8 May (live broadcast to seven remote sites in Qld).
245. **Darke, S.** *Suicide and overdose among methadone maintenance patients.* Brisbane Drug and Alcohol Services, Brisbane, 8 May.
246. **Darke, S.** *Results of the 2000 NSW Illicit Drug Reporting System.* NSW Police Development Training course, University of Western Sydney, 10 May.
247. **Degenhardt, L.** *Drug use among young people: trends, issues and consequences.* Association of Heads of Independent Girls' Schools (AHIGS). Tara Girls' High School, Sydney, 19 August.

248. **Degenhardt, L.** *Heroin use in Australia: Public health and public order.* Lecture to students from the Masters of Public Health course, University of Sydney, Sydney, 22 August.
249. **Degenhardt, L.** *Current drug trends 2001.* Lecture to students from the Masters of Psychological Medicine course at the University of NSW, Darlinghurst, Sydney, 4 September.
250. **Degenhardt, L.** *Current drug trends 2001.* Presented to Northholm High School, 5 September.
251. **Degenhardt, L.** *Research methods.* Lecture to students from the Masters of Psychological Medicine course at the University of NSW, Darlinghurst, 24 October.
252. **Degenhardt, L.** *Drug use in Australia: Current issues, emerging trends.* Seminar presented to Banks House Clinic, Bankstown Hospital, 20 November.
253. **Digiusto, E. & Mattick, R.** *National Evaluation of Pharmacotherapies for Opioid Dependence.* 2001 NDARC Seminar Series: NSW Drug Programs Bureau, 6 March.
254. **Dillon, P.** *Drug trends.* Presentation to the Life Education Educators Meeting, Sydney, 30 January.
255. **Dillon, P.** *Current drug trends.* Presentation to NIDA, Sydney, 22 February.
256. **Dillon, P.** *The use of performance enhancing drugs.* Presentation to the Association of Independent Schools AIS 2 Unit PDHPE Day, Sydney, 19 March.
257. **Dillon, P.** *Party drugs.* Presentation to the Mosman High School Drug Information Day, Sydney, 22 March.
258. **Dillon, P.** *Club drugs and your patients.* Presentation to Pfizer GP Meeting, Mandurah, 28 March.
259. **Dillon, P.** *Club drugs and your patients.* Presentation to Pfizer GP Meeting, Perth, 29 March.
260. **Dillon, P.** *Current NDARC research.* Next Step Seminar Series, Perth, 30 March.
261. **Dillon, P.** *The media: manipulator or manipulated.* WANADA Seminar, Perth, 30 March.
262. **Dillon, P.** *Club drugs and your patients.* Presentation to Pfizer GP Meeting, Underwater World, Hillarys, 31 March.
263. **Dillon, P.** *Young people and risk taking.* Chatham High School, Taree, 4 April.
264. **Dillon, P.** *Current drug trends.* Taree TAFE, Taree, 4 April.
265. **Dillon, P.** *Young people and risk taking.* Foster High School, Taree, 4 April.
266. **Dillon, P.** *Current drug trends.* Community Drug Action Team Community Meeting, Taree, 4 April.
267. **Dillon, P.** *Club drugs: an update.* HIV Prescribers Course, Sydney, 6 May.
268. **Dillon, P.** *Harm reduction: an overview.* TAFE Counsellors Training Course, Sydney, 7 May.
269. **Dillon, P.** *Treatments for alcohol and other drugs.* TAFE Counsellors Training Course, Sydney, 7 May.
270. **Dillon, P.** *Young people and risk taking.* Collary High School, Taree, 19 May.
271. **Dillon, P.** *Current drug trends.* Tamworth Drug Awareness Week Meeting, Taree, 19 May.
272. **Dillon, P.** *Current drug trends.* Waverley College, Bondi, 21 May.
273. **Dillon, P.** *Current party drug trends.* ASHM HIV/HCV Short Course, Darlinghurst, 1 September.
274. **Dillon, P.** *Young people and risk-taking.* Young Drivers' Expo, Tamworth, 4-6 September.
275. **Dillon, P.** *Current drug trends.* North West Slopes Division of General Practice, GP Liaison Project, Tamworth, 4 September.
276. **Dillon, P.** *Young women and party drugs.* Presentation at 'Rave and Rage – Challenges arising from substance use by young women', Ashfield, Sydney, 19 October.
277. **Dillon, P.** *Current drug trends.* Multicultural Drug Education Pilot Project Course, Sydney, 7 November.
278. **Dillon, P.** *Current drug trends.* GP Training, Nepean College of General Practice, Penrith, 6 June.
279. **Dillon, P.** *Current drug trends.* Muswellbrook Community Drug Forum, Muswellbrook, 7 June.

280. **Dolan, K.** *RCT of prison methadone*. 2001 NDARC Seminar Series: NSW Drug Programs Bureau, 1 May.
281. **Hall, W.** *An overview of NDARC research*. 2001 NDARC Seminar Series: NSW Drug Programs Bureau, 6 February.
282. **Hall, W.** *Evidence to House of Representatives Standing Committee on Family and Community Affairs Committee Inquiry into Drug Abuse: How are we handling it?* Sydney, 21 February.
283. **Hall, W.** *Logic of causal inferences*. Human Behaviour II, Medical Faculty, UNSW, 1 March.
284. **Hall, W.** *The medical uses of cannabis*. Central Sydney Area Health Services Drug and Alcohol Services, Gladstone Hall, 9 March.
285. **Hall, W.** *Towards evidence based addiction treatment*. Next Step Strategic Planning Day, Perth, Western Australia, 5 April.
286. **Hall, W.** *Cannabis and mental health*. World Health Day Seminar, WA Department of Health, Subiaco, Western Australia, 6 April.
287. **Hall, W.** *Comorbidity: What is it, why does it matter and what should we do about it?* WA Department of Health, Floreat, Western Australia, 9 April.
288. **Hall, W.** *The Illicit Drug Reporting System 1996-2001*. Intergovernmental Committee on Drugs, Adelaide, 19 April.
289. **Hall, W.** *How can we reduce opioid overdose deaths?* Psychology Department, University of Western Sydney, Milperra, 12 May.
290. **Hall, W.** *Minimising the harms caused by adolescent substance use*. Annual Conference of the Royal Australasian College of Physicians, Sydney, 15 May.
291. **Hall, W.** *How can we reduce opioid overdose deaths?* Psychology Department, University of Sydney, 26 May.
292. **Mattick, R.** *The National Evaluation of Pharmacotherapies for Opioid Dependence*. Intergovernmental Committee on Drugs, Adelaide, 19 April.
293. **Mattick, R.** *The National Evaluation of Pharmacotherapies for Opioid Dependence*. Ministerial Council on Drug Strategy, Adelaide, 31 July.
294. **Mattick, R.** *Western Australian Community Drug Summit: An Overview*. Western Australian Community Drug Summit, Perth, 13-17 August.
295. **Ross, J.** *Australian Treatment Outcome Study (ATOS)*. 2001 NDARC Seminar Series: NSW Drug Programs Bureau, 5 June.
296. **Ross, J.** *Comorbidity*. Paper presented at Rural GP Alcohol & Other Drug Conference, Orange, 3 November.
297. **Ross, J.** *Comorbidity*. Workshop presented at Rural GP Alcohol & Other Drug Conference, Orange, 3 November.
298. **Swift, W.** *Cannabis*. Lecture to students from the Master of Public Health course, Sydney University, 15 August.
299. **Topp, L.** *Stimulant use in Australia*. Paper presented at the NSW Cabinet Office Expert Advisory Committee for the Special Minister of State, 23 August.
- 2002
300. **Breen, C.** *Treatment for heroin dependence*. Paper to the Wentworth Area Health Service Seminar, 26 March.
301. **Copeland, J.** *The Australian Adolescent Cannabis Check-up*. Paper to the National Addiction Centre, Institute of Psychiatry, Kings College, London, UK, 22 February.
302. **Copeland, J.** *Cannabis: patterns of use, harms and medical uses*. Invited paper to the Human Development Teachers for the NSW Department of Education and Training: Sydney, 19 March.
303. **Copeland, J.** *Findings of the New South Wales Minimum Dataset of Clients of Alcohol and Other Drug Treatment Services*. NDARC in-house seminar, Sydney, 21 March.
304. **Copeland, J.** *Cannabis: patterns of use, harms and medical uses*. Invited paper to the Human Development Teachers for the NSW Department of Education and Training: Sydney, 22 March.
305. **Copeland, J.** *Adolescent Cannabis Check-up*. Invited paper to the University of Sydney Interdepartmental Substance Abuse Research Group Seminar, Sydney, 24 May.

- 306. Copeland, J.** *A RCT of Brief Interventions for Cannabis Problems Among Young Offenders in Australia: rationale, methodology and process issues.* Invited paper to the Collaborative Research Unit, NSW Department of Juvenile Justice, Sydney, 26 July.
- 307. Copeland, J.** *Cannabis: adolescent patterns of use, harms & interventions.* Invited lecture to Masters of Social Health, Macquarie University, 16 August.
- 308. Copeland, J.** *Women and drugs: gender-sensitive service provision.* Invited lecture to Masters of Social Health, Macquarie University, 16 August.
- 309. Copeland, J.** *The why and how of brief interventions for cannabis use disorder.* Invited lecture to the Wentworth Area Health Service, Nepean Hospital, 27 August.
- 310. Copeland, J.** *Young people and drugs.* Invited address to the Trimmingham Foundation Family Drug Support, Burwood, 28 October.
- 311. Copeland, J.** *Cannabis and adolescents: patterns of use, consequences and interventions.* Keynote address to the Tasmanian TAFE Community Forum, Launceston, 1 November.
- 312. Copeland, J.** *Cannabis: patterns of use, mental health and brief interventions.* Invited paper to the NSW Alliance of General Practitioners' Drug and Alcohol and Mental Health Forum, Sydney, 15 November.
- 313. Darke, S.** *Consequences of non-fatal overdose.* Central Sydney Area Health Service Needle and Syringe Exchange Program, Sydney, 29 January.
- 314. Darke, S.** *Consequences of non-fatal overdose.* Tower Clinic Drug and Alcohol Service, Central Sydney Area Health Service, Sydney, 19 February.
- 315. Darke, S.** *Overdose and suicide among heroin users.* Department of Psychology, University of NSW, 6 March.
- 316. Darke, S.** *Baseline data from the Australian Treatment Outcome Study (ATOS).* We Help Ourselves (WHOS), Sydney, 19 March.
- 317. Darke, S.** *Baseline data from the Australian Treatment Outcome Study (ATOS).* Tower Clinic Drug and Alcohol Service, Central Sydney Area Health Service, Sydney, 12 March.
- 318. Darke, S.** *Suicide among heroin users: rates, risk factors and methods.* Central Coast Area Health Service, Gosford, 14 May.
- 319. Darke, S.** *Heroin overdose: causes and circumstances.* Medically Supervised Injecting Centre Training Seminar, Sydney, 19 June.
- 320. Day, C.** *Discrimination of heroin users in Sydney: Is it based on drug use status or hepatitis C status?* Invited seminar presented at Resource and Education Program for Injecting Drug Users (REPIDU). 9 April.
- 321. Day, C.** *Treatment service use by heroin users in Sydney.* Invited seminar presented at Resource and Education Program for Injecting Drug Users (REPIDU). 9 April.
- 322. Degenhardt, L.** *GHB and crystal methamphetamine users in Australia.* Paper presented at Special Seminar for Sydney Youth Workers and Police Youth Liaison Officers, Ted Noffs Foundation, Randwick, Sydney, 18 January.
- 323. Degenhardt, L.** *Amphetamines: What's the story?* Wagga Wagga NSW Police Service/NDARC Information Session, Wagga Wagga, 6 August.
- 324. Dillon, P.** *Current drug trends.* Community Drug Action Team Information Evening, Peninsula, 7 February.
- 325. Dillon, P.** *Drugs and elite sportspeople.* Rugby Union Professional Development Course, NSW Academy of Sport, Sydney, 11 February.
- 326. Dillon, P.** *Current drug trends.* High Street Health Service Workshop, Harris Park, 12 February.
- 327. Dillon, P.** *Current drug trends.* Salvation Army Conference, Wollongong, 13 February.
- 328. Dillon, P.** *Current drug trends.* Southern Highlands Primary School Staff Training Evening, Mittagong, 13 February.
- 329. Dillon, P.** *Young people and risk-taking.* All Saints Catholic Girls College, Liverpool, 18 February.
- 330. Dillon, P.** *Current drug trends.* All Saints Catholic Girls College Staff Training, Liverpool, 18 February.
- 331. Dillon, P.** *Current drug trends.* All Saints Catholic Girls College Staff Parent Evening, Liverpool, 18 February.
- 332. Dillon, P.** *Young people and risk taking.* St Joseph's Regional High School, Port Macquarie, 20 February.
- 333. Dillon, P.** *Young people and risk taking.* Westport High School, Port Macquarie, 20 February.

334. **Dillon, P.** *Current drug trends.* Hastings Community Drug Action Team Public Forum, Port Macquarie, 20 February.
335. **Dillon, P.** *Young people and risk taking.* Wauchope High School, Wauchope, 21 February.
336. **Dillon, P.** *Young people and risk taking.* Camden Haven High School, Camden Haven, 21 February.
337. **Dillon, P.** *Current drug trends.* National Institute of Dramatic Arts, Sydney, 28 February.
338. **Dillon, P.** *Young people and risk taking.* Our Lady of Mercy College, Parramatta, 6 March.
339. **Dillon, P.** *Harm reduction and current drug trends.* TAFE Counsellors' Meeting, Sydney, 11 March.
340. **Dillon, P.** *What's happening in research?* TAFE Counsellors' Meeting, Sydney, 11 March.
341. **Dillon, P.** *Cannabis: What's the story?* Wentworth Area Health Service Cannabis Forum, Penrith, 12 March.
342. **Dillon, P.** *Young people and risk taking.* Marist College Penshurst, Mortdale, 3 April.
343. **Dillon, P.** *Current drug trends.* Bomaderry Public School Staff In-Service, Bomaderry, 8 April.
344. **Dillon, P.** *Current drug trends.* Bomaderry Public School Parent Evening, Bomaderry, 8 April.
345. **Dillon, P.** *Young people and risk taking.* McCarthy College, Emu Plains, 9 April.
346. **Dillon, P.** *Young people and risk taking.* Newtown High School of the Performing Arts, 10 April.
347. **Dillon, P.** *New drugs, new risks: the current state of play in Australia.* Invited presentation at the AMA Party Drug Summit, Canberra, 11 April.
348. **Dillon, P.** *Drug information.* Workshop presented in Padang, Indonesia, 22-26 April.
349. **Dillon, P.** *Drug information.* Workshop presented in Palembang, Indonesia, 29 April-3 May.
350. **Dillon, P.** *Current drug trends.* Juvenile Justice Meeting, Bungador, 8 May.
351. **Dillon, P.** *Young people and risk taking.* Kingscliff High School, 9 May.
352. **Dillon, P.** *Young people and risk taking.* Waverley College, Bondi, 13 May.
353. **Dillon, P.** *Current drug trends.* Waverley College, Bondi, 13 May.
354. **Dillon, P.** *Current drug trends.* Parent Seminar, Waverley College, Bondi, 13 May.
355. **Dillon, P.** *Young people and risk taking.* Callaghan College, Jesmond Campus, Newcastle, 15 May.
356. **Dillon, P.** *Current drug trends.* HYPE Hornsby City Council, 16 May.
357. **Dillon, P.** *Current drug trends.* Parent Seminar, Scots College, 17 May.
358. **Dillon, P.** *Ecstasy and the youth culture.* Guest lecture to Anthropology students at Macquarie University, Sydney, 20 May.
359. **Dillon, P.** *Young people and risk taking.* Bomaderry High School, 21 May.
360. **Dillon, P.** *Current drug trends.* Bethlehem College, Ashfield, 21 May.
361. **Dillon, P.** *Young people and risk taking.* Goulburn South High School, 27 May.
362. **Dillon, P.** *Young people and risk taking.* Mulwaree High School, 27 May.
363. **Dillon, P.** *Current drug trends.* Goulburn, 27 May.
364. **Dillon, P.** *Current drug trends.* Marist College, Penshurst, 28 May.
365. **Dillon, P.** *Current drug trends.* Department of Juvenile Justice Western Cluster Conference, Dubbo, 29 May.
366. **Dillon, P.** *Alcohol and tobacco trends: the new data.* NSW Education Department Meeting, Sydney, 30 May.
367. **Dillon, P.** *Current drug trends.* Mt St Joseph's College, Milperra, 4 June.
368. **Dillon, P.** *Young people and risk taking.* St John Basco College, Engadine, 6 June.
369. **Dillon, P.** *Drug information.* Workshop presented in Makassar, Indonesia, 17-21 June.
370. **Dillon, P.** *Current drug trends.* Granville South High School, Guildford, 22 July.
371. **Dillon, P.** *Current drug trends.* Scots College, Rose Bay, 22 July.
372. **Dillon, P.** *Current drug trends.* Loretto Normanhurst, Normanhurst, 23 July.
373. **Dillon, P.** *Young people and risk taking.* Loretto Normanhurst, Normanhurst, 24 July.
374. **Dillon, P.** *Current drug trends.* Community Drug Forum, Point Clair Public School, Woy Woy, 30 July.

375. **Dillon, P.** *Cannabis: What's the story?* Wagga Wagga NSW Police Service/NDARC Information Session, Wagga Wagga, 6 August.
376. **Dillon, P.** *Current drug trends.* Ballina Community Drug Information Expo, Ballina, 7 August.
377. **Dillon, P.** *Current drug trends.* Division of GPs, Hornsby Hospital, Hornsby, 8 August.
378. **Dillon, P.** *Young people and risk taking.* Freeman Catholic College, Bonnyrigg Heights, 19 August.
379. **Dillon, P.** *Current drug trends.* St Andrews Primary School, Marayong, 20 August.
380. **Dillon, P.** *Young people and risk taking.* August De La Salle College, Caringbah, 21 August.
381. **Dillon, P.** *Current trends in drug use.* Sydney Hospital, Sydney, 23 August.
382. **Dillon, P.** *Young people and risk taking.* Wenona College, North Sydney, 26 August.
383. **Dillon, P.** *Current drug trends.* Wenona College, North Sydney, 27 August.
384. **Dillon, P.** *Cannabis: What's the story?* Coffs Harbour NSW Police Service/NDARC Information Session, Coffs Harbour, 28 August.
385. **Dillon, P.** *Young people and risk taking.* Riverside Girls High School, Sydney, 29 August.
386. **Dillon, P.** *Current drug trends.* Erina High School Community Drug Summit, Erina, 3 September.
387. **Dillon, P.** *Young people and risk taking.* All Saints Catholic Senior College, Casula, 5 September.
388. **Dillon, P.** *Party drugs.* MPH Students Presentation, University of Sydney, 9 September.
389. **Dillon, P.** *Current drug trends.* Parramatta Diocese Catholic Education Office Teacher Training Workshop, Blacktown, 10 September.
390. **Dillon, P.** *Young people and risk taking.* Canberra College, Woden, 11 September.
391. **Dillon, P.** *Current drug trends.* Canberra College, Woden, 11 September.
392. **Dillon, P.** *Cannabis: What's the story?* Shoalhaven CDAT Community Drug Forum, Shoalhaven, 12 September.
393. **Dillon, P.** *Party drugs.* Shoalhaven CDAT Community Drug Forum, Shoalhaven, 12 September.
394. **Dillon, P.** *Cannabis: What's the story?* K-6 PDHPE Day, Inner West Catholic Education Office, Revesby, 16 September.
395. **Dillon, P.** *Party drugs.* The Kensington Colleges, University of New South Wales, 17 September.
396. **Dillon, P.** *Young people and risk taking.* Bethlehem College, Ashfield, 19 September.
397. **Dillon, P.** *Young people and resilience: Is my child likely to use drugs in the future?* Creating String Foundations for our Children, A Family Fair, South Tweed Heads, 21 September.
398. **Dillon, P.** *Cannabis: What's the story?* Regional Conference for CDATs, Tamworth, 26 September.
399. **Dillon, P.** *Party drugs.* Regional Conference for CDATs, Tamworth, 26 September.
400. **Dillon, P.** *Party drugs.* Commonwealth Department of Health and Ageing Update, Canberra, 27 September.
401. **Dillon, P.** *Current drug trends.* North Coast Regional CDAT Conference – 'Learning and Celebrating', Coffs Harbour, 7 November.
402. **Dillon, P.** *Cannabis: what's the story?* 'Coffee, Cake and Cannabis', Wentworth Area Health Service, 13 November.
403. **Dillon, P.** *Young people and risk taking.* RRISK Seminar, Lismore, 18-22 November.
404. **Dillon, P.** *New drugs, new risks: current state of play in Australia.* Paper to Party Drugs Seminar hosted by the Drug and Alcohol Services Council of SA, Adelaide, 3 December.
405. **Dillon, P.** *Current drug trends.* Paper to Youth Workers Meeting, Kempsey, 4 December.
406. **Dolan, K.** *Follow up study of a RCT of the NSW prison methadone program.* Presented at NSW Corrections Health Service Research Symposium, Sydney, 30 May.
407. **Dolan, K.** *Incidence of hepatitis C in prison.* Back to Basics Public Health Network: Epidemiology Special Interest Group, NSW Department of Health, Sydney, 12 June.
408. **Lawrinson, P.** *Implementation of routine outcome measures in alcohol and drug services: A consideration of key issues.* Presentation to Ministry of Health personnel (Mental Health), Wellington, New Zealand, 2 September.
409. **Matalon, E.** *Information on drug use amongst adolescents.* Invited to talk to parent self help group. Roseville, 8 April.

- 410. Matalon, E.** *Brief cognitive-behavioural intervention for cannabis use disorder, patterns of use and harms.* A series of nine workshops delivered to Alcohol and Other Drug workers and General Practitioners for the Division of General Practice, Melbourne 14-21 May.
- 411. Mattick, R.** *Research in alcohol and other drugs. Has it enhanced the field?* Paper to Odyssey House One-Day Forum, 24 October.
- 412. Spooner, C.** *Biopsychosocial perspectives on drugs and alcohol. Adolescents and substance use: Research trends on risk factors and protective factors and implications.* Paper presented UNSW Social Work Lecture Program, Sydney, 11 April.
- 413. Spooner C.** *The impact of the Medically Supervised Injecting Centre on public amenity and crime.* Presentation to the New South Wales Bureau of Crime Statistics and Research and invited others, 10 April.
- 414. Spooner C.** *The aetiology of drug use: A broader approach with implications for prevention and treatment.* Workshop for Next Step Drug and Alcohol Services, Perth, 9 May.
- 415. Swift, W.** *Current issues in cannabis use and brief interventions.* Paper presented at Pharmacology, psychostimulants and cannabis, a half-day seminar organised by the Ted Noffs Foundation, 18 January.
- 416. Swift, W.** *Current issues in cannabis use and brief interventions.* Paper presented to the Wentworth Area Health Service, 26 February.
- 417. Swift, W.** *Adolescent cannabis use and brief interventions.* Paper presented to the Early Psychosis Program, Sydney, May 9.
- 418. Topp, L.** *Ecstasy use in Australia: patterns of use and associated harms.* Paper presented at Special Seminar for Sydney Youth Workers and Police Youth Liaison Officers, Ted Noffs Foundation, Randwick, Sydney, 18 January.
- 419. Topp, L.** *Stimulant use in NSW.* Paper presented to the Senior Officers Coordinating Committee on Drugs, Office of Drug Policy, NSW Cabinet Office. Sydney, 20 February.
- 420. Topp, L.** *Chairing of forum hosted by the AIDS Council of NSW, Referral Pathways: A Focus on Methamphetamine.* Rushcutters Harbourside Hotel. Sydney, 22 February.
- 421. Topp, L.** *If you're going to use drugs, how do you reduce the risks?* Paper presented to the Kensington Colleges of UNSW, UNSW Kensington Campus, Sydney, 25 February.
- 422. Topp, L.** *Australian Drug Trends 2001.* Paper presented to the National Expert Advisory Committee for Illicit Drugs, Airport Stamford Hotel, Sydney, 25 February.
- 423. Topp, L.** *Ecstasy use in Sydney: Patterns of use and associated harms.* Paper presented at the Eastern Suburbs Early Psychosis Support Group, Waverly Council, Bondi Junction, May 7.
- 424. Topp, L.** *Who uses 'ecstasy' and why?* Paper presented at Party Drugs Seminar hosted by Drug and Alcohol Services Council of South Australia, North Adelaide, May 14.
- 425. Topp, L.** *What do you know about cannabis, speed and pills?* Two hour question and answer session presented to the Manly Youth Council, Manly, May 20.
- 426. Topp, L.** *Sydney's dynamic methamphetamine markets.* Paper presented at ADIS in-service staff training, St Vincent's Hospital, Sydney, June 26.
- 427. Topp, L.** *Ecstasy: Past and present.* Lecture presented to University of New South Wales Year II medical students enrolled in Health Maintenance, July 24.
- 428. Topp, L.** *Amphetamines: What's the story?* Coffs Harbour NSW Police Service/NDARC Information Session, Coffs Harbour, 28 August.
- 429. Topp, L.** *Synthetics: Destroying the fabric of our youth?* Lecture to the Australian Federal Police Management of Serious Crime Course, Australian Federal Police College, Barton, ACT, 30 October.
- 430. Topp, L.** *Implications for frontline workers of the emergence of potent forms of methamphetamine in Australia.* Paper to the Invited Seminar Series of Turning Point Alcohol and Drug Centre Inc, Melbourne, 21 November.
- 431. Topp, L.** *Implications for frontline workers of the emergence of potent forms of methamphetamine in Australia.* Paper to Wentworth Drug and Alcohol Service Seminar, Wentworth Area Health Service, Nepean Hospital, Penrith, 26 November.
- 432. Topp, L.** *Who uses ecstasy and why?* Paper to Party Drugs Seminar hosted by the Drug and Alcohol Services Council of SA, Adelaide, 3 December.